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Abstract 
The greatest obstacle to clinical application of cancer gene therapy is lack of effective delivery 
tools. Gene delivery vehicles must protect against degradation, avoid immunogenic effects and 
prevent off target delivery which can cause harmful side effects. The stealth liposomes has greatly 
improved tumor localization of small molecule drugs and is a promising tool for nucleic acid 
delivery as the polyethylene glycol coating its surface protects against immune recognition and 
blood clearance. In this study, DNA was fully encapsulated within in stealth liposomes by 
complexing the macromolecule with a cationic polymer before encapsulation. Formation methods 
and material compositions were then investigated for their effects on encapsulation. This 
technology was translated for protective delivery of siRNA designed for HPV viral gene silencing 
and cervical cancer treatment.  Stealth liposomes encapsulating siRNA were functionalized with a 
targeting peptide which binds to the alpha6 integrin, a cervical cancer biomarker. It was found that 
both targeting and polymer complexation before encapsulation were critical components to 
effective transfection. Varying the siRNA:polymer ratio revealed an optimal concentration for 
enhanced transfection, but no improvement to internalization, suggesting polymer complexation 
enhances transfection through an intracellular mechanism.  
Nanoparticles functionalized with cancer-targeting ligands have shown promise but are still 
limited by off-tumor binding to healthy tissues that nevertheless express low levels of the molecular 
target. Targeting two unique cancer biomarkers using dual-targeted heteromultivalent nanoparticles 
presents a solution to this challenge by requiring overexpression of two separate ligands for 
localization. In order to guide experimental design, a kinetic model was built to explore how the 
affinity and valency of dual-ligand liposomes affect the binding and selectivity of delivery to cells 
with various receptor expression. α5β1 and α6β4 integrin expression levels were then quantified on 
20 different cell lines to identify appropriate model cells for in vitro investigation. Dual-targeting 
heteromultivalent liposomes were synthesized using the alpha6 targeting peptide and an 
alpha5beta1 targeting peptide. Heteromultivalent liposomes with varying peptide ratios were 
delivered to cells with varying integrin concentrations. Binding and internalization was then 
evaluated to understand the effect of valency and avidity on binding kinetics and delivery. Dual-
ligand liposomes with equal valencies of each targeting peptide achieved enhanced binding 
efficiency and selectivity for cells expressing equal and high receptor levels. This liposome 
formulation was used as a gene delivery vehicle to achieve improved transfection to dual-receptor 
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expressing cells. The insights gained from this study inform rational design of modular 
heteromultivalent nanoparticles for enhanced specificity to target tissue, for the creation of more 
effective cancer treatments. 
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Chapter 1  Peptide Functionalized Nanoparticles for 
Nonviral Gene Delivery 
Introduction 
 Gene therapy has the potential to treat a myriad of diseases currently in need of improved 
therapies.  Though viruses were evolutionarily designed to transfer their genetic information into 
foreign cells with various tissue tropisms and highly efficient genetic transfer, their use as vehicles 
for therapeutic gene delivery is limited by their minimal DNA cargo capacity,1 immunogenic 
concerns,2,3 and insertional mutagenic potential4,5 with possible oncogenic effects.  The 
development of nonviral vectors with virus-like traits of efficient transfection and specific delivery 
that still minimize viral disadvantages remains a challenge to effective gene delivery.  Nonviral 
vectors are often easier to manufacture, can encapsulate much larger DNA loads and avoid the 
dangerous immune responses associated with viral vectors6–10 but lack the high transduction 
efficiency of viruses.  Many different materials and constructs have been investigated as synthetic 
gene delivery vehicles: Cationic polymers and lipids such as polyethyleneimine (PEI) and 1,2-di-
(9Z-octadecenoyl)-3-trimethylammonium-propane (DOTAP), natural molecules like poly-L-
Lysine (pLL), albumin and chitosan, and complex structures such as dendrimers have all been used 
as nucleic acid vectors. The nonviral vectors discussed in this review are included in Figure 1.  
Functionalization with polyethylene glycol (PEG) for stealth capabilities, cell penetrating peptides 
for increased uptake, polycationic peptides and lipids for endosomal escape, nuclear localization 
signals, and antibodies and peptides for targeting have been used to augment the function of these 
vectors.7,11–17  The focus of this review is on efforts within the last ten years to target gene delivery 
vehicles using peptides, both carefully designed biomimetic peptides and peptides identified 
through library screening.  The target, method of discovery, disease application and sequence of 
each peptide explored is listed in Table 1.  
 Peptide targeted gene delivery and expression within a cell follows the general pathway outlined 
in Figure 2.  Once the vector comes in contact with its target cell, the peptide can bind to its specific 
receptor. The receptor bound peptide and its gene vector will then enter the cell through receptor 
mediated endocytosis, placing the delivery vehicle within an endosome or other intracellular 
vesicle.  The specific intracellular trafficking of the vehicle depends on the mechanism of 
endocytosis: Clathrin-mediated, caveolae-mediated or clathrin- and caveolae-independent 
endocytosis.10,18 The nucleic acid and its vehicle will then escape the vesicle with a mechanism that 
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depends on the vector composition.  If the genetic cargo is siRNA, once it is released into the 
cytosol it will interact with RNA interference enzymes to downregulate its target gene.  If the  
genetic cargo is DNA, it will need to enter the nucleus where it can be transcribed into mRNA.18,19  
Since receptor binding of the peptide ligand is the first step in the gene delivery vehicle pathway, 
it is obvious that the target receptor must be chosen carefully, and the proper peptide must be paired 
with an efficient delivery vector.  The receptor should be specific to the cell type being targeted for 
delivery and should be naturally internalized within the cell.  The gene delivery vehicle has to be 
stable enough to reach the target cells and may possess endosome- or vesicle- escape abilities.  An 
efficient delivery vehicle combined with a highly specific receptor-ligand pair can mediate 
successful targeting and delivery of a nucleic acid cargo.  The ability to target the systemic delivery 
of nucleic acids, or any drug, can minimize side effects, maximize treatment to the target site and 
allow for more flexibility in dosing limits.   
 Peptides are ideal as in vivo targeting molecules because they are small with low toxicity and 
immunogenicity, can be selected for high affinity and specificity for their targets and are easily 
produced and chemically modified.20,21 Targeting peptides for a particular receptor can be designed 
using knowledge of the natural ligand’s binding site, sequence, and secondary structure to create a 
biomimetic peptide, or by screening of a large peptide library using phage display. Combining high 
affinity, high specificity peptide ligands with effective nonviral vectors that target disease tissue 
and avoid healthy tissue has the potential to make gene therapy a reality for cancer, cystic fibrosis, 
neurodegenerative diseases and an unlimited number of other pathologies. 
Peptide Targeted Cancer Gene Therapy 
 The development of malignant cancer requires multiple aberrant genetic events, some of 
which include the mutation and subsequent inactivation of tumor suppressor genes and proteins 
whose normal function is to regulate cell growth and correctly initiate apoptosis.22  One possible 
treatment, therefore, lies in the restoration of the functional tumor suppressor gene through gene 
therapy. p53, for example, is a cell cycle regulatory protein that is frequently mutated in human 
cancers resulting in a loss of its tumor suppression function.  The successful transfection of this 
gene in ovarian cancer patients has caused upregulation of p53 and other enzymes downstream 
from p53.23  Another common cancer genetic event comes from a mutation that causes the 
overexpression or overactivation of an oncogene, which then facilitates uncontrolled proliferation 
and cell survival.  One such oncogene commonly mutated in cancers, K-Ras, has been targeted for 
inhibition using siRNA.  RNA interference effectively inhibits the expression of the mutant protein 
and limits cell tumorigenicity.24  RNA interference can be used to inhibit other oncogenes such as 
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the anti-apoptosis gene livin, and cyclin-E.25  Prodrug activation is another potential cancer gene 
therapy application. Prodrug activation involves expressing an exogenous enzyme within the target 
tissue that can convert a systemically delivered nontoxic prodrug into a potent anti-tumor drug. An 
example of an enzyme-prodrug combination is the pair herpes simplex virus (HSV) thymidine 
kinase and phosphorylated gancyclovir. If gancyclovir is administered to a cell which has been 
transfected to express HSV thymidine kinase, the thymidine kinase will phosphorylate the 
gancyclovir converting it to a DNA synthesis inhibitor.26  Some of the other enzyme-prodrug pairs 
that have been suggested and tested for therapeutic efficacy include another DNA synthesis 
inhibitor cytosine deaminase and 5-Fluorouracil, and the DNA cross-linking agents nitroreductase 
and CB1954, and CYP and cyclophosphamide.26,27 The delivery of anti-angiogenic gene therapy 
also holds potential for tumor therapy by depriving tumors of necessary blood supply.28  While 
several of these gene therapy schemes have shown promise preclinically and in clinical trials, much 
of their success is limited by low transfection and the insufficient ability to target tumor tissue.29,30 
Peptide targeted gene therapy could potentially resolve some of these clinical limitations. 
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Figure 1. Structures of nanoparticles used for peptide targeted gene delivery.  
Adapted with permission from (84, 17, 93). Copyright (2009, 2007) American Chemical Society, Copyright 
(2004), from Elsevier. 
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Table 1. Peptide Targeted Gene Delivery Vehicles 
 
Name Peptide Sequence Application      Nanoparticle Molecular Target
Peptide 
Density
Discovery 
Method
Reference
2.5 – 10
a
7-10
b
GE11 YHWYGYTPQNVI cancer PEI, gel-based EGFR 30 – 50
a phage display 38-40
RGD RGDSPASSKP cancer poly(amidoamine) polyplex αvβ3 integrin 19
c biomimetic* 47
RGD cRGDfK cancer
albumin, pLL, 
silsesquioxane dendrimer, 
lipoplex, chitosan
αvβ3 integrin 2 – 500
b phage display
12, 49, 
50, 52, 53
5 – 20
a
1 – 20
b
GACRRETAWACG cancer pLL α5β1 integrin 50
a phage display 65
PR-b KSSPHSRN(SG)5RGDSP cancer Polymersome, liposome α5β1 integrin
0.7 – 
6.9
a biomimetic 77, 78
SIG SIGYPLPGGGSK16 cancer pHPMA coated pLL angiogenic vessels - phage display 59
APRPG cancer PEI angiogenic vessels 15.86
c phage display 82
YSA YSAYPDSVPMMS cancer core/shell nanogel EphA2 225
b phage display 84, 85
F3
AKVKDEPQRRSARLSAKPAPPKPEPKPKKAP
AKK
cancer quantum dots nucleolin 20
b phage display 93
NGR GNGRGGVRSSSRTPSDKYC cancer lipid protamine lipoplex aminopeptidase/ CD13 - phage display 96
B6 CGHKAKGPRK cancer PEI transferrin 50 – 70
a phage display 8
PF4zip
CGGRMKQLEDKVKKLLKKNYHLENEVARLK
KLVG
cancer star-shaped PEG polyplex heparin - biomimetic 104
*Biomimetic peptides are those developed through rational design mimicking the function of or selecting specific peptide sequences from the target’s natural 
ligand protein.
Peptide densities reported as 
a
 mole percent, 
b
 peptides per nanoparticle, or 
c
 peptides per PEI molecule.
11, 56-58, 
60-63
biomimeticαvβ3 integrinRGD4C
pLL, polycaprolactone 
polyplex, PEI, lipid 
protamine lipoplex
cancerACDCRGDCFC
MQLPLAT cancer
lipoplex, pLL, star-shaped 
copolymer, PEI
MC11 FGFR phage display 31, 33, 35
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Name Peptide Sequence Application      Nanoparticle Molecular Target
Peptide 
Density
Discovery 
Method
Reference
HIP CRPKAKAKAKAKDQTK cancer star-shaped PEG polyplex heparin - biomimetic 104
LHRH (pyroE)-HWSY-(dK)-LRP(amide) cancer PEI LHRH - biomimetic 108, 109
NL4 CTTTHTFVKALTMDGKQAAWRFIRIDTAC
neurological 
disease
pLL, PEI TrkA 100
a biomimetic 117, 118
Leptin30 YQQVLTSLPSQNVLQIANDLENLRDLLHLL
neurological 
disease
pLL dendrimers leptin receptor 100
a biomimetic 119, 120
RVG YTIWMPENPRPGTPCDIFTNSRGKRASNG
neurological 
disease
exosomes, polypeptide AchR - biomimetic 126-129
Tet1 HLNILSTLWKYRC
neurological 
disease
PEI trisialoganglioside 0.6
c phage display 132, 133
NT Pyr-LYENKPRRPYIL
neurological 
disease
PEI neurotensin receptor 8.2
c biomimetic 132
HC AA 408-859 of tetanus toxin heavy chain
neurological 
disease
PEI trisialoganglioside 5 – 25
a biomimetic 134
Secretin HSDGTFTSELSRLRDSARLQRLLQGLVGGC cystic fibrosis PEI secretin receptor - biomimetic 140
Tenascin PLAEIDGIELA cystic fibrosis lipoplex α9β1 integrin 0.05 – 5
a biomimetic/ 
phage display
144
Peptide Y GACYGLPHKFCG cystic fibrosis lipoplex
human airway epithelial 
cells
4
b phage display 145, 146
Peptide E SERSMNF cystic fibrosis lipoplex
human airway epithelial 
cells, ICAM-1
2,750
b phage display 147
Molossin ICRRARGDNPNNRCT
corneal 
disorder
pLL αvβ3 and α5β1 integrins - biomimetic 154
CAP DWRVIIPPRPSA osteoarthritis PEI rabbit cartilage 4.86
a phage display 157
LAB NSMIAHNKTRMHGGGSC
bone 
regeneration
poly(amidoamine) 
dendrimers
bone tissue 2 – 4
b phage display 156
HAB SGHQLLLNKMPNGGGC
bone 
regeneration
poly(amidoamine) 
dendrimers
bone tissue 2 – 8
b phage display 156
NGR GNGRGGVRSSSRTPSDKYC
DNA 
vaccination
PLGA coated PEI aminopeptidase/ CD13 10
c phage display 160
*Biomimetic peptides are those developed through rational design mimicking the function of or selecting specific peptide sequences from the target’s natural 
ligand protein.
Peptide densities reported as 
a
 mole percent, 
b
 peptides per nanoparticle, or 
c
 peptides per PEI molecule.
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Figure 2. General pathway of cell binding, entry, and gene expression for peptide targeted gene delivery. 
Gene Delivery with Peptides Targeting Growth Factors 
One approach to targeted gene delivery for the treatment of cancer takes advantage of elevated 
levels of growth factor receptor expression in tumors and tumor vasculature.  For example, 
fibroblast growth factor receptors (FGFR) have been shown to be overexpressed in various cancer 
cells, including breast, colon, ovarian, renal, and lung carcinomas,31 as well as on proliferating 
endothelial cells during angiogenesis.  Fibroblast growth factor (FGF) is a known mitogen which 
stimulates cell division when bound to FGFR. FGFR is a promising target for delivery of 
therapeutic agents to cancerous cells and tumors where angiogenic vessels grow rapidly to feed the 
surrounding tumor tissue; yet the size, stability, and mitogenic effects of FGF are not ideal for 
nanoparticle functionalization.32  In the hope of avoiding these mitogenic effects within an FGFR 
targeting molecule, Seymour et al identified a linear FGFR binding peptide, MQLPLAT, via phage 
display and biopanning against cells expressing FGFR.33  Phage display and biopanning are 
techniques used to study peptide-substrate interactions and select for peptides bound to a specific 
target using affinity selection.  Briefly, random peptide libraries are fused to a phage protein coat, 
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these peptide displaying phages are incubated with cells expressing FGFR, and unbound phages 
are removed with a wash.  Addition of FGF allows FGFR specific phages to be eluted, cloned, and 
sequenced. The most successful peptide sequence, MQLPLAT, was also delivered on phages to an 
ex vivo human tumor model to confirm tumor specificity and was found to preferentially 
accumulate in tumor tissue over healthy tissue.33  
 
Figure 3. In vivo tumor therapy using FGFR targeted star-shaped polymers.   
Tumor growth profile after injection of therapeutic plasmid complexed with PEI25k, EAPP (nontargeted 
star-shaped polymer) and EAPPM (targeted star-shaped polymer) or NS (normal saline) via tail vein. 
Reprinted with permission from (35). Copyright (2010) American Chemical Society. 
 
 The identified peptide was found to be non-mitogenic and has been shown to improve cellular 
uptake and transfection efficiency when conjugated to PEGylated-PEI polyplexes, or polymer-
DNA complexes.34 PEI is an extremely common, extremely successful polycationic transfection 
agent. The high transfection efficiency of PEI has been attributed to its ability to escape from 
vesicles mediated by its ‘proton sponge effect’. When PEI is encapsulated within an intracellular 
vesicle with low pH, the high concentration of amines present within its structure lead to buffering 
which causes an influx of ions and subsequent osmotic swelling and vesicle rupture.35  
 Niu et al used the FGFR specific, phage display identified peptide to target a glioma mouse model 
for delivery of plasmid DNA.  The plasmid was carefully designed to include a cytotoxic domain 
to induce cell apoptosis and membrane permeability and secretory domains to encourage the 
expressed protein to travel intercellularly, also known as the bystander effect.  The targeting peptide 
was attached at the end of the PEG stealth functionalized lipid based delivery agent.  The in vitro 
results indicated a 2 fold increase in plasmid expression and a 3 fold improvement in cell death 
achieved with the cytotoxic designed plasmid compared to delivery with nontargeted lipoplexes.  
However, the targeted lipoplexes provided no statistical improvement to tumor growth inhibition 
in vivo compared to the nontargeted lipoplexes, and biodistribution was not investigated.32  
 Li et al modified the same peptide sequence, MQLPLAT, to include a spacer sequence, GGGC, 
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for conjugation to PEI and to improve peptide accessibility on the nanoparticle surface.36  This 
peptide was attached to the end of an eight armed block copolymer of PEG for stealth properties 
and PEI for DNA condensation. The star copolymer was designed to effectively deliver DNA while 
minimizing the toxicity usually associated with PEI.  When these targeted polyplexes were 
delivered to FGFR positive cells, they achieved a 10 fold increase in expression over nontargeted 
star polyplexes, and 100 fold increase compared to nonPEGylated PEI polyplexes.   In vivo 
biodistribution measured in the tumor, lung and liver of a mouse liver carcinoma model showed 
much higher transfection in tumor cells with the targeted star copolymers compared to nontargeted 
delivery agents and compared to the other tissues.  When the load included a cytotoxic gene, tumor 
growth inhibition was observed with the targeted polyplexes.  The tumors in the mice receiving 
targeted polyplex gene therapy were only a quarter of the size of those treated with PEI polyplexes 
as shown in the tumor growth profile in Figure 3. 
 Overexpression of epidermal growth factor receptors has also been identified to play a role in 
several types of cancer.  Of the four EGFR family members, HER1 and HER2 have recently been 
targeted for gene delivery using peptide ligands.  Both receptors are frequently overexpressed in 
several common human cancers, and HER2 is associated with particularly aggressive tumors and 
poor prognosis.  HER1 has several known native ligands, while HER2 has no known native ligands, 
but participates in EGFR activation.37,38 A HER1 specific peptide, GE11 (YHWYGYTPQ NVI), 
was identified via in vitro phage display and biopanning against purified HER1.39 The binding 
affinity and specificity of the GE11 peptide were quantified in vitro and in vivo using 125I labeled 
peptides. Intravenous delivery of GE11 peptide showed that 6% of the peptide accumulated in 
tumor tissue 30 minutes after injection and that co-injection of unlabeled GE11 peptide resulted in 
an almost threefold decrease in accumulation in the tumor.  Four hours after injection GE11 
accumulation was limited to the tumor and the blood, each with about 3% accumulation.    The Kd 
of GE11 for EGFR was found to be 22 nM, 10 times less than that of native EGF; yet GE11 was 
found to be 5 times less mitogenically stimulative than EGF. This GE11 peptide has been used to 
improve targeted gene delivery in applications including prostate and pancreatic cancer and has 
demonstrated superior mitogenicity and binding to cancer cells compared to several other designed 
and discovered EGFR peptide ligands.39–41  The GE11 peptide was conjugated to gel-based 
engineered nanocarrier systems (GENS), which can encapsulate and protect plasmid DNA, while 
preserving its natural supercoiled structure.  When delivered to a pancreatic cancer cell line, these 
EGFR targeted gene delivery vehicles achieved 48% transfection efficiency, better than both a 
commercial transfection agent and nontargeted GENS.41  When conjugated to PEI for condensation 
with DNA, the GE11 peptide achieved up to a 10 fold increase in transfection efficiency in vitro 
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with EGFR positive cells.39,40  These targeted PEI polyplexes have up to 1000 fold higher 
transfection efficiency compared to nontargeted polyplexes when delivered to tumor mouse models 
either intratumorally or intravenously.  Biodistribution of the expression of the delivered plasmid 
shows that the agents preferentially accumulate in the tumor compared to 7 other organs, including 
liver.39,40  
 
Figure 4. Effect of chitosan nanoparticles on ovarian cancer growth.  
Treatment was started 1 week after intraperitoneal (I.P.) injection of tumor cells into mice. A) Integrin 
positive cell line (SKOV3ip1). B) integrin negative cell line (A2780). Either control or POSTN-targeted 
siRNA-incorporated into nontargeted (CH-NP) or targeted (RGD-CH-NP) was given twice weekly at a dose 
of 150 μg/kg body weight through intravenous injection. Docetaxel was diluted in PBS and injected i.p. once 
per week, at a dose of 100 μg, in 200 μL of PBS. Treatment was continued until mice in any group became 
moribund (typically 4 to 5 weeks depending on tumor cell) Reprinted with Permission from (54). Copyright 
(2010) American Association for Cancer Research. 
 
Gene Delivery with Peptides Targeting Integrins 
The αvβ3, αvβ5, and the α5β1 integrins are promising targets for specific delivery of cancer 
therapeutics.  Expression of these integrins is upregulated in many tumor cells and tumor 
endothelium.  The αvβ3 and αvβ5 integrins bind vitronectin and the α5β1 integrin specifically binds 
fibronectin.  The RGD motif is found in many components of the extracellular matrix, including 
fibronectin, vitronectin, laminin, and collagen, and has been found to facilitate cell adhesion and 
nanoparticle delivery. The motif is also found in the penton base, the protein that forms the vertex 
of the capsid of adenovirus, where it is known to bind to the αvβ3 integrin.11  The RGD peptide has 
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been used to functionalize PEI, PEI-PEG conjugates, gold nanoparticles, magnetic nanoparticles 
for combined molecular imaging, poly-L-lysine and many other vector molecules for improved 
specific in vitro uptake and transfection of genetic material.42–45 The RGD containing peptides 
RGDSPASSKP and GRGDSP were identified as conserved sequences within the cell binding 
region of fibronectin, and their integrin binding affinity and specificity were suggested by their 
ability to reversibly inhibit fibronectin-mediated cell spreading.46,47  The RGDSPASSKP peptide 
was used to functionalize PEG polyamidoamine DNA  nanoparticles for integrin targeting, but did 
not show any improvement to plasmid transfection to A549 or 3T3 cells with the conjugation of 
the RGD peptide to their polyplexes, which was suggested to be caused by poor release of the DNA 
after internalization.48  
 While some groups have successfully enhanced gene delivery via functionalization with the 
linear RGD sequence, others have investigated the effect of a constrained secondary structure in 
cyclic forms of RGD on targeted gene delivery.12  In particular, the effect of additional amino acids 
on the conformation, activity, and affinity of cyclic RGD pentapeptides of the form RGDXY was 
investigated, where X and Y represent both L- and D- natural and non-natural amino acids.  This 
study found that the c(RGDfK) sequence maintained a higher affinity for the αvβ3 integrin 
compared to linear RGD containing sequences.49  
 c(RGDfK) targeted silsesquoxane dendrimers delivering siRNA achieved 50% gene silencing.50 
c(RGDfK) conjugated to a PEG molecule attached to albumin was used to deliver antisense 
oligonucleotides attached to the surface of the albumin to a cell line derived from lung metastases.51  
The antisense oligonucleotide induced expression of luciferase by correction of incorrect splicing 
sites.52  The targeted albumin oligonucleotide vector induces high levels of luciferase expression 
compared to nontargeted PEGylated albumin, and expression was comparable to that achieved by 
delivering the oligonucleotides with lipofectamine.53  Kunath et al found that the transfection 
efficiency of DNA delivery strongly depended on the ratio of the PEI-RGD vector to DNA 
concentration. The dependence of transfection efficiency on the amount of PEI-RGD could either 
be caused by increased integrin targeting with RGD or increased endosomal escape induced by 
PEI, or a combination of these effects.54  DNA vectors formed from c(RGDfK) conjugated to 
cationic convertible detergent lipids with DOPE for endosomal escape still required the addition of 
chloroquine, a lysosomotropic agent, in the media to achieve 1000 times lower transfection levels 
than PEI in vitro.12  
 c(RGDfK) functionalized chitosan nanoparticles with  encapsulated siRNA targeting the 
oncogene POSTN were delivered to mice with tumors produced from ovarian cancer cells positive 
for αvβ3 integrin expression.  Targeting the chitosan nanoparticles resulted in negligible delivery to 
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the brain, heart, lung, spleen, kidney and liver compared to nontargeted nanoparticles, and a 50% 
reduction in POSTN expression in the tumor tissue.  These targeted vectors resulted in 71% 
reduction in tumor weight compared to control siRNA and 24% reduction compared to nontargeted 
siRNA nanoparticles (Figure 4).  Tumor weight was furthered reduced when delivered with 
docetaxol.55  Similar results were seen with siRNA targeting the oncogene FAK, where tissue 
specificity and therapeutic efficacy of RGD-functionalized chitosan nanoparticles for siRNA 
delivery were demonstrated.55  
 Other cyclic RGD-containing peptides targeting the αvβ3 integrin have been developed using a 
combination of rational biomimetic design and phage display techniques.  The RGD4C peptide 
(ACDCRGDCFC) was identified via phage display of a random peptide library in which sequences 
were flanked with cysteines on either end (CX5C, CX6C, CX7C, and CX9C).56  The RGD4C peptide 
contains two disulfide bonds and was found to inhibit cell attachment to vitronectin surfaces 20 
fold, indicating that the peptide binds to the αvβ3 and αvβ5 integrins in a way that blocks vitronectin 
binding.56,57  Despite the effective integrin blocking, the disulfide bonds present in the RGD4C 
peptide increased the hydrophobicity of the molecule, causing poor solubility in aqueous systems. 
Additionally, these disulfide bonds have the potential to form improper crosslinks yielding inactive 
peptides.  These features made incorporating functional RGD4C peptides into targeted delivery 
systems more challenging due to the limited solubility and activity of the peptide. 
Linear and cyclic structures of RGD4C inspired peptides with one or two disulfide bonds were 
investigated to address the necessity of the potentially problematic disulfide linkages.  Methionine 
was substituted for cysteine as shown in Figure 5, and the CDMRGDMFC peptide-functionalized 
lipoplexes gave promising results compared to the CDCRGDCFC peptide-functionalized 
lipoplexes. 57,58 
 
Figure 5. RGD4C and modified RGD4C analogs with disulfide bonds between indicated cysteine residues. 
 
 The RGD4C peptide was modified to include a positively charged pLL tail to facilitate the 
condensation of negatively charged DNA resulting in 100 times greater transfection than 
nontargeted pLL condensed DNA.59,60 Other groups have addressed the poor solubility of the 
RGD4C peptide in aqueous environments by conjugating a PEG spacer to the N-terminus tail of 
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the peptide to improve the physicochemical properties of the DNA containing polyplex and to 
reduce the surface charge.11,61,62  This RGD4C modification to target PEG-polycaprolactone 
polyplexes, combined with a cell penetrating peptide derived from HIV termed TAT, only achieved 
a level of transfection that was comparable to a commercially available transfection reagent, 
however, PEG-RGD4C conjugated to PEI in DNA polyplexes caused significant improvement in 
gene delivery both in vitro and in vivo.11,61–63  Anti-VEGF siRNA delivered in vivo with targeted 
RGD4C-PEG-PEI  significantly inhibited tumor growth compared to all controls, as measured by 
tumor volume of sub-cutaneous tumors established from CT26 cell inoculation.61 The moderate 
transfection levels achieved with the targeted PEG-polycaprolactone vectors could be caused by 
the lack of endosomal escape function, which is probably achieved by the other polyplex systems 
with the presence of PEI.  Kim et al investigated the specificity of PEI-PEG-RGD4C with gene 
delivery to angiogenic and angiostatic endothelial cells, modelling tumor vasculature compared to 
healthy vasculature.  The RGD4C targeted polyplexes improved transfection in angiogenic cells 
compared to PEI and inhibited transfection in angiostatic cells, indicating a strong in vivo targeting 
potential to the rapidly proliferating tumor vasculature.64  
 The α5β1 integrin, like the αvβ3 integrin, is overexpressed on tumor and tumor endothelial cells.  
Unlike αvβ3, which is expressed on platelets, macrophages and endothelial cells throughout 
adulthood, the expression of α5β1 decreases during development and is expressed at low levels in 
healthy adult cells.65  The decreased expression of the α5β1 integrin in healthy cells and tissues 
makes it a potentially more selective target for the delivery of cancer therapeutics.  Ruoslahti et al 
performed extensive integrin affinity studies using phage display and biopanning of RGD-
containing ligands and identified an α5β1-specific peptide (GACRRETAWACG).56  Hart et al 
modified this α5β1-specific peptide with a pLL tail for complexation with plasmid DNA and 
significantly improved transfection efficiency.66  
 The Kokkoli group has designed a fibronectin mimetic peptide,67 PR_b 
(KSSPHSRN(SG)5RGDSP), with high affinity and specificity for the α5β1 integrin, and has 
conjugated it to a dialkyl ester tail, shown in Figure 6, or to diblock polymers.67–69 The peptide was 
designed to include both the primary cell adhesion site (RGDSP) and the synergy site (PHSRN) as 
well as a linker ((SG)5) that mimics both the length and hydrophobicity/ hydrophilicity of the 
distance between binding sites in the native fibronectin protein.67,70,71  PR_b functionalized 
liposomes and polymersomes have shown enhanced binding, intracellular uptake, and delivery of 
their encapsulated loads compared to non targeted and GRGDSP-functionalized nanoparticles 
delivered to colon, prostate, and breast cancer cells, and porcine islets of Langerhans, as well as the 
capability to deliver a wide variety of therapeutic cargoes including siRNA.69,72–78  PEGylated PR_b 
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liposomes and polymersomes internalized via receptor-mediated endocytosis and were initially 
found in early endosomes, but localized within late endosomes and lysosomes at later times.77,78 
PR_b has been used to functionalize both liposomes and polymersomes for delivery of DNA and 
siRNA for cancer therapy.78,79 PR_b functionalized stealth liposomes encapsulating condensed 
plasmid DNA mediated improved transfection compared to nontargeted stealth liposomes and free 
condensed DNA, specifically in colon cancer cells overexpressing the α5β1 integrin in vitro. 
Furthermore, when administered in vivo to metastatic tumor bearing mice, imaging showed that 
PR_b functionalized stealth liposomes outperformed nontargeted liposomes and delivered genes 
specifically to the tumor site, thereby distinguishing between healthy and tumor sites on the liver.79 
 
Figure 6. The PR_b peptide is a fibronectin mimetic specific for the α5β1 integrin. 
The four repeats of the fibronectin (FN) fragment III7–10 are shown. The synergy site PHSRN is in the III9 
repeat and RGDSP is in the III10.  The schematic drawing of the PR_b peptide-amphiphile shows the four 
building blocks of the peptide headgroup (a KSS spacer, the PHSRN synergy site, a (SG)5 linker, and the 
RGDSP binding site) as well as the dialkyl ester tail ((C16)2GluC2). Reproduced with permission from (19). 
Copyright (2012) John Wiley and Sons. 
 
Gene Delivery with Peptide Targeting to Other Receptors 
 Tumor vascular cells grow and divide more rapidly than most healthy vasculature, and changes 
in the expression of cell surface molecules and receptors have been characterized for many cancer 
types and tumor vasculature.  Targeting the delivery of therapeutic nanoparticles to tumor 
vasculature attempts to utilize these biological and molecular differences to achieve improved 
specificity in delivery.  Nicklin et al used phage display and biopanning methods to identify a 
peptide, SIG (SIGYPLP), which specifically binds proliferating endothelial cells.  Four rounds of 
biopanning against human umbilical vein endothelial cells (HUVECs) were followed by counter 
selection or preclearing steps to remove all phages which bound vascular smooth muscle cells, 
hepatocytes, or peripheral blood mononuclear cells.80  The identified sequence was originally used 
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for applications to treat atherosclerosis, hypertension, and postangioplasty restenosis.  Parker et al 
used the SIG peptide as a more generally applicable target for cancer treatments, targeting 
angiogenic vessels rather than tumor specific cell markers.  By modifying the SIG peptide with a 
GGGS spacer sequence to mimic the phage stalk and a pLL tail to facilitate DNA condensation 
(SIGYPLPGGGSK16), the peptide was incorporated into poly[N-(2-hydroxypropyl) 
methacrylamide] (pHPMA) coated pLL polyplexes.60  The SIG-labeled pHPMA coating of these 
polyplexes facilitated serum stability without compromise of transfection efficiencies. These 
HUVEC targeted polyplexes achieved up to a 2 fold increase in uptake in endothelial cells 
compared to epithelial cells, however, this uptake was lower or comparable to that achieved with 
RGD functionalized polyplexes. While significant uptake was seen in endothelial cells, little 
transfection was achieved, which was attributed to the slow cell division rate of these cells.  High 
transfection efficiency was achieved in epithelial cells, but efficiencies higher than RGD mediated 
gene delivery were only achieved with addition of chloroquine to the media. The investigators then 
used the SIG peptide to alter adenovirus tropism for DNA delivery.60  
 Recently, a short peptide sequence homing to angiogenic vasculature (APRPG) has been 
identified using an angiogenic mouse model for in vivo phage display.81 The APRPG peptide 
selectively binds to angiogenic vessels and not to tumor cells, making it a potential candidate for 
tumor dormancy therapy, in which the angiogenic vessels feeding the tumor are destroyed via 
targeted delivery to tumor vasculature.82 This vessel homing peptide was used to target stealth 
siRNA PEI polyplexes for downregulation of VEGF and inhibition of vascular growth.  The in 
vitro transfection efficiency using both targeted and nontargeted nanoparticles correlated with their 
internalization efficiency.  The gene delivery vector was then used to deliver a fluorescent model 
molecule to mice with established tumors to investigate biodistribution.  While much higher levels 
of delivery to the tumor were achieved with the APRPG vector than with the free molecule or with 
nontargeted vectors, higher levels of fluorescent protein were measured in the heart, kidney and 
liver than in the tumor with the targeted nanoparticles. Intratumoral protein expression and tumor 
growth was monitored after in vivo delivery of VEGF silencing siRNA complexed within APRPG 
functionalized polyplexes.  The tumor growth inhibition and VEGF mRNA knockdown achieved 
with the targeted siRNA delivery was significant compared to the PBS treated control but showed 
no improvement over PEI complexed or free siRNA.83  
 The erythropoietin producing hepatocellular A2 (EphA2) receptor is a tyrosine kinase target 
whose expression is limited to activated adult blood vessels and several tumor cells, including 
breast, prostate, colon, skin, and esophageal cancers.  The YSA peptide (YSAYPDSVPMMS), 
identified via phage display, is a functional mimetic of ephrin-A  as it has been shown to bind to 
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its receptor, the EphA2 receptor, with a nanomolar Kd and to stimulate EphA2 receptor signaling.84 
Blackburn et al coupled the YSA peptide to the surface of poly(N-isopropylmethacryl amide) 
core/shell nanogels (nanogels with different polymer compositions within the core and the outer 
shell) to improve targeted delivery of siRNA to ovarian cancer cells.85  
 The targeted nanogels exhibited high siRNA encapsulation efficiencies and retention (66% after 
36 hours in serum) and low cytotoxicity.  When EGFR specific siRNA was encapsulated within 
the YSA functionalized nanogels and delivered to ovarian cancer cells, up to an 80% reduction in 
EGFR expression was achieved, and significant gene silencing was maintained for up to 120 hours.  
The specificity of the targeted nanogel was confirmed through delivery to EphA2 positive and 
negative cell lines, resulting in low delivery and gene silencing in EphA2 negative cells.  Since 
EGFR expression has been found to be closely related to chemosensitivity in cancer cells, the effect 
of EGFR silencing on docetaxel induced cell death using the targeted nanogel encapsulated siRNA 
was investigated. An 8 fold increase in sensitivity to docetaxel induced cell death was observed 
with this targeted gene therapy, and controls performed with YSA peptide and with YSA-nanogels 
not loaded with siRNA caused a less significant increase in sensitivity.  This could be caused by 
the interactions between the EphA2 receptor and EGFR.85,86  
 An N-terminal fragment of human high mobility group protein 2 (HMGN2) that selectively binds 
to both bonemarrow endothelial progenitor cells and tumor vasculature was identified via phage 
display of complimentary DNA libraries generated from mRNA using reverse transcriptase.87  This 
peptide, designated the F3 peptide (AKVKDEPQRRSARLAKPAPPKPEPKPKKAPAKK), binds 
nucleolin expressed on the surface of rapidly growing tumor cells and vasculature.  Nucleolin is a 
phosphoprotein which is localized in the nucleolus of cells and plays a role in control of ribosomal 
DNA transcription, ribosomal RNA maturation, and transport between the cytoplasm and nucleus.  
It has been shown that the amount of nucleolin is highly elevated in rapidly proliferating cells, such 
as cancerous cells and virus harboring cells.88–91  More recently, it has been shown that nucleolin 
localizes on the cell surface in several cancer cell lines and that it acts as a receptor for cytokines 
and the HIV virus.92 Cell surface nucleolin of cancerous cells readily binds and internalizes the F3 
peptide trafficking it to the cell nucleus, making F3 an ideal targeting molecule for gene therapy 
applications.93  Derfus et al utilized the F3 peptide to functionalize PEGylated quantum dots to 
deliver siRNA to HeLa cells, resulting in 30% knockdown in the target protein expression.94  
Another tumor vasculature homing peptide was identified from in vivo phage display and 
termed the NGR peptide (GNGRGGVRSSSRTPSDKYC). The molecular target of this peptide was 
not known at the time, though the binding affinity of NGR to integrins was significantly lower than 
that of RGD-containing peptides.95  The molecular target for the NGR peptide was later identified 
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as aminopeptidase N (also called CD13), a membrane protein expressed in endothelial cells and 
macrophages involved in chemokine processing and invasion.  CD13 expression has been shown 
to be limited to tumor blood vessels and vasculature undergoing angiogenesis.96 NGR 
functionalized LPD (lipid-polycation-DNA) nanoparticles have been shown to increase 
transfection efficiency and to decrease nonspecific accumulation in the liver, kidneys, and other 
organs indicating that the NGR  peptide preferentially binds CD13 and is a promising homing 
peptide for angiogenic tumor vasculature.97 
 
Figure 7. Transfection efficiency of dual ligand PEI polyplexes targeted to transferrin receptor and αvβ3. 
Transfection efficiency was measured by luciferase activity of B6- and RGD- dual targeted polyplexes 
(B6&RGD) vs. B6- or RGD- single targeted polyplex formulations and nontargeted (PEI) and nontargeted 
stealth (PEG) polyplex formations in DU145 (transferrin+ and integrin+) and PC3 (transferrin + and integrin 
-) cells. Reprinted from (8).Copyright (2011), with permission from Elsevier. 
 
 The rapid cell division characteristic of cancerous tumors leads to an increased metabolic 
demand; as a result of increased oxygen consumption, expression of transferrin receptors is often 
upregulated on tumor cells.  The B6 peptide (CGHKAKGPRK) was identified via phage display 
and was able to bind to transferrin receptors with high affinity.98 Nie et al created B6-RGD dual 
targeted PEI polyplexes for the delivery of siRNA to prostate cancer cells in vivo.  The dual 
targeting was intended to improve transfection efficiency and specificity of delivery.  It was 
observed that the B6 peptide mediated the majority of polyplex internalization while integrin 
mediated internalization via the RGD binding sequence played only a minor role in this system.8 
Dual targeting of DNA polyplexes improved their transfection efficiency almost 4 fold compared 
to the single ligand complexes and 60 fold compared to nontargeted complexes, in a prostate cancer 
cell line with high expression of both target molecules (Figure 7).   The results of the competition 
and internalization assays performed suggested a synergistic targeting method, where the RGD 
peptide mediated cell association, and cell uptake occurred primarily through the B6-transferrin 
receptor interactions. 
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Figure 8. VEGF silencing from siRNA delivery using LHRHR targeted PEGylated polyplexes. 
A) Modified LHRH peptide. Modifications are labeled and highlighted B) VEGF silencing in LHRHR 
positive (A2780) and LHRH negative (SK-OV-3) human ovarian carcinoma cells compared to untreated 
control. Cells were transfected with anti-VEGF siRNA in targeted (siRNA/PEG-LHRH/PEI) and nontargeted 
(siRNA-PEG/PEI) complexes. Reprinted with permission from (108). Copyright (2008) American Chemical 
Society. 
 
 Three heparin binding peptides previously identified in the literature to improve internalization 
and transfection efficiency of star-PEG polyplexes were investigated as potential ligands for gene 
delivery.  By substituting the lysine residues of the heparin binding domain of platelet factor 4 
(PF4) into the GCN4 leucine zipper, a peptide called PF4zip (CGGRMKQLEDKVKKLLKKN 
YHLENEVARLKKLVG) was produced that successfully reproduced the natural heparin binding 
affinity of PF4.99–101  A heparin interacting peptide analogue, HIP (CRPKAKAKAKAKDQTK), 
was identified by analysis of sequence homology of mouse, rat, and human heparin binding proteins 
to deduce the functional heparin binding sequence.102 The third peptide used was the K121-A134 
heparin binding segment of the antithrombin III protein and was designated ATIII 
(CK(βA)FAKLAARLY RKA).103,104 Star-shaped PEG polyplexes functionalized with PF4zip and 
HIP were found to increase the heparin affinity and cellular internalization of the polyplexes 
compared to PEI, while functionalization with the ATIII peptide was found to be very cytotoxic to 
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hamster kidney cells (BHK-21).105 The high internalization rates of the PF4zip and HIP targeted star 
PEG polyplexes did not mediate efficient transfection compared to PEI alone, suggesting that 
improving internalization does not necessarily augment transfection efficiency. 
 For some types of cancer, hormone receptors are promising targets for specific gene delivery.  
Luteinizing hormone releasing hormone (LHRH) receptors are expressed on breast, ovarian and 
prostate cancer cells but not expressed in healthy visceral organs.  The activity of the native LHRH 
decapeptide is limited due to rapid degradation by potent enzymes present in the hypothalamus, the 
site of release, and the pituitary, the site of action.106 These enzymes have been shown to 
preferentially cleave LHRH at the Gly6-Leu7 bond.  To increase the potency of LHRH signalling a 
LHRH peptide analogue was developed, replacing the Gly6 residue with a D-Lys residue to slow 
enzymatic degradation ((pyroE)HWSY(D-K)LRP(amide)) (Figure 8a).107,108 This LHRH peptide 
has been used in targeted, PEGylated dendrimers and polyplexes for the delivery of siRNA. The 
presence of the LHRH peptide significantly increased the gene silencing abilities and the specificity 
of siRNA stealth nanoparticles to LHRH positive and negative cell lines (Figure 8b).109,110  
Gene Therapy Targeted to the Central Nervous System for the 
Treatment of Neurological Diseases 
 While palliative treatments exist for many neurodegenerative diseases, including Parkinson’s, 
Alzheimer’s and Multiple Sclerosis, neural-targeted gene delivery offers the possibility of new 
curative treatments.  Inducing the expression of enzymes found within the dopamine production 
pathway or delivering genes encoding glial cell line-derived neurotrophic factor has improved 
behavior in mouse models of Parkinson’s111–113 and the viral transduction of growth factors has 
been used for neuroprotection in a Huntington’s disease model.114 Neuronal transfection must 
overcome the additional challenges of crossing the blood brain barrier and internalizing and 
trafficking within polarized, morphologically elongated cells, challenges that could be solved with 
receptor-ligand targeting.10  Several peptides which specifically bind neural cells with high affinity 
have been identified and used to improve targeted delivery of plasmid DNA and siRNA.   
 One approach to gene delivery for neurodegenerative diseases targets peptides to receptors 
specifically expressed in various brain cell types.  Neuronal cells in the central nervous system 
(CNS) express the potential neural target, neurotrophic tyrosine kinase receptor (TrkA).  Binding 
of nerve growth factor (NGF) to TrkA causes dimerization and autophosphorylation of the tyrosine 
residues in TrkA which results in a transduction of activation signaling.115  Studies of the structure 
of NGF, including site-directed mutagenesis and crystal structure analysis, have identified several 
regions responsible for binding TrkA; the N-terminus, hairpin loop2, and loop4.  Small peptide 
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mimetics of the loop4 region were explored as ligands for TrkA, and several have been shown to 
bind and activate TrkA and promote neurotrophic effects similar to NGF.116,117  The cyclic 29 amino 
acid sequence of loop4 (C80-C108), termed NL4, was modified with a 10 Lysine (10K) tail to 
facilitate DNA binding and condensation.  It was confirmed that the NL4 peptide maintained the 
biological function of NGF as well as its binding capabilities. The NL4-K10 complexed DNA 
delivered to TrkA positive cells achieved marked improvement in specific transfection, but only 
when delivered with an endosomolytic agent.118 Condensation with PEI eliminated the need for the 
addition of an endosomolytic agent.118,119  
 
Figure 9. DNA delivery to the brain via leptin receptor targeted, PEGylated pLL polyplexes. 
The in vivo distribution of labeled DNA intravenously administered and delivered within A) unPEGylated 
nontargeted nanoparticles and B) PEGylated nanoparticles functionalized with the leptin 30 peptide. Images 
were taken 80 min after injection. Reprinted from (120). Copyright (2010), with permission from Elsevier. 
  
 Another potential target for delivery to the nervous system is leptin, a 16 kDa hormone secreted 
by adipocytes, which is involved in regulation of appetite and metabolism through leptin receptor 
binding in the hypothalamus and other regions of the brain.  The high molecular weight of leptin 
prevents its passive diffusion across the blood brain barrier. Thus, to explain leptin accumulation 
in the brain, leptin receptor mediated transport across the blood brain barrier is thought to be a 
possible mechanism of transport.  Barret et al identified the leptin30 peptide, comprised of amino 
acids 61-90 in the native leptin protein, which specifically binds leptin receptors in the 
hypothalamus and brain with a higher affinity than other leptin derived peptides studied.120 
PEGylated pLL nanocarriers functionalized with the leptin30 peptide improved the transfection 
efficiency and specificity of delivery of plasmid DNA in vitro and in vivo.121 Intravenous 
administration of leptin targeted DNA pLL dendrimers into mice resulted in significant delivery 
and transfection within the brain compared to nontargeted dendrimers (Figure 9). Protein 
expression measured in the brain of the mice that received leptin-targeted nanoparticles was twice 
that measured in the control mice. Biodistribution of the gene delivery vehicle was measured in 
major organs, showing that the extent of transfection was unaltered by the targeting peptide in liver 
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and spleen and was decreased in the kidney. High levels of transfection were measured in the heart 
with the delivery of unPEGylated, nontargeted nanoparticles but these levels were decreased with 
PEGylation and by the addition of the leptin30 peptide, indicating that the accumulation in the heart 
was caused by the DNA dendrimers.121  
 The neural acetylcholine receptor (AChR) has been targeted for gene delivery with the RVG 
peptide (YTIWMPENPRPGTPCDIFTNSRGKRASNG) derived from the native CNS specific 
rabies virus (RV) glycoprotein.  The RV glycoprotein is responsible for cell attachment and 
internalization of the virus, and studies of infection progression have shown that the rabies virus 
localizes in regions containing high densities of acetylcholine receptors.122,123 Neurotoxins from 
snakes are known to bind with high affinity to the nicotinic AChR, and homology studies have 
revealed conserved sequences and similarities between snake venoms and the RVG peptide.124  
Lentz et al showed that the RVG peptide sequence competitively and specifically bound to nicotinic 
acetylcholine receptors.125,126 Alvarez et al designed AChR targeted exosomes for gene delivery 
using the RVG peptide.127  Exosomes are vesicles that can be released by cells for intracellular 
communication.  They have been found to deliver functional mRNA from one cell to another and 
are therefore hypothesized to be a potential cell derived nonviral gene delivery vehicle.128  
Exosomes were isolated from dendritic cells which had been stably transfected to express Lamp2b-
RVG fusion proteins as exosome cell surface markers.  The RVG functionalized exosomes 
significantly improved siRNA delivery and gene silencing in neuronal cells (Neuro2a), comparable 
to the knockdown achieved with lipofectamine.127  Immunological tolerance was evaluated both in 
vitro, with a mixed splenocyte reaction measuring lymphocyte growth after RVG exosome 
addition, and in vivo, by monitoring the change in expression of immunostimulatory molecules. 
RVG exosomes did not trigger T cell proliferation in vitro and caused no significant change in the 
expression of immunostimulatory molecules monitored, suggesting that the targeted exosomes are 
highly immunologically tolerable.127 In vivo gene delivery and biodistribution of the targeted 
exosomes was compared to naked siRNA targeting a model gene (GAPDH) which silenced 
approximately 50% of its target mRNA in liver, spleen, and kidney, and caused no significant 
silencing in brain, muscle or heart.  When the siRNA was delivered within the RVG functionalized 
exosomes, mRNA silencing was achieved only in the brain and the kidney.  The siRNA targeted 
protein expression, however, was not found to be significantly silenced, even after two doses of the 
targeted siRNA delivery.127  Significant protein expression silencing was achieved when the target 
protein was BACE1, an enzyme responsible for β-amyloid generation and thought to be significant 
in Alzheimer’s pathology.129  In addition, β-amyloid levels were significantly decreased, suggesting 
therapeutic potential for this gene delivery system.127  
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Figure 10. Transfection within the brain using AChR targeted polyplexes.  
Luciferase expression measured in different tissues at 24, 48, 72 and 120 hours after intravenous 
administration of RVG-targeted polyplexes into mice. Reprinted from (129). Copyright (2012) with 
permission from Elsevier. 
 
 The RVG peptide was also used as a ligand to target plasmid DNA delivery to the brain.  Gong 
et al conjugated the RVG peptide to a polyhistidine buffering peptide and a polyarginine DNA 
binding peptide and complexed this multifunctional peptide to plasmid DNA.  This targeted peptide 
DNA complex achieved higher levels of transfection in Neuro2a cells than DNA delivered with 
lipofectamine, an improvement over the in vitro results seen with RVG-targeted exosomes.130  This 
enhanced transfection compared to lipofectamine appears to be from its superior endosomal escape 
capabilities. Highly specific in vivo transfection was also achieved with this targeting peptide. 
Biodistribution of reporter gene expression was measured in six different organs, and expression 
within the brain was approximately 5-6 fold that in all other organs (Figure 10).130  
 The Tet1 peptide (HLNILSTLWKYRC) was identified by screening a 12mer phage peptide 
library on trisialoganglioside (GT1b), and eluting with tetanus toxin fragment C (HC).  Fragment C 
of tetanus toxin is known to specifically interact with motor neurons through interaction with GT1b, 
a major component of neural cell membranes.  The Tet1 peptide binds with high specificity and 
high affinity to GT1b positive cells, such as primary motor neurons and dorsal root ganglion cells, 
but unlike the tetanus toxin, Tet1 is non-toxic.131  Another neuron-targeted ligand is neurotensin 
(NT), a short neuropeptide which is rapidly internalized upon binding to its high affinity receptor, 
neurotensin receptor which is specifically expressed on motor neurons.132 Both Tet1 and NT 
peptides have been used to functionalize PEI nanoparticles and both peptides have been shown to 
improve the transfection efficiency of PC-12 cells undergoing neuron-like differentiation induced 
by NGF, though Tet1 conjugated PEI (Tet-PEI) performs better.133,134  Tet1-PEI modified with a 
membrane lytic peptide increased transfection 2 fold over Tet1-PEI and 1000 fold over unmodified 
PEI.134 Neither Tet nor NT successfully improved transfection efficiency or specificity in mature 
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neurons or NGF-differentiated PC-12 cells, indicating that these peptides may not be useful for 
targeted gene delivery in adult disease states.133,134  Oliveira et al found that thiolated PEI 
conjugated to tetanus toxin fragment C via a bifunctional PEG spacer improved transfection 
efficiency in fully differentiated neurons and dissociated dorsal root ganglion cells.135 Though Tet1 
and HC peptides competitively bind to the same target, HC functionalized polyplexes achieved 
transfection in primary neuron cells while Tet1 and NT functionalized polyplexes could not.  It was 
suggested that the ability of the HC peptide to traffic to the neuronal cell body via retrograde axonal 
transport facilitates this improvement in transfection.135–137  
Peptide Targeted Gene Therapy for the Treatment of Cystic Fibrosis 
 Cystic fibrosis (CF) is a recessive genetic disorder characterized by the lack of a functional cystic 
fibrosis transmembrane regulator (CFTR) gene.  The lack of CFTR causes abnormal chloride and 
sodium ion transport in epithelial cells, resulting in thick viscous mucosa secretions which inhibit 
normal respiratory and digestive functions.  The replacement or supplementation of this CFTR gene 
is a promising therapy for the treatment of cystic fibrosis.138,139  
 McKay et al used a secretin receptor (SR) targeted cationic polyplex system to improve delivery 
and transfection efficiency of plasmid DNA delivered to modified SR-expressing CHO cells.  SR 
is specifically expressed on biliary and pancreatic duct epithelial cells, the same cells that normally 
express CFTR in the non-disease state.  Another feature of this targeting system attractive for gene 
delivery is the rapid internalization of the secretin-SR complex into endosomes.140  The C- and N- 
termini of the secretin have no secondary structure and the N-terminus is responsible for the high 
SR affinity, leaving the C-terminus free for manipulation and conjugation.141  McKay et al used 
full length secretin with a GGC spacer at the C-terminus where the neutral glycines act as a physical 
spacer between the bioactive sequence and the charged DNA binding region, and the cysteine was 
required to form a disulfide linkage with linear PEI 
(HSDGTFTSELSRLRDSARLQRLLQGLVGGC-PEI).140 When compared to plasmid DNA 
transfection with nontargeted linear PEI, the secretin-conjugated PEI improved transfection in cells 
expressing the secretin receptor, and actually inhibited transfection in cells not expressing the 
secretin receptor, causing 10 fold transfection efficiency improvement in SR expressing cells over 
the control cell line.140  This suggests that specific targeting could be achieved when delivered in 
vivo. 
 The α9β1 integrin is another attractive target for gene therapy treatment of cystic fibrosis because 
it is expressed on epithelial cells of the upper airways.  Yokosaki et al identified the tenascin peptide 
which specifically binds the α9β1 integrin via substitution mutagenesis of the third fibronectin type 
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III repeat in the tenascin-C (TNfn3) protein.  Alanine residues were sequentially substituted for 
acidic residues in or adjacent to the exposed loops of the expected structure as determined by the 
solved crystal structure of TNfn3.  Only substitutions in the B-C loop region resulted in a marked 
reduction in the attachment of α9β1-expressing cells, indicating that this region is critical to α9β1 
integrin binding.142  Peptides based on the human sequence of the exposed A-B and B-C loops of 
TNfn3 were evaluated for their ability to block adhesion of α9-transfected SW480 cells to wild type 
TNfn3. The AEIDGIEL sequence was identified as the only sequence to effectively block the α9β1 
integrin and inhibit binding to wild type TNfn3.142  The sequence PLAEIDGIELTY was also 
identified by Schneider et al by screening a phage library of overlapping regions of human TNfn3 
and by competitive binding inhibition assays.143 The tenascin peptide sequence (PLAEIDGIELA) 
has been used in lipid based nanoparticle carriers to improve specificity of delivery and transfection 
efficiency of tracheal cells.144 Incorporating the tenascin peptide into DNA lipoplexes increased 
transfection in both α9-integrin expressing and non α9-integrin expressing cell lines. Some 
improvement to specificity was achieved by altering the overall particle charge, but nonspecific 
cell association was still significant.145  
 Several peptide sequences have been identified via phage display of a CX7C disulfide-
constrained peptide library against human airway epithelial cells.  The most frequent phage clones 
were peptide E (GACSERSMNFCG) and peptide Y (GACYGLPHKFCG), both of which were 
analyzed with Basic Local Alignment Search Tool (BLAST) to identify similarities between the 
peptide sequences and known protein sequences.146  Peptide Y resembles a protein of the respiratory 
pathogen legionella pneumophila whose function and receptors are not yet known; peptide Y was 
found to improve transfection efficiency in multiple cell types, including human microvascular 
endothelial cells, human keratinocytes, human fibrosarcoma, and rabbit adventitial fibroblasts.146 
Peptide E shares similarities with the receptor targeting proteins of the respiratory pathogens 
rhinovirus and listeria monocytogenes known to bind intercellular cell adhesion molecule 1 
(ICAM-1).146 In vitro delivery of siRNA lipoplexes targeted with peptide Y resulted in 80% 
knockdown in the expression of the gene of interest, compared with only 20% with nontargeted 
siRNA.147  Manunta et al investigated the aerosolisation of peptide E functionalized plasmid DNA-
lipid nanoparticles for nebulized inhaler delivery and subsequent transfection within the upper 
respiratory tract of mice.  These targeted lipoplexes achieved significant transfection within the 
tracheas of mice treated with nebulized nanoparticle solutions.148  
Peptide Targeted Gene Therapy for Additional Disease Treatment 
 Corneal transplantation as well as corneal disorders stand to benefit from targeted gene therapies.  
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For example, graft rejection could be limited by the expression of soluble tumor necrosis factor 
alpha (TNF-α) receptors or interleukin-10 (IL-10).149,150  Expression of the enzyme β-glucuridonase 
has been used to treat corneal clouding caused by mucosaccharidosis, genetic transfer of the genes 
for interferon alpha-1 (IFNα-1) and interleukin-2 (IL-2) can prevent herpes-simplex virus 
reinfection and keratitis, and pathological angiogenesis within the cornea can be prevented with 
gene therapy using a soluble VEGF receptor.151–153 The use of viral vectors for these treatments has 
been known to trigger immune response, indicating that they would greatly benefit from the 
development of efficient nonviral vectors for corneal gene therapy.149  
 The molossin peptide is a cyclic, RGD-containing peptide derived from pit viper venom 
(ICRRARGDNPNNRCT) which has been shown to bind the αvβ3 and α5β1 integrins.154  Collins et 
al used the molossin peptide in a bifunctional peptide with a pLL chain for electrostatic 
condensation of DNA (K16–ICRRARGDNPNNRCT) to target corneal epithelial cells.  The 
bifunctional peptide was used in combination with a membrane disrupting peptide to deliver 
plasmid DNA to corneal cells; however, the control systems with K16-RGE peptide performed as 
well as the molossin peptide, indicating that integrin specific internalization was not the mechanism 
responsible for improved gene delivery.155  
 Gene therapy also has the potential to treat osteoarthritis caused by cartilage degradation.   It has 
been suggested that gene expression of various growth factors, bone morphogenic proteins or 
regulatory transcription factors, which cannot easily be delivered in their soluble form to cells, or 
the inhibition of certain inflammatory cytokines could prevent cartilage degradation and even 
encourage chondrocyte matrix restoration.  Targeted gene therapy to chondrocytes, synovium and 
bone derived mesenchymal stem cells could be useful for this application.156,157  
 A cartilage affinity peptide CAP (DWRVIIPPRPSA), was identified via phage display 
biopanning of a peptide library against rabbit cartilage, with negative selection procedures against 
synovial tissue.  The phages identified via tissue biopanning and negative selection were then put 
through rounds of cell biopanning against isolated chondrocytes.  The combination of tissue and 
cell biopanning yielded the CAP peptide with both tissue specificity and high cell affinity. The 
peptide was subsequently evaluated for species specificity through primary human cell binding 
measurements and was found to exhibit high affinity and specificity for human as well as rabbit 
cartilage.158  
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Figure 11. CD13 targeted polyplexes designed for delivery to dendritic cells.  
Transfection efficiency was measured by β galactose expression of plasmid DNA delivered within 
nontargeted, unPEGylated complexes (SHA-PEI/pDNA), nontargeted, PEGylated complexes (PEG/PDBA-
SHA-PEI/pDNA) and targeted, PEGylated complexes (NGR/PEG/PDBA-SHA-PDNA). Reprinted from 
(160). Copyright (2006), with permission from Elsevier. 
 
 The CAP peptide was conjugated to PEI for DNA complexation and subsequent in vivo delivery 
to rabbits for cartilage-targeted gene delivery.  Transfection efficiencies of CAP-functionalized and 
scrambled peptide-functionalized vectors were compared between cartilage and synovium 2-7 days 
after in vivo administration.  The highest transfection efficiency was achieved after 96 hours. The 
targeted DNA complex exhibited 9 fold higher transfection than the scrambled peptide DNA 
complex in harvested cartilage and both complex types achieved significantly lower but 
indistinguishable transfection in the synovium.  The targeted vector fulfilled its design goal of 
specific in vivo gene delivery to cartilage compared to synovium, illustrating its potential for 
delivery of cartilage disorder gene therapy.158  
 Two bone targeting peptides were identified via in vivo phage display in mice; low affinity 
binding (LAB) peptide: NSMIAHNKTRMHGGGSC and high affinity binding (HAB) peptide: 
SGHQLLLNKMPNGGGC.159 Poly(amidoamine) dendrimers were functionalized with LAB and 
HAB peptides and used to compact plasmid DNA.  HAB functionalized dendrimers with 4 and 8 
peptides per dendrimer improved transfection compared to both nontargeted dendrimers and a 
commercial transfection reagent composed of partially degraded dendrimers at 48 hours. Higher 
levels of transfection were achieved with dendrimers with only 4 peptides attached to their surfaces, 
possibly because of a local saturation of the target receptors,157 highlighting the importance of 
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ligand valency optimization.   Using these peptide targeted dendrimer vectors, the specific in vitro 
transfection of multipotent mesenchymal stem cells was significantly improved.157  
 CD13, originally targeted for cancer therapy, is also expressed on dendritic cell precursors and 
on differentiated dendritic cells.160  The NGR peptide (GNGRGGVRSSSRTPSDKYC), identified 
by phage display to specifically target CD13, was therefore used as a targeting ligand for potential 
DNA vaccine delivery to dendritic cells.44,95 DNA microparticles were composed of a 
salicylhydroxamic acid (SHA) derivatized PEI and a NGR peptide conjugated to PEG and 
phenyl(di)boronic acid, then encapsulated within PLGA-PEG-PLGA. These targeted DNA 
microparticles improved transfection compared to nontargeted particles, but more markedly, they 
showed a release profile that extended over weeks, which translates into an extended and increasing 
transfection efficiency as demonstrated in Figure 11.161  
Discussion 
 In order for nonviral gene therapy to become a clinical reality, gene delivery needs to be stable, 
nontoxic, efficient and specific.  To address specificity, several groups have designed nonviral gene 
delivery vehicles coupled with peptide targeting ligands.  These targeting peptides have been 
designed and selected for tumor associated receptors, epithelial cells, endothelial cells, cartilage 
tissue, neuron specific receptors and various other targets. They have been used directly or modified 
with amino acids to act as linkers to vector molecules, to mimic natural ligand spacing, to prevent 
degradation or to increase solubility.  The overwhelming impact of cancer has encouraged countless 
groups to target malignant tissue for gene therapy.  Cancer cells provide many useful receptors for 
peptide targeting, as the disease state causes abnormal upregulation of many cell surface molecules.  
The highly proliferative nature of tumor tissue allows for easier access to the nucleus which can 
facilitate transfection efforts.  Peptide targeted gene delivery has therefore seen much success in in 
vitro and in vivo models of cancer states. Targeted gene delivery to the CNS provides additional 
challenges to effective transfection, but a few peptide targeted vectors have addressed these 
obstacles.  Cystic fibrosis is an appealing application for peptide targeted gene delivery because it 
is caused by a single genetic loss, is localized to a particular tissue type, and has seen success in 
vivo with nebulized, targeted nanoparticles.  A few carefully designed phage display investigations 
have identified useful peptides for bone and cartilage targeting.   
 Plasmid DNA encapsulated within liposomes bearing the integrin targeting PR_b peptide 
achieved highly specific in vivo tumor targeting.  The PR_b peptide has been designed for superior 
integrin binding and uptake over the many RGD peptides, because it combines the natural RGD 
binding site with the synergy site found within fibronectin.67,69–71  Combining this improved integrin 
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binding peptide with highly stable PEGylated liposomes encapsulating PEI condensed DNA with 
endosomal escape abilities resulted in an extremely effective in vivo gene delivery system.79  YSA 
functionalized nanogels, peptide Y functionalized lipoplexes and LHRH peptide functionalized 
dendrimers achieved 80% or higher specific target gene knockout with delivery of siRNA in 
vitro.85,110,147,148  Both YSA and peptide Y were identified by phage display but are functional or 
sequence mimetics of different ligands. The LHRH peptide is a native ligand with a few careful 
modifications to increase its stability which provided exceptional gene therapy targeting.106,107 
Peptide E functionalized lipoplexes were also successfully used to transfect the airways of CF 
model mice.148  The biomimetic neuron targeting peptide RVG preferentially delivered plasmid 
DNA to tumor tissue.127 These targeted vehicles all have great potential for further development 
and clinical success.   
 Each in vivo study was precluded by extremely successful in vitro results indicating specific 
augmented transfection.  However, positive in vitro results do not always translate into positive in 
vivo results, as seen with the gene delivery work by Lu et al and Nui et al, emphasizing the 
importance of in vivo biodistribution studies to analyze tissue specificity, as nonspecific delivery 
can result in poor therapy.32,83 With respect to increased specificity, the peptide CAP, identified 
for delivery to cartilage while avoiding synovial tissue, achieved through negative selection 
screening, highlights the advantages of negative selection to avoid nonspecific delivery.158  
Combining two ligands to target tumor cells improved the targeting capabilities of DNA 
polyplexes, suggesting the potential improvement of any of these delivery vehicles by combining 
more than one ligand on one vehicle.8  
 Each disease or tissue however comes with unique challenges.  Receptors upregulated and unique 
to cancer cells often stimulate proliferative effects when activated with their native ligands. 
Targeted peptides that exhibit antagonistic behaviour will block these stimulatory effects and can 
be used as inhibitory drugs.  Cyclic RGD peptide, for example, has been used as an antagonist for 
endothelial cell angiogenesis in a tumor vasculature model, because it prevents binding and 
angiogenic signalling between vitronectin and the αvβ3 integrin.162  As ligands for gene delivery 
vehicles, a peptide’s ability to block binding and signalling from the native ligand is much less 
important than the affinity and subsequent internalization of the peptide and its load.  It is important, 
however, that the targeting peptide has no agonist action and is nonmitogenic. This is the case for 
the peptides developed to target the growth factor receptors FGFR and EGFR.  FGF stimulates 
proliferation upon binding with its native receptor FGFR, but the rate of proliferation of cells in the 
presence of the MC11 FGFR binding peptide was no different than that of untreated cells.33  EGF 
also activates mitogenic pathways upon binding with its receptor, EGFR, but the EGFR binding 
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peptide GE11 was found to have no cell growth stimulating ability.39  In addition to limiting 
mitogenicity, both peptides exhibited high affinity for their respective receptors (in the nanomolar 
or sub-nanomolar range) and were extremely successful gene targeting peptides.33,34,36,39–41 
Biodistribution of phage display identified MC11-functionalized star shaped copolymers and phage 
display identified GE11 functionalized PEI that showed clear transfection specificity for tumor over 
healthy tissue, while the MC11 star shaped copolymers provided significant therapeutic benefits to 
a tumor mouse model.36,39,40 These growth factor receptors present a valuable gene delivery target 
because they both hold important nuclear functions such as to interact with transcription factors, 
and are therefore trafficked to the nucleus after endocytosis.163,164  Since plasmid DNA must 
localize to the nucleus for transfection to occur, association with these nuclear-localized receptors 
enhances transfection efficiency more than simply increased cell association would. 
 Gene delivery vehicles transfecting neurons must overcome the added intracellular barrier of 
traversing the axon to reach the nucleus;165 and neurons and other noncancerous cell types are often 
post-mitotic which limits access to the nucleus by delivered DNA. Delivery vehicles targeting the 
CNS in vivo have the added obstacle of penetrating the blood brain barrier (BBB).166  Leptin30, 
identified from the leptin protein which is known to be taken up into the brain, can cross the BBB 
and localizes within the parenchyma of the brain. The in vitro investigation of the leptin30 
functionalized dendrimers was performed with a model primary neuron cell line, and positive 
results with this model combined with a peptide designed with the in vivo challenges in mind, 
translated to successful in vivo transfection.121  PEI functionalized with Tet1 or NT peptides, though 
they could transfect PC-12 cells undergoing differentiation, did not successfully transfect fully 
differentiated PC-12 cells or primary neurons. However, a similar vector with a different neuron 
targeting peptide, HC peptide, significantly improved transfection in differentiated neurons and 
primary ganglion cells.133–135,167 The HC and Tet1 peptides traffic rapidly toward the cell body 
where the neuronal nucleus is contained, using retrograde axonal transport that avoids late 
endosomes and lysosomes.168 This transport ability could indicate the superior performance of these 
peptides compared to NT. The HC peptide was combined with thiolated PEI complexes, a vector 
designed to readily release DNA within the reducing intracellular environment.169 The HC 
peptide’s ability to traffic towards the nucleus combined with the ability of thiolated PEI to release 
its cargo within the cell accounts for the exceptional neuronal transfection achieved with this vector. 
 The results of the last ten years in peptide-targeted gene delivery have proven that efficiency and 
specificity are closely intertwined.  Carefully designed peptides do not necessarily achieve positive 
results with every gene delivery vector. For example, lipoplexes functionalized with an integrin 
targeting peptide c(RGDfK) achieved 1000 fold lower transfection efficiency than nontargeted PEI, 
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but c(RGDfK) functionalized chitosan nanoparticles encapsulating siRNA provided therapeutic 
effect that reduced 71% of tumor weight compared to controls when delivered to tumor mouse 
models.12,55 Chitosan is thought to mediate a simultaneous escape from intracellular vesicles and 
decondensation with nucleic acids, releasing its genetic cargo into the cytosol.170  When the gene 
therapy consists of gene silencing siRNA, the nucleic acids need only to be released into the cytosol 
to be functional, so condensation within chitosan which mediates efficient cytosolic release and 
targeting with an RGD peptide is therapeutically effective.  The transfection efficiency of the RGD 
functionalized lipoplexes was enhanced with the addition of a lysosomotropic agent, indicating that 
the targeted lipoplexes alone were limited by their lack of this intrinsic function. The same targeting 
peptide performed so poorly with one vector and so successfully with another because gene 
delivery involves several potential rate limiting steps and each one is important to consider when 
designing an efficient gene delivery vehicle. The addition of a lysosomolytic agent to the media for 
in vitro gene delivery with SIG labeled polyplexes resulted in significant improvements in 
transfection,57 and condensation with PEI of NL4 peptide polyplexes eliminated the need for 
additional endosomolytic agents.60,105,118,119 Both of these examples suggest that endosomal escape 
may be an important aspect of many targeted vectors.   
 In other instances, peptides that achieve highly efficient, specific internalization do not always 
translate to high levels of transfection.  In certain cell types, SIG labeled polyplexes achieved high 
levels of internalization but low levels of transfection.57  The addition of endosomolytic agents had 
no effect on transfection, indicating that an inability to traffic to or penetrate the cell nucleus was 
the barrier to efficient SIG-mediated gene therapy.  Star polyplexes functionalized with several 
heparin binding peptides exhibited higher levels of internalization than nontargeted PEI, but with 
several different targeting vector compositions could not achieve even 100 fold less transfection 
than nontargeted PEI.60,105  The star polyplexes in this investigation are composed only of PEG, 
with no intrinsic vesicle escape function or intracellular trafficking mechanism.  Though the vectors 
are efficient for targeted delivery, they have no mechanism for reaching the cell nucleus and did 
not mediate highly efficient transfection.105  
 Once gene delivery vehicles bind and internalize within a target cell, the nucleic acids must often 
be released from both the intracellular vesicle and the vehicle.  Plasmid DNA must also travel to 
and enter the nucleus.  The mechanisms of transport and escape strongly depend on the ligand-
receptor interactions and subsequent internalization pathway.  Gene delivery with EGFR or FGFR 
needs no endosomal escape ability, because the growth factor receptors travel directly to the 
nucleus.  Most of the receptors targeted with the peptides in this review are internalized primarily 
via clathrin mediated endocytosis53,171–189 which eventually traffics to endosomes and lysosomes.  
 31 
 
The transferrin receptor, for example, is internalized via clathrin mediated endocytosis, requiring 
peptides targeted to transferrin to be combined with gene vectors with efficient endosomal escape 
capabilities such as the PEI polyplexes used with the transferrin receptor targeting peptide B6.8 
LHRH has been shown to internalize via caveolae190 which may not traffic to vesicles with low pH 
such as late endosomes and lysosomes, so that PEI, which relies upon low pH for its escape 
mechanism, may be unnecessary.  EphA2, AChR, Secretin, and ICAM-1 internalize via caveolae- 
and clathrin-independent internalization mechanisms.191–194  Pairing appropriate gene delivery 
vehicles with peptide ligands targeting these receptors may be more challenging since much less 
characterization of the mechanisms and subsequent intracellular trafficking of these more recently 
described internalization schemes has been done.  
 Efficiency and specificity could be simultaneously improved by carefully pairing vectors and 
ligands that exploit the cell’s natural intracellular trafficking pathways. Unfortunately, our 
knowledge of intracellular trafficking and vesicle and vector release are still very limited, 
preventing the implementation of well characterized targeting peptides with consistently successful 
transfection agents.19,170,195,196 We continue to improve each piece of the gene delivery vehicle 
separately, but what is really needed to advance gene delivery into the clinic is intelligent, 
integrated design methods.   
Conclusions 
 Peptide targeting has been used to improve nonviral gene delivery for several disease states that 
could potentially be treated with gene therapy. The applications for targeted gene delivery include 
cancer therapy, genetic treatment for central nervous system diseases, genetic correction of cystic 
fibrosis and a few other tissue specific disorders, with cancer applications receiving the most 
attention.  The addition of a targeting peptide to the surface of a gene delivery vehicle often results 
in an increase in transfection and cell specificity, with the best formulations achieving efficiently 
targeted in vivo gene expression localized to the target tissue and even positive therapeutic results.  
These successful targeting peptides were identified via phage display to particular receptors, cells 
or tissues or designed via biomimetic function and sequence of natural ligands. The method of 
discovery, choice of target, affinity and specificity of each of these peptides was discussed with 
respect to its gene transfection potential and ability.  It was found that the most successful gene 
delivery vehicles utilize a peptide with high affinity and specificity and take advantage of the 
appropriate intracellular pathways.  Strategic pairing of well characterized peptide ligands with 
effective gene delivery vehicles with respect to the overall route of gene delivery could make 
targeted clinical gene therapy a reality. 
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Chapter 2 Preparation and Characterization of 
Liposome-Encapsulated Plasmid DNA for Gene 
Delivery  
Introduction 
Effective non-viral delivery remains a major obstacle to clinical gene therapy.  Non-viral 
vehicles overcome the issues of toxicity, tumorigenicity and low versatility of viral vectors but still 
struggle to achieve the same high transfection efficiencies.197,198  The nonviral vectors that have 
received the most attention and have been most thoroughly investigated are lipoplexes and 
polyplexes. Lipoplexes and polyplexes consist of cationic lipids, liposomes or polymers that 
electrostatically condense nucleic acids into nanoparticles. However, these charged complexes 
maintain several disadvantages during in vivo delivery including rapid aggregation, high clearance 
from the blood stream and inflammatory toxicity. 197,199  Attempts have been made to improve the 
pharmacokinetics and reduce inflammatory toxicity of these nanoparticles by adding polyethylene 
glycol (PEG) to the surface of the nanoparticle as a stealth moiety.200–202  While this addition has 
been shown to increase circulation time of cationic liposomes, PEGylated neutral liposomes 
containing doxorubicin maintained higher plasma concentration, achieved higher localization 
within the target tissue and delivered more effective therapy in vivo than the  cationic liposomes 
when directly compared.202   
PEG modified liposomes (stealth liposomes) exhibit prolonged blood circulation times and 
avoid aggregation, improving delivery and in vivo distribution and are currently approved for 
clinical use for the treatment of  several cancer types including Kaposi’s sarcoma and ovarian 
cancer.203–205  Stealth liposomes present a potential solution to the disadvantages associated with 
cationic polyplexes and lipoplexes.  They are also easily modified with targeting molecules for 
improved specific delivery.18,20,72,73,77,79,198,206 While cationic DNA lipoplexes have been extensively 
studied,17,63,197,200,201,207–209 DNA encapsulation within neutral PEGylated liposomes has been 
investigated less often.79,210  Previous work has shown that plasmid DNA (pDNA) encapsulated in 
neutral stealth liposomes that were functionalized with a targeting peptide, exhibited efficient and 
specific gene delivery to cancer cells in vitro and in vivo.79 Therefore, further characterization and 
investigation of parameters that can influence pDNA encapsulation in neutral stealth liposomes is 
warranted.  
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Quantification of condensed pDNA encapsulated in liposomes, or other nanoparticles, is 
crucial for appropriate evaluation of the performance of the gene therapy nanoparticles. However, 
no simple and reliable quantification methods have been verified for this gene delivery vehicle that 
has the condensed pDNA encapsulated in a stealth liposome.  On the other hand, most cationic 
lipoplexes undergo no purification, therefore requiring no final quantification.17,63,208,209 Synthetic 
vectors were first quantified for DNA content by measuring radioactivity from radioactively 
labeled nucleotides, which is a reliable method of quantification, however, the associated risk of 
radioactive exposure limit its convenience.210 Ethidium bromide or the PicoGreen DNA 
quantification reagent are often used to measure the extent of condensation of lipoplexes,211,212 as 
they fluoresce when bound to uncomplexed double stranded DNA, but cannot intercalate within 
complexed DNA.  PicoGreen has been used to measure encapsulation efficiency of lipoplexes, 
calculating the encapsulation efficiency using the difference in fluorescence intensity before and 
after addition of the detergent Triton X-100, which releases the complexed DNA.213 However, 
extreme inconsistencies have been identified between PicoGreen analysis and UV absorbance 
measurement of DNA extracted and purified from plant tissues.214  UV spectrophotometric analysis 
is another common DNA quantification tool, but is inappropriate for gene delivery vehicles because 
the method is sensitive to contamination from lipids and polymers.215 Since DNA quantification is 
vital for gene delivery studies with nanoparticles that encapsulate DNA, it was necessary to develop 
and verify a simple, accurate DNA quantification tool for condensed DNA encapsulated within 
stealth liposomes.  Covalently labeled DNA presents a possible improvement to the limitations of 
the current quantification methods. Intracellular imaging of transfected nucleic acids uses covalent 
labeling to visualize DNA and RNA.216  Fluorescently labeled DNA has been used as an alternative 
to PicoGreen and other intercalating dyes for the measurement of complexed DNA released from 
polymer scaffolds.217  A DNA quantification method based on fluorescently labeled DNA was 
developed for liposomal vectors encapsulating condensed DNA and verified for accuracy and 
consistency with radioactively labeled DNA, as well as compared to the commercially available 
PigoGreen reagent. 
Unilamellar liposomes can be produced via several different means, including detergent 
dialysis, ethanol injection and thin film (TF) hydration. The detergent dialysis method begins with 
a solution of mixed micelles that convert to bilayered vesicles as detergent is removed from 
solution.218  It is effective at encapsulating lipophilic drugs within its forming bilayer, and is often 
used to incorporate membrane proteins into bilayers for functional studies.219,220  Detergent dialysis 
is also useful for production of lipoplexes.207 Ethanol injection, which involves injecting ethanol-
dissolved lipids into an aqueous phase to form liposomes, is a simple, easily scalable liposome 
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formulation method, but is more efficient at encapsulating ethanol soluble molecules.221,222  Ethanol 
injection can be used to produce cationic liposomes for later complexation with nucleic acids.223,224 
Since plasmid DNA is neither lipophilic nor ethanol-soluble, these methods are not feasible for 
DNA encapsulated liposome formation.  For TF hydration, liposomes are formed by adding an 
aqueous solution to an adsorbed lipid film, which causes it to swell and detach, forming bilayered 
vesicles.225,226  It is a useful method for encapsulating hydrophilic drugs, and is appropriate for 
DNA encapsulation, however, it relies on the lipid film reforming into vesicles around the DNA, 
so it has to be determined if it is the most efficient DNA encapsulation method.  Two preparation 
methods, reverse phase evaporation (REV) and asymmetric liposome formation, have been 
proposed as alternative encapsulation methods, specifically for gene delivery. REV uses biphasic 
emulsion solvent dispersion, where the encapsulant and the lipid solutions are immiscible, to 
maximize internal aqueous space.  REV has been used for encapsulation of many drugs, including 
small molecules for cancer chemotherapy, antimicrobial oils, and even oligonucleotides.227–229  
Asymmetric liposome preparation is an inverse emulsion method that has been used to encapsulate 
oligonucleotides and siRNA for gene delivery.230,231  These methods were compared to the common 
TF method to determine the most efficient DNA-encapsulating liposome preparation method. 
 Here we describe the optimized preparation and characterization of liposome encapsulated 
plasmid DNA as a nonviral gene delivery vehicle. A simple, accurate DNA quantification method 
was verified for this gene delivery vehicle and the effect of different parameters, such as preparation 
method, lipid content and DNA concentration on DNA encapsulation was also evaluated. This 
analysis provides the basis for production of neutral stealth liposomes for the delivery of plasmid 
DNA for gene therapy. 
Materials and Methods 
Plasmid DNA Labeling and Quantification 
pT2/Cal (7.5 kbp)232 encoding firefly luciferase was the pDNA used throughout this study.  
Fluorescently-labeled pDNA was produced by conjugating Cy5 fluorescent dye to pT2/Cal using 
LabelIT Cy5 nucleic acid labeling reagents (Mirus, Madison, WI) according to the manufacturer’s 
protocol.  The fluorescent label is covalently attached to the DNA through an alkylation reaction 
between the label and the oxygen and nitrogen species within the DNA bases, predominantly with 
nitrogen species in guanine.233,234  Radioactively-labeled pDNA was produced using a nick 
translation kit (Invitrogen, Grand Island, NY) following the manufacturer’s protocol, with a 
reaction replacing deoxycytodine triphosphate (dCTP) bases with [H3] dCTP (Moravek, Brea, 
CA).  pDNA was labeled with approximately 15 mCi/nmol pDNA.  A fluorescent or radioactive 
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DNA concentration standard curve was generated from the condensed pDNA or the pDNA and the 
liposomes at the hydration phase of the thin film liposome preparation process.  Fluorescence 
intensity was measured using a fluorescence microplate reader (Biotek, Winooski, VT) and 
radioactivity was measured using a Beckman LS 6500 liquid scintillation counting (Beckman, 
Fullerton, CA) without liposome release via detergent addition or uncondensation of pDNA via 
heparin.  For quantification using the PicoGreen reagent (Invitrogen, Grand Island, NY), the 
liposome encapsulated pDNA was released from the liposomes by incubation with 0.5 % Triton X-
100 (Sigma Aldrich, St. Louis, MO) and uncondensed by incubation with 5 mg/mL heparin (Sigma 
Aldrich, St. Louis, MO).  The heparin, Triton X-100, branched polyethyleneimine (bPEI) and lipids 
were removed from this sample via dialysis through 1000 kDa MWCO membranes (Spectrum 
Labs, Rancho Dominguez, CA) and the remaining pDNA was quantified with PicoGreen according 
to the manufacturer’s protocol. For all pDNA quantification, only the final purified pDNA 
concentration in the pDNA-encapsulated liposome formulations was quantified.   
DNA Condensation  
pDNA was condensed with 10% fluorescently labeled pDNA and/or 1% radioactively labeled 
pDNA. 20 µg pDNA was dissolved in 10 mM tris-HCl buffer and an equal volume of 25 kDa bPEI 
(Sigma Aldrich, St. Louis, MO) in water was added to the pDNA solution at an amine to phosphate 
(N/P) ratio of 8, vortexed for 5 min and incubated at room temperature for 30 min.79  The size of 
the condensed pDNA was measured using dynamic light scattering (DLS) with a 660 nm laser at 
±1 nm reproducibility (Brookhaven Instruments Corporation, Holtsville, NY). 100 nm or smaller 
condensed pDNA particles were used for subsequent liposomal formulations. 
Liposome Formation 
Thin film liposome formation 
1,2-dipalmitoyl–sn-glycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-phospho 
ethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) (PEG2000) and 
cholesterol were purchased from Avanti Polar Lipids, Inc (Alabaster, AL).  60 mol% DPPC, 35 
mol% cholesterol and 5 mol% PEG2000 dissolved in chloroform were combined in a round bottom 
flask in the appropriate amounts (0.5-20 µmol), and dried under argon at 60 °C to produce a 
homogenous lipid film.  This film was hydrated with condensed pDNA at 45 °C until the entire 
film peeled off of the bottom of the flask.  All liposome formation was performed below 45 °C to 
ensure nanoparticle stability as temperature studies performed with pDNA and DNA nanoparticles 
indicated that thermal stability of pDNA is maintained up to 90 °C and size stability of 
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nanoparticles is maintained above 50 °C.235,236  These liposomes were then extruded 11 times using 
a manual extruder (Avestin, Ottowa, ON) through 200 nm membranes and the unencapsulated 
pDNA was removed with overnight dialysis purification through a 1000 kDa MWCO membrane 
(Spectrum Labs, Rancho Dominguez, CA). Lipid concentration was measured using a phosphorus 
assay as described elsewhere.237 Liposome size and charge were measured using DLS and zeta 
potential analysis (Brookhaven Instruments Corporation, Holtsville, NY).  In previous studies, final 
PEG2000 mol% in liposomal formulations was measured using H-NMR and found to be in 
consistent agreement with the mol% initially added to the lipid film.206  Therefore, the final mol% 
of PEG2000 in all liposomal formulations prepared was estimated to be 5%. 
Reverse phase evaporation liposome formation 
Films were prepared as described above and liposomes were prepared from these films as 
described elsewhere.238 Lipid films were dissolved in a 1:1 ratio of chloroform and diethyl ether.  
Condensed pDNA dissolved in water was added to this solution and the suspension was 
homogenized with sonication for at least 2 min.  The organic solution was evaporated off with 
argon at 45 ºC.  These liposomes were then extruded using a manual extruder (Avestin, Ottowa, 
ON) through 200 nm membranes and the unencapsulated pDNA was removed with overnight 
dialysis purification through a 1000 kDa MWCO membrane (Spectrum Labs, Rancho Dominguez, 
CA).  Lipid concentration was measured using a phosphorus assay as described elsewhere.237 
Liposome size and charge were measured using DLS and zeta potential analysis (Brookhaven 
Instruments Corporation, Holtsville, NY).  In previous studies, final PEG2000 mol% in liposomal 
formulations was measured using H-NMR and found to be in consistent agreement with the mol% 
initially added to the lipid film.206  Therefore, the final mol% of PEG2000 in all liposomal 
formulations prepared was estimated to be 5%. 
Asymmetric liposomes 
Liposomes were prepared using the asymmetric liposome formation method.230 62.5 mol% 
DPPC, 35 mol% cholesterol and 2.5 mol% PEG2000 were dissolved in squalene (Fisher Scientific, 
Hanover Park, IL) were combined to compose the outer lipid membrane, placed on top of 1.5 mL 
of water in a round bottom flask and allowed to equilibrate for 1.5 h.  65 mol% DPPC and 35 mol% 
cholesterol dissolved in squalene were combined to compose the inner lipid membrane. Squalene 
was compared to other solvents in the investigation of siRNA encapsulation using asymmetric 
liposomes and was found to yield the highest encapsulation efficiency.230 PEG was included only 
in the outer lipid membrane solution in an amount equivalent to that included in the outer bilayer 
of the REV and TF liposomes. The amount was estimated from a geometrical argument comparing 
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the outer surface area to the inner surface area of the liposomes. Condensed pDNA was added to 
the inner lipid membrane solution, sonicated for 1 h and extruded using a manual extruder (Avestin, 
Ottowa, ON) through 200 nm membranes.  This inverse emulsion was gently added to the outer 
lipid membrane mixture and centrifuged for 1 h at 115 g.  The squalene was decanted and the 
unencapsulated pDNA was removed with overnight dialysis purification through a 1000 kDa 
MWCO membrane (Spectrum Labs, Rancho Dominguez, CA).  Lipid concentration was measured 
using a phosphorus assay as described elsewhere.237 Liposome size and charge were measured 
using DLS and zeta potential analysis (Brookhaven Instruments Corporation, Holtsville, NY).  In 
previous studies, final PEG2000 mol% in liposomal formulations was measured using H-NMR and 
found to be in consistent agreement with the mol% initially added to the lipid film.206  Therefore, 
the final mol% of PEG2000 in all liposomal formulations prepared was estimated to be 5%. 
Cryo-Transmission Electron Microscopy (Cryo-TEM) 
4.5 L of condensed pDNA or condensed pDNA liposome sample was deposited onto a lacey 
formvar/carbon copper grid (Ted Pella, Redding, CA) and vitrified in liquid ethane by Vitrobot 
(Vitrobot parameters: 4 sec blot time, -1 offset, 5 sec wait time, 5 sec relax time, 95% humidity). 
Following vitrification, the grid was transferred to a Tecnai G2 Spirit TWIN 20-120 kV / LaB6 
TEM. Images were captured using an Eagle 2k CCD camera with an accelerating voltage of 120kV. 
Results and Discussion  
Liposome Formulation Method Comparison 
Liposomes are commonly formed by addition of an aqueous solution to an adsorbed film of 
lipids that will then swell and detach to form unilamellar and multilamellar vesicles, encapsulating 
the aqueous volume nearest to the lipids when they form.  Encapsulating condensed pDNA presents 
more challenges than encapsulation of small molecule drugs because of its large size.  REV and 
asymmetric liposome formation have been proposed as methods that could improve the 
encapsulation of large oligonucleotides. 210,230,238  These methods were compared to the common 
TF method for their encapsulation yields.   
REV liposomes are produced by first introducing an aqueous solution of the cargo to an organic 
phase containing lipids, and sonicating this mixture to produce small bubbles of aqueous phase 
within the organic solvent. The amphiphilic lipids will form reverse micelles around the bubbles of 
aqueous phase and cargo and, as the organic phase is dried off, will form liposomes containing 
aqueous phase and the encapsulant.238,239  Asymmetric liposomes are prepared by again creating 
reverse micelles around small droplets of water and encapsulant within an oil phase.  These droplets 
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are passed through a monolayer of lipids that form the outer liposomal layer, forming bilayered 
vesicles encapsulating the cargo.  Since the inner and outer layers are added separately, their 
compositions can be separately controlled, for example, to alter the charge of the inner layer while 
maintaining a neutral outer layer, or including bulky PEG functionalizations only outside the 
liposomes.  Asymmetric liposomes have been used successfully to encapsulate small oligomers.230 
To ensure consistent encapsulant size for direct comparison between liposomes formation 
methods, the liposomes within each experiment were prepared from the same batch of condensed 
pDNA.  The prepared liposomes had an average effective diameter of 150 nm with an average 
polydispersity index of 0.19 (polydispersity is a measure of the relative width of the size 
distribution), as measured by DLS, with a charge of -20 ± 2.4 mV. This liposome size is in 
agreement with other reports of liposomes (157 nm) produced via extrusion using the same 
apparatus and extrusion membrane size.240  The size of extrusion membrane (200 nm) resulting in 
150 nm liposomes was chosen based on the range of liposome size that take advantage of the rapidly 
formed vasculature within tumor tissue in a disorganized, irregular and ‘leaky’ blood vessel 
structure, allowing nanoparticles to more easily extravasate into the surrounding tissue.  In a study 
identifying optimal liposome size for tumor drug delivery, PEGylated liposomes of different sizes 
were delivered intravenously to a tumor mouse model and the liposome distribution was measured.  
Liposomes of 100-200 nm accumulated most efficiently into the tumor compared to the blood and 
other organs, while liposomes above 300 nm did not.241 Since the pDNA to be encapsulated is 100 
nm or smaller, liposomes were prepared at the upper limit of the range of sizes of liposomes that 
achieve efficient tumor accumulation.  
pDNA-encapsulated liposomes were prepared using the three liposome formation methods, and 
pDNA yield was determined by measuring radioactivity from radioactively labeled pDNA.  As 
seen in Figure 12 the REV formation method provided no advantage over the TF method in terms 
of overall pDNA yield.  REV and TF liposomes retained 9.0 ± 1.4 and 10.6 ± 1.2 g/mL pDNA 
respectively from the initial pDNA concentration of 13.3 g/mL.  The asymmetric method gave 
very low yields in comparison to both REV and TF, with final pDNA concentrations of 2.2 ± 0.6 
g/mL, and preparing asymmetric liposomes with negatively charged lipids (1,2-dipalmitoyl-sn-
glycero-3-phospho-(1'-rac-glycerol)) in the inner layer provided no improvement to pDNA yield.  
REV uses organic solvents during liposome formation which could have adverse effects on the 
stability of biological encapsulants, and any residual solvent could introduce toxicity concerns.239  
Since the TF method avoids the use of organic solvents during liposome formation and produced 
statistically the same yield of pDNA concentration as the REV method, the TF method was chosen 
as the best plasmid encapsulation method for further experiments.  A comparison of cationic 
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lipoplexes prepared using REV, TF and ethanol injection methods also identified the TF method as 
the best lipoplex formation method because it resulted in highly stable particles with a lower 
tendency to aggregate even after 60 days.224   
 
Figure 12. Comparison of liposome-encapsulated pDNA formulation methods. 
pDNA, condensed with bPEI, was encapsulated in stealth liposomes prepared using asymmetric, TF or REV 
formation methods and final pDNA concentration was measured using radioactively labeled pDNA. Data are 
shown as the mean ± standard error of three separate experiments (n=3), each performed in triplicate. 
Student’s t test statistical analysis was performed and statistical significance noted for the bracketed data 
(*** p < 0.005). Comparison of a pair resulting in a p > 0.5 is noted with a †. 
Electron Microscopy and Characterization of TF Prepared Liposomes 
The condensed pDNA and pDNA encapsulated stealth liposomes produced by the TF method 
were visualized using cryo-TEM (Figure 13).  Unencapsulated bPEI condensed pDNA formed 100 
nm or smaller spherical particles and the particle sizes shown in Figure 13A are consistent with the 
DLS analysis of condensed pDNA with an average effective diameter of 88 nm and an average 
polydispersity index of 0.26.  Representative DLS data is shown in Figure 14 to illustrate the 
liposome size distribution. pDNA encapsulated liposomes formed by the TF method existed as 
unilamellar vesicles with some liposomes appearing to contain spheres enclosed within them that 
resemble the unencapsulated pDNA particles.  This unilamellar structure is in contrast to the 
bilayered structures observed with cationic DNA lipoplexes, which can form multilamellar 
vesicles, bilamellar invaginated vesicles and liposomes with DNA condensed on their outer 
surfaces.17,242–245  These images suggest successful encapsulation of condensed pDNA particles 
inside unilamellar liposomes.  
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Figure 13. Cryo-TEM images of bPEI condensed pDNA and condensed pDNA encapsulated in stealth 
liposomes.  
A) bPEI condensed pDNA prepared with an N to P ratio of 8. B) bPEI condensed pDNA (N/P=8) 
encapsulated in stealth liposomes prepared using the TF method from a 20 µmol lipid film. 
 
 
Figure 14. Representative DLS particle sizing data from pDNA-encapsulated liposomes. Distribution is 
typical of pDNA encapsulated liposomes with polydispersity index of 0.26. 
 
DNA Quantification 
A DNA quantification method based on fluorescently labeled pDNA was developed for 
liposome encapsulated pDNA.  Fluorescent labeling was chosen as an appropriate assay because 
of its relative ease of conjugation, the linear dependence of fluorescence intensity with the pDNA 
concentration and the ability to measure fluorescent intensity of pDNA without sample destruction 
(i.e. without addition of detergents to release pDNA).  With the goal of encapsulating pDNA in our 
150 nm liposomes (in order to best take advantage of the leaky vasculature of tumor tissue241), the 
pDNA was electrostatically condensed using the cationic polymer bPEI.  Condensation of DNA 
brings the strands and fluorophores conjugated to backbone atoms in close proximity causing some 
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degree of quenching of the fluorescent signal.246  The extent of quenching then depends on the 
extent of condensation. A fluorescent signal standard was therefore produced after the pDNA 
condensation reached a stabilized state, immediately after lipid hydration occurs (Figure 15A).  
Figure 15B confirms that the presence of lipids and PEG have little effect on the fluorescent signal 
measured in the concentration standards.    To ensure the pDNA condensation is stable and that the 
Cy5 fluorescently labeled pDNA provides an accurate quantification tool for this application, this 
method was compared, along with the method using the common pDNA quantification reagent 
PicoGreen, to quantification using radioactively labeled pDNA.  Radioactive decay is unaffected 
by environment, so it provides a reliable standard by which to compare the other quantification 
methods.  
 
Figure 15. Cy5 labeled condensed pDNA concentration standards 
A) Concentration standard for 10% Cy5 labeled condensed pDNA after hydration step of liposome 
formation, showing the linear dependence of fluorescence intensity on pDNA concentration. Concentration 
standard for 10% Cy5 labeled condensed pDNA and 10% Cy5 labeled pDNA in the presence of empty 
liposomes, showing the linear dependence of fluorescence intensity on pDNA concentration and the 
invariance of fluorescence intensity in the presence of lipids and PEG. Data are shown as the mean ± 
standard error of three separate experiments (n=3), each performed in triplicate. 
 
 Liposomes were prepared with condensed pDNA containing both fluorescently labeled and 
radioactively labeled pDNA, and after purification, final pDNA concentration was quantified via 
fluorescence (either by using the Cy5-labeled DNA or the PicoGreen assay) or radioactivity as 
shown in Figure 16.  The pDNA concentration determined by Cy5 fluorescence and radioactivity 
are not statistically different while the concentrations measured using PicoGreen are significantly 
different.  It was also found that the PicoGreen assay was extremely inconsistent when measuring 
the same sample more than once (data not shown).  PicoGreen is a DNA intercalating dye that relies 
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on access to the space between DNA bases in uncondensed DNA to bind and fluoresce.217  
PicoGreen, therefore, cannot access the condensed pDNA or pDNA encapsulated within liposomes, 
necessitating the use of additional reagentss to break the liposomes, uncondensed the pDNA and 
purify the reagents before PicoGreen can be effective, introducing many opportunities for error, 
loss and contamination that inhbits PicoGreen fluorescence.  The fluorescence and radioactivity 
from fluorescently and radioactively labeled DNA are measurable in their condensed, encapsulated 
state, simplifying the assay and ensuring greater accuracy.  Cy5 fluorescently labeled pDNA 
therefore has been validated with radioactively labeled pDNA as an appropriate and useful tool for 
pDNA quantification of liposome encapsulated pDNA.   
 
Figure 16. Comparison of liposome-encapsulated pDNA quantification methods.   
pDNA (condensed with bPEI) concentration of prepared stealth liposomes measured using Cy5 labeled 
pDNA, radioactively labeled pDNA and the PicoGreen reagent. Data are shown as the mean ± standard error 
of five separate experiments (n=5), each done in triplicate. Student’s t test statistical analysis was performed 
and statistical significance noted for the bracketed data (* p < 0.05). † indicates statistical similarity (p > 0.7). 
Effect of Lipid Concentration on pDNA Encapsulated Stealth Liposomes  
Using the Cy5 fluorescently labeled pDNA as the quantification method, neutral stealth liposomes 
encapsulating condensed pDNA via bPEI were further characterized for the effect of lipid content on yield 
and fraction of pDNA filled liposomes.   
Liposomes were produced from lipid films containing several different amounts of lipids (0.5 
– 20 µmol, lipid content).  The pDNA and liposome concentrations of the purified liposomes were 
then measured to evaluate plasmid encapsulation.  The pDNA yield was calculated as the pDNA 
content within the liposome formulation after purification divided by the pDNA content initially 
added to the lipid film.  In general, lipid films with fewer lipids resulted in lower pDNA yields, 
with 20 µmol lipids giving 27.4 ± 6.2 % pDNA yield and 0.5 µmol of lipids resulting in only 10.6 
± 1.6% pDNA yield, as shown in Figure 17A.   
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In order to estimate the fraction of prepared liposomes containing condensed pDNA (Figure 
17B), the final number of liposomes and condensed pDNA particles were estimated.  The final 
liposome concentration of each formulation was calculated using the following equation 
2 4*2
  
r
SANl
L
lipidA

  
where L is liposome concentration [liposomes/mL], l is lipid concentration [mol/mL],  lipidSA  is the surface 
area of DPPC (0.65 nm2),247 AN  is Avagadro’s number and r is the radius of spherical liposomes (75 nm). 
A maximum number of pDNA molecules per condensed pDNA particle can be calculated from 
the volume occupied by a pDNA molecule assuming a cylindrical shape248,249 
2*** rbplV 
                                                         
 
where r  is 1.35 ± 0.2 nm,250 the radius of a DNA helix,248 l  is 0.34 nm, the length of one base 
pair,248 and bp  is the number of base pairs in the plasmid, which for pT2/Cal is 7537.  Using 
Equation 2, the minimum volume of a monomolecular pDNA particle is 14.7*103 nm3. A spherical 
pDNA particle with a diameter of 88 nm occupies a volume of 356*103 nm3, corresponding to a 
maximum number of pDNA molecules condensed in an 88 nm particle of 24.  The calculated 
maximum number significantly overestimates the number of molecules actually found within a 
condensed pDNA particle. The length of a base pair is a well characterized parameter, but the radius 
of a DNA helix is less studied.  Since the volume calculation depends on the square of the radius, 
the estimation of this parameter has a larger effect on the volume estimations for condensed DNA 
than the value of the length of a base pair, however, underestimating the radius by the experimental 
error of 0.2 nm changes the calculated number of DNA molecules per particle by only 24%, and 
overestimating by 0.2 nm changes the result by 38%.  The overestimation is therefore most likely 
caused by the fact that the solvent and the bPEI polymer also occupy particle volume and this 
volume is not taken into account in the calculations.248,251  Previous work has shown that a 6 kbp 
pDNA molecule occupies only 10% of the volume of a bPEI-condensed pDNA particle.249  
Therefore, 2.4 pDNA molecules would occupy 10% of the volume of our 88 nm particle.  Other 
experimental investigations of the number of pDNA molecules per bPEI-condensed particle have 
reported 90 molecules per particle for 5 kbp pDNA complexed with bPEI at a N/P ratio of 15,248 
and 3.5 molecules per particle for 6 kbp pDNA complexed at a N/P ratio of 6 and 10.249  The 
condensation conditions used for this study correspond more closely to those used in the latter 
study. Using the theoretical calculations with a 10% volume occupancy per particle and the 
literature values, 3 molecules per particle was determined as an appropriate estimate for calculating 
the fraction of pDNA filled liposomes. It was also assumed that all the condensed pDNA particles 
(1) 
(2) 
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were encapsulated within the liposomes in order to calculate the maximum fraction of stealth 
liposomes with encapsulated condensed pDNA.  
 
 
Figure 17. Yield and load fraction of liposome-encapsulated pDNA prepared with varying lipid film content.  
A) Comparison of the yield of pDNA measured using 20 µg Cy5 labeled pDNA that was condensed with 
bPEI and encapsulated in stealth liposomes prepared via the TF method. B) Theoretical calculation of the 
fraction of liposomes with encapsulated condensed pDNA from the liposomes shown in (A). Fraction is 
calculated using the average liposome size and the liposome size at 93% relative intensity above (170 nm) 
and below (120 nm) average as measured by DLS. Data are the mean ± standard error of three separate 
experiments (n=3), each performed in triplicate. Student’s t test statistical analysis was performed and 
statistical significance noted for the bracketed data (* p < 0.05, ** p < 0.02, *** p < 0.005, † p > 0.05). 
 
B 
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Though liposomes produced with lower initial lipid content had lower overall yields, they were 
estimated to have a larger fraction of pDNA filled liposomes, with 9.0 ± 1.6% full liposomes 
(Figure 17B). This means that approximately 90% of the stealth liposomes contain no pDNA.  
 For stealth liposomes, the fraction of pDNA filled liposomes can be controlled by increasing 
or decreasing the lipid film content. Previous characterization of liposomes encapsulating small 
molecules have shown that increasing lipid concentration decreases encapsulation efficiency, 
because increasing the lipid concentration encourages the formation of multilamellar vesicles.252 
However, the liposomes formed in this study even at the highest lipid content of 20 µmol formed 
unilamellar vesicles, as seen in Figure 13B, therefore an increase in concentration correlates with 
an increase in the total number of available liposomes, which improves the potential for pDNA 
encapsulation, but also increases the number of empty liposomes. Figure 18 quantitatively relates 
the lipid film content and theoretical calculation of the fraction of liposomes with encapsulated 
condensed pDNA. 
 
Figure 18. Quantitative relationship between the lipid film content and theoretical calculation of the fraction 
of liposomes with encapsulated condensed pDNA.  
Stealth liposomes were prepared via the TF method with varying lipid film content using 20 µg Cy5 labeled 
pDNA that was condensed with bPEI. pDNA concentration was measured using fluorescence. Data are the 
mean ± standard error of three separate experiments (n=3), each performed in triplicate. 
 
Liposomes were also prepared with two different amounts of pDNA to understand the effect 
of initial pDNA content on the fraction of liposomes containing pDNA. Liposomes prepared from 
a 20 µmol lipid film with 13.3 µg/mL pDNA had a 2 fold higher fraction of filled liposomes 
compared to liposome prepared with 6.6 µg/mL pDNA (Figure 19). This suggests that higher initial 
pDNA concentrations will result in more liposomes loaded with pDNA and fewer empty liposomes. 
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Figure 19. Load fraction of liposome-encapsulated pDNA prepared with varying initial pDNA content. 
Theoretical calculation of the fraction of liposomes with encapsulated condensed pDNA measured using Cy5 
labeled pDNA that was condensed with bPEI and encapsulated in stealth liposomes prepared via the TF 
method from a 20 µmol lipid film. Data are the mean ± standard error of three separate experiments (n=3), 
each performed in triplicate. Student’s t test statistical analysis was performed and statistical significance 
noted for the bracketed data (* p < 0.05).   
 
These results provide a guide for pDNA encapsulated liposome production, depending upon 
the optimization goals of the process. In order to maximize overall pDNA encapsulation, the lipid 
concentration should be increased, but in order to minimize the number of empty carriers within 
the formulation higher pDNA concentrations should be used along with lower lipid concentrations. 
Conclusions 
Different processes of forming stealth liposomes that can encapsulate pDNA and pDNA 
quantification methods were examined. Comparing three different liposome formation methods 
thought to be beneficial for pDNA capture, it was determined that the TF method was best for 
pDNA encapsulation because of its higher yield and use of aqueous solvents for film hydration. 
The gene delivery field has, until recently, been lacking a simple, reliable quantification method 
that is compatible with the presence of lipids and PEI polymer and can be performed without 
sacrificing any amount of sample. Many pDNA quantification tools exist, but few are accurate for 
unpurified gene delivery vehicles. A fluorescence quantification method using Cy5 labeled pDNA 
was therefore developed for this delivery system and was verified for accuracy by comparing it to 
a radiolabeled pDNA assay. This comparison also confirmed that the commonly used commercial 
PicoGreen pDNA quantification assay is unreliable for this type of delivery vehicle. The effect of 
initial lipid concentration on pDNA encapsulation and fraction of pDNA loaded liposomes was 
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also explored. Higher lipid concentrations encapsulated a higher amount of pDNA but produced a 
high number of empty liposomes as well. Conversely, a lower lipid concentration encapsulated 
fewer pDNA particles, but the resulting formulation contained a higher fraction of pDNA loaded 
liposomes. Increasing pDNA concentrations also increased the number of filled liposomes. 
Therefore, the careful control of pDNA yield and fraction of pDNA encapsulated liposomes may 
be beneficial during production. For example, maximizing DNA yield may be an important aspect 
of production because of the cost of plasmid production. Inversely, for DNA liposomes that are 
targeted to bind to cell surface receptors, high encapsulation fraction may be more desirable to 
minimize the binding of unloaded liposomes to cells. Gene therapy has the potential to treat and 
cure many common ailments, but its success is limited by the lack of efficient delivery vehicles. 
The tools described here could contribute to the advancement of the stealth liposome as a delivery 
vehicle of encapsulated pDNA for gene therapy.    
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Chapter 3 Targeting HPV-Infected Cervical Cancer 
Cells with Stealth Liposomes Encapsulating siRNA and 
the Role of siRNA Complexation with Polyethylenimine 
Introduction 
Rapid advancements in genetic technologies have given researchers the ability to target and 
modify individual genetic events involved in disease progression, providing potential treatment 
avenues for previously untreatable diseases.253–255  A particularly valuable tool for characterization 
and modification of disease-associated genes is RNA interference (RNAi), a cellular pathway 
which can selectively silence the expression of a target gene. When short (~22 base pair) RNA 
sequences are introduced into the cytoplasm of a cell, they can be incorporated into an RNA-
induced silencing complex (RISC), molecular machinery which identifies the complementary 
mRNA sequence of the incorporated RNA for degradation, thus preventing translation and 
expression of the target gene. Selective gene silencing can be especially useful for treating diseases 
such as cancer or viral infection, where disease progression is driven by undesirable or aberrant 
gene expression.254,256,257 One such example of the potential of RNAi therapy is demonstrated by 
the treatment of cervical cancer by silencing key genes within the cellularly integrated genome of 
the oncovirus human papillomavirus (HPV). The oncogenic nature of HPV has been attributed to 
the aberrant expression of the E6 and E7 viral proteins, and their interference with native cell cycle 
regulatory pathways. E6 and E7 bind to tumor suppressor proteins p53 and pRb, marking them for 
degradation or blocking their binding sites, thereby preventing apoptosis and driving cellular 
proliferation.258,259 With the knowledge of the genetic mechanism of this oncovirus, several siRNA 
sequences targeting the gene sequences that encode the E6 and E7 proteins have been developed, 
demonstrating rescue of the p53 and pRb tumor suppression pathways, resulting in cell cycle arrest 
and apoptosis in HPV-infected cancer cells both in vitro and in vivo. 260–264  
In order for the potential of clinical gene therapy to be realized, several key obstacles to 
efficient in vivo delivery need to be overcome. For successful transfection and therapy to occur, 
siRNA must be internalized into the cells and released into the cytosol to mediate gene silencing. 
While traversing the blood stream to reach the target tissue, siRNA must avoid degradation by 
nucleases, recognition by the immune system, and renal clearance. Several technologies have been 
developed to address each of these barriers to siRNA delivery, including chemical modification, 
nanoparticle complexation, and addition of targeting moieties.253–257,265 In this study, we developed 
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cancer gene therapy delivery vehicles composed of targeted stealth liposomes encapsulating 
siRNA. Stealth liposomes are hollow, spherical phospholipid nanoparticles functionalized with a 
layer of polyethylene glycol (PEG) which have seen clinical success for the delivery of 
chemotherapeutic agents.203–205 The addition of the PEG layer prolongs blood circulation times and 
minimizes immunogenicity of the liposomes, promoting tumor accumlation.203–205 Stealth 
liposomes are also less immunogenic than cationic lipoplexes and polyplexes, the most common 
siRNA transfection agents.197,199  Stealth liposomes functionalized with ligands designed to bind to 
upregulated surface receptors can enhance cellular association and internalization into cancer cells. 
The α6β4 integrins are upregulated surface receptors associated with metastatic behavior in several 
cancer types, including cervical cancer.266–268 The AG86 peptide was identified as an α6 integrin 
binding ligand,269 and was investigated here for specificity for the α6β4 integrin and for targeting to 
HeLa cervical cancer cells.  Polyethyleneimine (PEI) complexation with nucleic acids alone has 
been shown to aid in endosomal escape through the proton sponge effect, whereby the high 
buffering capacity of PEI can cause osmotic swelling and rupture of intracellular organelles.35,270,271 
Previously, we have demonstrated successful encapsulation of plasmid DNA (pDNA) complexed 
with PEI within the aqueous core of stealth liposomes.272 With the addition of a targeting ligand, 
liposome encapsulated PEI-complexed pDNA achieved efficient transfection in colorectal cancer 
cells.273,274   We therefore hypothesized that siRNA/PEI complexation could enhance transfection 
efficiency within stealth liposomes as well. We engineered AG86-functionalized stealth liposomes 
encapsulating PEI complexed siRNA as a delivery scheme to address each of the barriers to 
effective gene delivery. Optimal targeting and complexation properties of this vehicle were 
identified for successful gene silencing of the HPV-E7 gene in cervical cancer cells.  
Experimental Section 
siRNA Labeling and Quantification  
si18E7-674 (CTAGCACGAGCAATTAAGCGA), shown to silence the HPV-E7 gene,264 (GE 
Dharmacon, Lafayette, CO) and used throughout this study, was fluorescently labeled using Cy5 
Label IT Tracker Intracellular Nucleic Acid Localization Kit (Mirus, Madison, WI). The 
conjugation was carried out according to the manufacturer’s protocol using the maximum 
recommended reagent volume and a reaction time of 3 h. For liposome encapsulated siRNA used 
for silencing, 5% of the total siRNA encapsulated was labeled with Cy5. For liposome encapsulated 
siRNA used for siRNA binding and internalization studies, 25% of the total siRNA encapsulated 
was labeled with Cy5. An siRNA concentration standard curve was produced from the complexed 
siRNA following the hydration step of liposome formation.272 Fluorescence intensity of the 
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standard and of the liposome sample were measured using a Synergy H1 fluorescence microplate 
reader (Biotek, Winooski, VT). Yield was calculated as final siRNA content after purification 
compared to initial siRNA content used for encapsulation (100 pmol).  
siRNA/PEI Complexation  
100 pmol of total siRNA (5% fluorescently labeled siRNA, si18E7-674264) was complexed 
using 25 kDa branched PEI (Sigma-Aldrich, St. Louis, MO). 100 pmol of siRNA was dissolved in 
6 mM HEPES buffer, mixed with an equal volume of PEI in 6 mM HEPES at the desired amine to 
phosphate (N:P) ratio at a final siRNA concentration of 67 nM, was vortexed for 5 sec and 
incubated at room temperature for 20 min. The size of complexed siRNA nanoparticles was 
measured using a NanoSight LM10 (Malvern Instruments, Malvern, UK) with a 405 nm laser, and 
zeta potential analysis (Brookhaven Instruments Corporation, Holtsville, NY) was used to measure 
the surface charge of the particles.  
Isothermal Calorimetry (ITC) 
siRNA and PEI were prepared in the same buffer to minimize mixing effects. PEI was then 
injected at 2 μL increments into the siRNA solution using a MicroCal Auto-iTC 200 System to 
measure the power required to maintain a constant chamber temperature. Using the MicroCal Auto-
iTC200 software, the resulting power versus time data were integrated to determine heat exchange 
associated with each injection. The heat of dilution was accounted for by subtracting the heat data 
obtained from injections of PEI into buffer from the heat data obtained from injecting PEI into an 
siRNA solution. The resulting heat curve was fitted to a “one set of sites” binding model, which 
uses n, the number of binding sites, K, the binding association constant, and ∆H, the enthalpy of 
binding, as fitting parameters where all n binding sites have the same K and ∆H.275,276 The data 
were fitted to the following equations:  
𝐾 =  
𝜃
(1 − 𝜃)[𝑋]
 
 
𝑋𝑡 = [𝑋] +  𝑛𝜃𝑀𝑡 
 
𝑄 = 𝑛𝜃𝑀𝑡∆𝐻𝑉𝑜 
 
∆𝑄(𝑖) =  𝑄(𝑖) +
𝑑𝑉𝑖
𝑉𝑜
[
𝑄(𝑖) +  𝑄(𝑖 − 1)
2
] − 𝑄(𝑖 − 1)  
(4) 
(5) 
(6) 
(3) 
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where 𝜃 is the fraction of sites occupied by the siRNA, [𝑋] is the free siRNA concentration, 𝑋𝑡 is 
the bulk siRNA concentration, 𝑀𝑡 is the bulk PEI concentration, Q is the total heat content of the 
solution, ∆𝑄(𝑖) is the heat released from the ith injection, 𝑉𝑜 is the volume of the chamber, and 𝑑𝑉𝑖 
is the injection volume at the ith injection.   
 Liposome Formation  
1,2 Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-phospho 
ethanolamine-N-[methoxy(poly(ethylene glycol))-2000] (ammonium salt) (PEG2000), and 
cholesterol were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). AG86 peptide 
(KSSLGGLPSHYRARNI)269 was purchased from United Biosystems (Herndon, VA) and the 
peptide-amphiphile was synthesized as described previously.67 x mol% AG86 peptide-amphiphile 
(x = 0-10), (60-x) mol% DPPC, 35 mol% cholesterol and 5 mol% PEG2000 dissolved in 
chloroform were combined in a round bottom flask at a total lipid content of 5 μmol and dried under 
a stream of argon. The solution was dried under argon at 60 °C to produce a homogeneous lipid 
film, followed by overnight incubation in a vacuum oven. This film was hydrated with 0.75 mL of 
2 mM calcein or 1.5 mL of complexed siRNA/PEI at 45 °C for 1.5 h. These liposomes were 
extruded 11 times using a manual extruder (Avestin, Ottowa, ON) through 200 nm membranes. 
For siRNA liposomes, the unencapsulated siRNA was removed with overnight dialysis purification 
through a 1000 kDa MWCO cellulose ester membrane (Spectrum Laboratories, Rancho 
Dominguez, CA) and stored at 4–8 °C for up to 4 weeks.79,272 Calcein liposomes were purified 
using a Sepharose CL-4B gel filtration column to remove unencapsulated material and stored at 4–
8 °C for up to 4 weeks. Lipid concentration was measured using a phosphorous assay as described 
elsewhere237 and peptide concentration was measured using a BCA Protein Assay Kit (Pierce 
Biotechnology, Rockford, IL). Liposome size and charge were measured using dynamic light 
scattering (DLS) and zeta potential analysis (Brookhaven Instruments Corporation, Holtsville, 
NY). A fluorescence standard relating calcein fluorescence to total lipid concentration was used to 
quantify the amount of bound and internalized lipid for calcein liposome experiments.  siRNA 
quantification is described above. 
Binding and Internalization of Fluorescent Liposomes 
HeLa cervical cancer cells (American Type Culture Collection, Manassas, VA) were 
subcultured in black 96-well plates at 5,000 cells/well containing 200 μL Minimum Essential Media 
(MEM) supplemented with 10% fetal bovine serum, 100 units/mL penicillin and 0.1 mg/mL 
streptomycin. Targeted stealth liposomes encapsulating calcein with varying AG86 content (0-10 
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mol%) were incubated with HeLa cells for 3, 6, and 24 h at 37 °C and 5% CO2 at a lipid 
concentration of 100 μM. After incubation, the cells were washed 3 times with phosphate buffered 
saline (PBS) and maintained at -80 °C for 24 h. The frozen cells were then thawed, lysed with lysis 
buffer (Promega, Madison, WI) and the calcein fluorescence was quantified at excitation/emission 
wavelengths of 485/515 nm. The total amount of bound and internalized lipids was calculated based 
on a standard curve relating fluorescence and lipid concentration.  
Peptide and Antibody Blocking of Fluorescent Liposome Binding 
HeLa cervical cancer cells were fixed by incubation in 4% paraformaldehyde (Sigma, St. Louis, 
MO) for 10 min at 25 °C, and aliquoted in 4 °C 1% w/v bovine serum albumin (ThermoFisher, 
Grand Island, NY), 0.9 mM CaCl2, 0.5 mM MgCl2 PBS at 5x106 cells/mL. Cells were incubated 
with 10 µg/mL AG86 peptide, 1:100 dilution of rat anti-human CD49f/α6 (eBioscience, Inc., San 
Diego, CA), or 1:100 dilution of MAΒ1964 mouse anti-human β4 (EMD  Millipore, Darmstadt, 
Germany) at 4 °C for 30 min. 50 µM AG86-functionalized stealth liposomes were added and 
incubated at 4 °C for 1 hr, then washed twice with 4 °C PBS and analyzed immediately on a BD 
Accuri C6 flow cytometer (Masonic Cancer Center, University of Minnesota). 
Silencing of HPV-E7 Gene mRNA 
HeLa cells were subcultured in clear 12-well plates at 50,000 cells/well in 2 mL of MEM and 
incubated for 24 h. 2.5 nM si18E7-674264 was delivered to each well with the different transfection 
agents for 24 h at 37 °C and 5% CO2. RNA extraction was conducted using the E.Z.N.A Total RNA 
Isolation Kit I (Omega Biotek, Norcross, GA) according to the manufacturer’s protocol. The 
concentration of extracted RNA was quantified using an absorbance microspot reader (Biotek, 
Winooski, VT) and 1 μmol of RNA was converted to cDNA using RNA to cDNA EcoDry™ 
Premix (Double Primed) according to the manufacturer’s protocol (Clontech, Mountain View, CA). 
HPV-E7 expression was quantified through a reverse-transcription polymerase chain reaction (RT-
PCR) using PerfeCTa qPCR mix (Quanta Biosciences, Gaithersburg, MD) in a MX3000P qPCR 
machine (Agilent, Santa Clara, CA). The geometric mean of the reference gene threshold cycles 
(Ct,ref1, Ct,ref2) were used to normalize the HPV-E7 threshold cycle for each sample. TATA-binding 
protein (TBP) and tyrosine 3-monooxygenase activation protein-zeta (YWHAZ) were chosen as 
reference genes to minimize the effect of apoptosis on reference gene expression and subsequent 
mRNA expression measurements.277 A buffer and RNA control were included for each experiment.  
The reference gene threshold was calculated as  
𝐶𝑡,𝑟𝑒𝑓 = √𝐶𝑡,𝑟𝑒𝑓1𝑥𝐶𝑡,𝑟𝑒𝑓2 (7) 
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where Ct,ref1 and Ct,ref2 are the threshold cycles of the individual reference genes.   
HPV-E7 gene silencing was calculated using the following equations. First, the normalized 
sample threshold cycle, ΔCt, was determined by subtracting the reference gene threshold cycle 
(Ct,ref) from the target gene threshold cycle (Ct,x) for each sample.  
∆𝐶𝑡 = 𝐶𝑡,𝑥 − 𝐶𝑡,𝑟𝑒𝑓 
The difference between treated and untreated threshold cycles, ΔΔCt, was then calculated by 
subtracting the ΔCt,untreated of the untreated sample from the ΔCt,treated of the treated sample.  
−∆∆𝐶𝑡 = −(∆𝐶𝑡,𝑡𝑟𝑒𝑎𝑡𝑒𝑑 − ∆𝐶𝑡,𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑) 
The fold silencing that was achieved in the treated sample relative to the untreated sample was 
calculated as follows.  
𝐹𝑜𝑙𝑑 𝐷𝑒𝑐𝑟𝑒𝑎𝑠𝑒 = 2−∆∆𝐶𝑡 
Binding and Internalization of siRNA Liposomes 
HeLa cells were subcultured in clear 12-well plates at 50,000 cells/well in 2 mL of MEM and 
incubated for 24 h. 2.5 nM encapsulated si18E7-674 was delivered and allowed to incubate for 24 
h at 37 °C and 5% CO2. Cells were then harvested with TrypleE Express cell dissociation agent 
(ThermoFisher Scientific, Grand Island, NY), pelleted by centrifugation at 500 g for 2.5 min, 
washed twice with 4 °C PBS and analyzed immediately on a BD Accuri C6 flow cytometer 
(Masonic Cancer Center, University of Minnesota). Fluorescence intensities were normalized to 
siRNA concentration with the concentration standard used to determine yield. 
Cell Viability 
HeLa cells were subcultured in clear 96-well plates at 5,000 cells/well in 200 µL of MEM and 
incubated for 24 h. 2.5 nM liposome encapsulated si18E7-674, nonsilencing siControl siRNA 
(siGENOME Nontargeting siRNA #2, GE Dharmacon, Lafayette, CO) or 750 nM (lipids) empty 
liposomes were delivered and allowed to incubate for 24 h at 37 °C and 5% CO2. Cell viability was 
then measured using a WST-1 Cell Proliferation Reagent (Roche, Indianapolis, IN) following the 
manufacturer’s protocol. Absorbance was measured using a Synergy H1 microplate reader (Biotek, 
Winooski, VT). Cell viability was normalized to untreated cells.   
Statistics  
ANOVA analysis and Tukey Kramer honest significant difference (HSD) test were performed 
to calculate p-values and determine statistical significance between means. When only two means 
were compared within an experiment, student’s t test was used to calculate p-values.    
(8) 
(9) 
(10) 
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Results 
Binding and Internalization of Fluorescent Liposomes Delivered to HeLa Cells 
To investigate the ability of AG86-functionalized stealth liposomes  to target cervical cancer 
cells, calcein loaded liposomes were prepared with 0-10 mol% AG86 targeting peptide and 
delivered to HeLa cells for 3, 6 and 24 h at 37 °C. As delivery time increased, binding and 
internalization increased for all targeting peptide concentrations. Increasing the concentration of 
the targeting peptide results in a nonlinear increase in binding and internalization (Figure 20), which 
is likely mediated by increased peptide valency resulting in binding avidity.278,279 Liposomes 
prepared with 5 mol% AG86 achieved significantly more efficient delivery compared to 0, 2 and 3 
mol% peptide at all time points (Table 2), and was chosen as a sufficient targeting peptide 
formulation for subsequent gene delivery studies.  To further verify that the AG86 peptide was 
responsible for liposome binding to HeLa cells, the binding of AG86-functionalized stealth 
liposomes was measured after incubation with free AG86 peptide and compared to binding without 
peptide blocking (Figure 21A).  The presence of the free peptide decreased liposome binding by 
98%, confirming AG86-mediated binding.  The initial discovery of the AG86 peptide demonstrated 
specific interaction with the α6 integrin.269  The presence of anti-α6 antibodies disrupted 40% of 
cellular adhesion to AG86 peptide coated surfaces.269  The α6 integrin is known to dimerize with 
either the β1 or the β4 integrin,280 and while blocking with a β1 specific antibody demonstrated that 
AG86 binding is not specific for the α6β1 heterodimer, binding to the β4 integrin was not explored.269  
We therefore investigated the binding interactions of the AG86 peptide using antibody blocking of 
AG86-functionalized stealth liposome binding to cells (Figure 21B).  In the presence of anti-α6 and 
anti-β4 integrin antibodies, liposome binding is decreased by 66% and 86% respectively, verifying 
the α6β4 integrin as the binding target of the AG86 peptide.   
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Figure 20. Binding and internalization of fluorescent targeted stealth liposomes.  
0-10 mol% AG86-functionalized, calcein loaded, stealth liposomes were delivered at 100 μM lipids to HeLa 
cells for 3, 6, and 24 h at 37 °C and binding and internalization was examined by lysing cells and measuring 
fluorescence. Data are presented as the mean ± SE (n = 3-4, performed in triplicate). All p-values from 
statistical analysis are listed in Table 2. 
 
  
Figure 21. Peptide and antibody blocking of AG86-functionalized stealth liposomes 
5-6 mol% AG86-functionalized, calcein loaded, stealth liposomes (green) were delivered at 50 μM lipids to 
HeLa cells at 4 °C for 1 h after a 30 min incubation of (A) 10 μg/mL free AG86 peptide (blue) or (B) 100x 
dilution of anti-α6 (blue) and anti-β4 (red) integrin antibodies. Binding was measured using flow cytometry. 
Untreated cells (grey) were measured for background fluorescence. 
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Table 2. p-values from ANOVA statistical analysis for Figure 20 showing binding and internalization of 
fluorescent liposomes with varying peptide concentration and incubation times.   
 
Characterization of siRNA/PEI Complexes 
Before encapsulation in targeted liposomes, anionic siRNA was complexed with the cationic 
polymer PEI. siRNA was complexed at several different nitrogen:phosphate  ratios (N:P) to 
investigate the effect of N:P ratio on yield and transfection efficiency. None of the particle sizes 
are significantly different between different N:P ratios (Figure 22).281 As N:P ratio was increased 
from 2 to 8 and more positively charged polymer was added during complexation, the zeta potential 
increased from -11 to 13 mV (Figure 22). The larger standard error of the average particle size for 
siRNA/PEI complexes at N:P = 4 is indicative of the high size polydispersity observed from these 
complexes, as is commonly seen at N:P ratios that produce particles approaching a neutral charge 
or at the transition from negative to positive zeta potential associated with increasing N:P.282–284  
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Figure 22. Size and zeta potential measurements of siRNA/PEI complexes. 
siRNA/PEI particles were complexed at various N:P ratios, and size and charge were determined. Data are 
presented as the mean ± SE (n = 4-11). * p-value <0.05, ** p-value <0.005 comparing zeta potential 
measurements. There was no significant statistical difference for pairs without brackets. 
 
Isothermal Calorimetry (ITC) Exploring siRNA/PEI Complexation 
Microcalorimetric titrations of PEI into siRNA solutions were performed to monitor the 
thermodynamic properties associated with the formation of siRNA/PEI complexes. Titrations were 
performed over the entire range of N:P ratios investigated for transfection (Figure 23A, C). The 
calorimetry results over this N:P range showed complete saturation of siRNA with PEI between 
N:P 1 and 2. Others have observed DNA/PEI saturation between N:P of 2-3 using branched PEI of 
similar size,276,282,285 and between 1-2.5 for siRNA/PEI.286 In order to better observe the transition 
from free to fully complexed siRNA, titrations were also performed spanning N:P ratios of 0-2.5 
(Figure 23B, D). A “one set of sites” model was used to calculate binding affinity, enthalpy and 
entropy of binding, and stoichiometry (Figure 23 and inset). The calculated binding affinity K = 
3.1 x 106 ± 1.2 x 106 M-1 and stoichiometry n = 0.57 ± 0.02 are similar to those measured from ITC 
experiments of DNA/PEI complexes.276,282 An n of 0.57 corresponds to an siRNA:PEI ratio of 25 
and a negative to positive charge ratio of 1.7:1.  This deviation from a charge ratio of 1:1 could be 
explained by a difference in linear intercharge spacing between siRNA (0.17 nm)275 and PEI (0.25-
0.35 nm).287  Normalizing to the charge ratio, it’s reasonable to expect the interaction of siRNA and 
PEI to resemble the interaction of DNA with PEI. The binding of siRNA and bPEI in distilled water 
was characterized using similar thermodynamic parameters, however an n of 2.26 was identified, 
requiring more PEI molecules for condensation of 1 siRNA molecule.286  This discrepancy could 
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be caused by differing buffer conditions.275 In Figures 23 A and B, large endothermic (positive) 
peaks are observed at the transition between free and complexed siRNA, and this has been 
attributed to an endothermic reorganization of saturated siRNA:PEI complexes into less siRNA-
dense particles.286 
  
   
Figure 23. Representative ITC experiments showing raw (A-B) and integrated (C-D) data for the titration of 
PEI into siRNA in 6 mM HEPES buffer.  
PEI was titrated into siRNA over N:P ranges of 0-8 (A, C) and 0-2.5 (B, D). 
 
Characterization of Targeted Stealth Liposomes Encapsulating siRNA   
siRNA/PEI complexes (N:P = 2-8) or uncomplexed siRNA (N:P = 0; no PEI) were 
encapsulated within 5 mol% AG86-functionalized stealth liposomes. The N:P ratio had no 
significant effect on liposome size or zeta potential and results were no different than size or zeta 
potential measured for empty stealth liposomes (Figure 24). The yield of siRNA encapsulation was 
measured using a standard created from the fluorescently labeled siRNA included in the complexes 
n = 0.57 ± 0.02 
K = 3.1x106±1.2x106 M-1 
∆H = -1312 ± 50 cal/mol 
∆S = 25.3 cal/mol/K 
A B 
C D 
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(Figure 25).272 Encapsulation of siRNA in neutral lipid delivery systems is historically limited by 
low entrapment efficiency.288 However, targeted stealth liposomes encapsulating siRNA 
complexed to PEI achieved yields of up to 60% as shown in Figure 25. 
  
Figure 24. Size and zeta potential measurements of targeted stealth liposomes encapsulating siRNA. 
siRNA/PEI complexes were prepared at various N:P ratios, then encapsulated in stealth liposomes (5-6 mol% 
AG86) for characterization. N:P = 0 indicates encapsulation of uncomplexed siRNA (no PEI). There was no 
significant statistical difference for pairs without brackets. Empty stealth liposomes (5.3 mol% AG86) were 
prepared by hydrating lipid films with buffer. Data are presented as the mean ± SE (n = 3-6).  
 
 
Figure 25. siRNA encapsulation yield in targeted stealth liposomes.  
siRNA/PEI complexes were first prepared at various N:P ratios, then encapsulated in the targeted  stealth 
liposomes for characterization. N:P = 0 indicates encapsulation of uncomplexed siRNA (no PEI). Yield is 
calculated as siRNA present in final liposomes solution compared to initial siRNA. Data are presented as the 
mean ± SE (n = 3-6, performed in triplicate). There was no significant statistical difference for all pairs. 
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mRNA Silencing from Targeted Stealth Liposomes Encapsulating siRNA 
siRNA/PEI complexes encapsulated in targeted stealth liposomes and free siRNA/PEI were 
delivered to HeLa cells, and the resulting mRNA silencing from the delivery of HPV-E7 specific 
siRNA was measured 24 h after delivery using RT-PCR (Figure 26). The level of mRNA silencing 
increased with increasing N:P ratio up to N:P = 6 for both the free and encapsulated siRNA/PEI 
complexes. The encapsulated siRNA/PEI formed at N:P = 6 achieved significantly higher levels of 
silencing compared to the unencapsulated complexes at N:P = 6 and to targeted stealth liposome 
encapsulated siRNA/PEI formed at N:P = 0-4. HPV-E7 mRNA expression was reduced to 32 ± 7% 
of control levels with the N:P = 6 encapsulated siRNA/PEI complexes, a 10 fold improvement in 
silencing over free siRNA delivery (unencapsulated and uncomplexed siRNA, N:P = 0). Notably, 
the encapsulated siRNA/PEI complexes at N:P = 6 achieved a 2.6 fold decrease in expression 
compared to targeted stealth liposomes encapsulating uncomplexed siRNA (N:P = 0). Since the 
same siRNA concentration was used for all formulations, this suggests a benefit to transfection 
from the presence of PEI. The silencing achieved by the highest performing targeted stealth 
liposome formulation (complexed siRNA/PEI at N:P = 6 encapsulated in targeted stealth 
liposomes) was also compared to the silencing efficiency from nontargeted liposomes 
encapsulating siRNA/PEI complexes at the same N:P ratio and from Lipofectamine RNAimax, a 
commercial RNAi transfection reagent (Figure 27). The siRNA/PEI encapsulated in the targeted 
stealth liposomes achieved 1.9 fold decreased expression compared to the nontargeted 
formulations, and 2.2 fold decrease in expression compared to Lipofectamine, displaying superior 
in vitro delivery and transfection ability.   
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Figure 26. mRNA silencing from siRNA/PEI complexes in solution or encapsulated in targeted stealth 
liposomes. 
HeLa cells were transfected with 2.5 nM siRNA for 24 h. mRNA expression was measured as % expression 
of HPV-E7 mRNA in HeLa cells compared to untreated cells. N:P = 0 indicates delivery of uncomplexed 
siRNA (no PEI). Data are presented as the mean ± SE (n = 3-7, performed in triplicate). * p-value <0.05, ** 
p-value <0.005 comparing targeted stealth liposome-encapsulated siRNA/PEI, and † p-value <0.05 
comparing targeted stealth liposome-encapsulated siRNA/PEI to siRNA/PEI complexes in solution at the 
same N:P. There was no significant statistical difference for pairs without brackets. 
 
 
Figure 27. mRNA expression after siRNA transfection with various reagents.  
siRNA was complexed with PEI at N:P = 6 and encapsulated in targeted (5.5 ± 0.2 mol% AG86) or 
nontargeted stealth liposomes, or mixed with Lipofectamine. mRNA silencing of HPV-E7 in HeLa cells was 
compared to untreated cells, 24 h after delivery of 2.5 nM of siRNA. Data are presented as the mean ± SE (n 
= 3-7, performed in triplicate). * p-value <0.05. There was no significant statistical difference for pairs 
without brackets. 
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Internalization of siRNA Encapsulated in Targeted Stealth Liposomes  
In order to investigate further the benefit observed from complexation of siRNA with PEI 
before encapsulation, targeted stealth liposomes encapsulating uncomplexed siRNA (N:P = 0) or 
siRNA/PEI complexes (N:P = 6) were delivered to HeLa cells and the fluorescence intensity from 
the Cy5-labeled siRNA was used to compare the amount of the fluorescently labeled siRNA in the 
cells through binding and internalization of the two formulations. The fluorescence intensity from 
delivery of the targeted liposomes encapsulating complexed or uncomplexed siRNA was similar 
(Figure 28).  The effect of siRNA loading in the targeted stealth liposomes was also considered. 
The theoretical fraction of loaded liposomes was calculated as reported previously,272 using an 
average of 26.8 siRNA molecules per siRNA/PEI complex based on the number of siRNA-PEI 
binding sites (n = 0.57 ± 0.02) calculated using the ITC data shown in Figure 23. The theoretical 
loading of the uncomplexed siRNA in the targeted stealth liposomes is 100% compared to 34.0 ± 
3.9% for the complexed siRNA. A difference in the fraction of loaded liposomes would therefore 
not explain the difference in transfection efficiency and since the presence of PEI has no apparent 
effect on the binding and internalization efficiency of the targeted liposomes encapsulating the 
siRNA, this suggests that the improved transfection efficiency observed in the presence of PEI is 
realized after internalization.  
 
Figure 28. Binding and internalization of targeted stealth liposomes encapsulating siRNA. 
Binding and internalization of targeted stealth liposomes encapsulating complexed siRNA/PEI (N:P = 6, 5.5 
± 0.2 mol% AG86) or uncomplexed siRNA (N:P = 0, 5.8 ± 0.2 mol% AG86) quantified using flow cytometry. 
2.5 nM of Cy5-labeled siRNA were delivered to HeLa cells for 24 h. Background fluorescence of untreated 
cells was subtracted from data. Data are normalized to fluorescence vs. concentration standards for each 
liposome batch. Data are presented as the mean ± SE (n = 6). There was no significant statistical difference 
between the pair of means. 
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Cytotoxicity of siRNA Encapsulated in Targeted Stealth Liposomes 
The optimized targeted stealth liposomes encapsulating siRNA/PEI at N:P = 6 were evaluated 
further for their cytotoxicity against α6β4-expressing, HPV-containing cancer cells in vitro. The 
targeted stealth liposomes encapsulating either complexed (N:P = 6) or uncomplexed siRNA (N:P 
= 0) were delivered to HeLa cells and cell viability was assayed 24 h later. As Figure 29 shows, the 
nanoparticles with the complexed siRNA decreased cell proliferation by 30%, while those 
encapsulating the uncomplexed siRNA had no effect on cell proliferation. Increasing the 
concentration of liposome encapsulated, complexed siRNA delivered did not significantly increase 
the effect on cell proliferation (data not shown). 2.5 nM siRNA delivered using targeted stealth 
liposomes achieved 68% mRNA silencing, as shown in Figure 26, however protein expression and 
subsequent phenotypic effects are not quantitatively predicted by mRNA expression and may 
account for the observed 30% cell toxicity.289,290  Our results are in agreement with previous 
findings where it was shown that silencing of the HPV-E7 gene using RNAi promoted 80-90% 
mRNA silencing and resulted in 40-60% inhibition of cell proliferation at early time points.264,291  
Therefore, continued doses of siRNA may be necessary to achieve more potent cytotoxicity effects.  
  
Figure 29. Cytotoxicity of targeted stealth liposomes encapsulating siRNA. 
Cytotoxicity of targeted stealth liposomes encapsulating siRNA either complexed with PEI (siRNA/PEI at 
N:P = 6, 5.5 ± 0.2 mol% AG86) or  uncomplexed siRNA (N:P = 0, 5.8 ± 0.2 mol% AG86). 2.5 nM of siRNA 
were delivered to HeLa cells for 24 h and toxicity from HPV-E7 silencing was measured by comparing cell 
viability of treated and untreated cells. Data are presented as the mean ± SE (n = 4, performed in triplicate). 
* p-value <0.05. 
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complexes of a nonspecific sequence were delivered to the HeLa cells either free in solution or 
encapsulated in the targeted liposomes. As Figure 30 shows, none of the isolated components 
exhibited significant cytotoxicity compared to the untreated control, thus concluding that the 
toxicity observed in Figure 29 was the result of transfection of the si18E7-674 siRNA sequence.   
 
 
Figure 30. Toxicity from the components of targeted stealth liposomes used for siRNA delivery.  
The targeted stealth liposomes (750 nM lipids or 2.5 nM siRNA) were delivered to the cells. Empty targeted 
liposomes (5.3 ± 0.1 mol% AG86), siRNA/PEI particles (N:P = 6) of nonsilencing siRNA, and siRNA/PEI 
particles (N:P = 6) of nonsilencing siRNA encapsulated in the targeted liposomes (4.9 ± 0.2 mol% AG86) 
were delivered to HeLa cells for 24 h and toxicity was measured by comparing cell viability of treated and 
untreated cells. Data are presented as the mean ± SE (n = 3, performed in triplicate). There was no significant 
statistical difference between any pairs. 
Discussion 
Numerous gene silencing targets with therapeutic potential to treat cancer, viral infections and 
respiratory diseases have been identified, but effective systemic gene delivery strategies are critical 
for successful pursuit of these genetic targets.255,256,265  While cationic polyplexes or lipoplexes 
mediate extremely effective RNAi transfection in vitro, their instability and immunogenicity in 
vivo preclude their clinical success, which has inspired numerous synthetic 
alternatives.197,199,254,257,288,292  Most notably, stable nucleic acid lipid particles (SNALPs), liposome-
polycation-DNA, cyclodextrin nanoparticles, and lipidoids are cationic lipid and polymer based 
nanoparticles that have become extremely popular for preclinical exploration of siRNA delivery 
for cancer therapy.253,254,293 Liposome-polycation-DNA particles composed of both DNA and 
siRNA complexed with protamine, coated with cationic liposomes, shielded with PEG and targeted 
to a lung cancer biomarker were used to deliver growth receptor silencing siRNA to lung tumors 
in mice and achieved extremely high tumor localization. Interestingly, the presence of the targeting 
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ligand didn’t improve tumor localization, but did mediate enhanced cellular uptake and therefore 
silencing and tumor cell apoptosis. However, the targeted nanoparticles also elicited high levels of 
cytokine production.294 siRNA complexed with a cationic peptide, encapsulated in cationic 
liposomes and coated in cleavable PEG were designed for the PEG to be cleaved upon exposure to 
tumor associated matrix metalloproteinases. The addition of PEG or cleavable PEG improved 
tumor accumulation 10-20 fold over naked nanoparticles, but silencing was significantly improved 
only in nanoparticles modified with cleavable PEG, allowing for internalization and transfection.295 
A large lipidoid library was synthesized to develop structure function relationships for amine 
functionalized lipid molecules used for the production of biodegradable siRNA lipidoid 
nanoparticles.296 Structure function relationships developed from transfection efficiency analysis 
of this lipidoid library were used to predict and design highly efficient siRNA delivery vehicles. 
The optimal PEGylated siRNA lipidoid nanoparticles achieved more than 95% protein silencing in 
vivo in hepatocytes.296 Interestingly, surface pKa of a particular lipidoid was a critical parameter 
for predicting transfection efficiency for a particular lipidoid nanoparticle.296  The SNALPs are a 
well-studied nontargeted lipid based delivery vehicle which has seen great success in preclinical 
studies. In one study, SNALPs were used to silence polo-like kinase 1 in tumors while abrogating 
activation of innate immune response and reducing tumor size by 75%.297  Transferrin targeted 
cyclodextrin particles have also successfully delivered siRNA to tumors in vivo, and an 
accumulation/function study again revealed similar tissue accumulation for targeted and 
nontargeted nanoparticles, but enhanced transfection associated with targeting.298 Preclinical 
results from SNALP and cyclodextrin nanoparticle development motivated clinical trials for 
oncogene silencing and cancer treatment.293  With these advances, many biodistribution challenges 
have been addressed, and often the key barrier lies in specific cellular uptake and appropriate 
intracellular release.198,265  
Previous work within our group has shown that pDNA condensed with PEI can be fully 
encapsulated within neutral stealth liposomes composed of the same materials as FDA approved 
doxil and other clinical liposomal cancer treatments.79,272 Stealth liposomes encapsulating 
pDNA/PEI complexes were functionalized with a targeting peptide for specific delivery to α5β1-
expressing cancer cells and demonstrated excellent in vivo delivery and transfection in a metastatic 
colorectal mouse model.79  Furthermore, a modular multifunctional gene delivery system was 
prepared in our group by combining the extracellular targeting ability of peptide-functionalized 
stealth liposomes with a new form of transcriptional targeting, by designing a therapeutic pDNA 
under the control of an NF-κB responsive element. The targeted nanoparticles (encapsulating 
pDNA/PEI complexes) specifically killed close to 70% of cancer cells while minimally affecting 
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healthy cells in vitro.299 Mechanistic investigations revealed that stealth liposomes targeting the 
α5β1 integrin and encapsulating pDNA/PEI complexes internalized into DLD-1 colorectal cancer 
cells through macropinocytosis and caveolar mediated endocytosis. The targeted stealth liposomes 
achieved higher transfection efficiency and more efficient endosomal release than pDNA/PEI 
complexes alone, suggesting a cooperative effect on internalization and intracellular delivery 
mediated by the targeted stealth liposomes encapsulating pDNA/PEI complexes.274   
Our in vitro and in vivo delivery success with plasmid transfection prompted translation of 
targeted stealth liposomes encapsulating pDNA condensed with PEI to the equally challenging 
technology of specifically delivering siRNA. Our discoveries, along with evidence in the literature 
from various nonviral gene delivery vehicles that the key delivery barriers may lie in intracellular 
activity,265,272 inspired the hypothesis that PEI complexation of siRNA, though not necessary for 
encapsulant size considerations as in the case of pDNA, may provide additional benefits to siRNA 
delivery using targeted stealth liposomes. In this work, we designed AG86-functionalized stealth 
liposomes that targeted α6β4-expressing HeLa cervical cancer cells with the goal of delivering the 
si18E7-674 siRNA sequence, developed to silence the HPV-E7 gene. The delivery vehicle design 
considerations addressed here included identifying 5 mol% as a sufficient AG86 peptide 
concentration for binding and internalization, exploring the necessity of PEI complexation before 
encapsulation, and then identifying the optimal N:P ratio for effective transfection efficiency.   
ITC analysis demonstrated that siRNA complexes are saturated with PEI at N:P = 2, however 
increasing the N:P ratio increased the zeta potential of the complexes. This seemingly conflicting 
result seems to support the binding model proposed in the literature, where siRNA escapes from 
initial nanocomplexes near N:P = 1 and reorganizes into nanoparticles with fewer siRNA molecules 
per particle in the presence of additional polymer,286,300,301 which would result in more positive 
charge dense complexes without significantly changing complex size.  siRNA complexed with PEI 
was efficiently encapsulated in targeted stealth liposomes, achieving on average 60% encapsulation 
yield, where other neutral lipid based vehicles encapsulated 10% or less.288   It was found that there 
was no significant statistical difference in encapsulation yield between targeted stealth liposomes 
encapsulating siRNA/PEI complexed at different N:P ratios, while silencing increased with 
increasing N:P up to N:P = 6. Others have also observed an increase in siRNA transfection using 
PEI with increasing N:P up to a certain ratio, followed by a decrease in transfection efficiency. The 
increase in transfection with increasing N:P ratio was attributed to higher uptake, and the decrease 
attributed to increasing cytotoxicity at higher N:P ratios.270,281,284,286 Since binding and 
internalization of the targeted stealth liposomes is largely driven by the targeting peptide as shown 
before and in Figure 20,274 and not by the presence of PEI in the liposomes, this explanation is 
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insufficient. Therefore, we speculate that the increase in siRNA silencing with an optimal N:P ratio 
of the encapsulated siRNA/PEI is more likely caused by an optimization of the local buffering 
capacity within the liposome.302–304 Since targeted stealth liposomes encapsulating siRNA/PEI 
complexes at N:P = 6 showed no difference in binding and internalization compared to liposomes 
encapsulating uncomplexed siRNA (N:P = 0), as shown in Figure 28, but achieved 3.7 fold higher 
silencing efficiency (Figure 26), this indicates that the PEI complexation of siRNA in these gene 
delivery vehicles may have improved efficiency either through carrier release, endosomal escape, 
or a combination of both. PEI mediated endosomal release could minimize immunogenicity, as it 
has been found that the endosomal acidification process is crucial to siRNA induction of the 
interferon and cytokine response.305  
Active targeting has been shown to significantly improve transfection for several other gene 
delivery vehicles.294,298,306  Targeting can be desirable as it can both increase the concentration of 
internalized siRNA and influence trafficking pathways into the cell. Therefore, in addition to any 
benefit PEI may provide, the actual internalization pathway of the targeted delivery vehicle  after 
binding to the receptor of choice may play a synergistic role, as shown in the case of stealth 
liposomes targeting the α5β1 integrin and encapsulating pDNA/PEI complexes.274 The 
internalization pathways of the α6β4 integrin have yet to be elucidated,280,307–310 but it is possible 
that they may play a synergistic role in transfection efficiency.  
Targeted stealth liposomes encapsulating siRNA/PEI at N:P = 6 decreased the proliferation of 
HeLa cells by 30% on average with 2.5 nM si18E7-674, demonstrating a potential therapeutic 
effect for this system while suggesting that repeated doses of this siRNA sequence may be 
necessary to achieve more potent cytotoxicity effects. 
 A significant challenge for cancer therapy lies in the effective discrimination between healthy 
and tumor tissue. Targeting delivery vehicles to cancer biomarkers in order to improve delivery 
specificity has been explored in depth, however, off target delivery is a common limitation of this 
scheme.311,312  Additional genetically mediated targeting could potentially overcome this obstacle 
by removing off target effects from the therapy itself.299,313,314  Each aspect of the targeted stealth 
liposome encapsulating siRNA/PEI complexes, provided a significant delivery mediator: the 
vehicle targeting mediating cell internalization and improving bioavailability of the therapy at the 
tumor site, and the viral-specific gene silencing minimizing off target effects since healthy cells 
lack the targeted viral genome. Combined with the improvement to intracellular availability and 
transfection through PEI complexation, targeted stealth liposomes encapsulating siRNA/PEI 
complexes provide an example of a modular gene delivery vehicle designed to address each barrier 
to gene therapy.   
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Chapter 4  Theoretical and In Vitro Understanding 
of the Effect of Ligand-Receptor Valency on Dual-
Ligand Nanoparticle Delivery 
Introduction 
Effective chemotherapy is limited by the nonspecific delivery of toxic cancer drugs, causing 
harmful side effects and limiting clinical dosages. Targeted drug delivery strategies have increased 
the bioavailability of therapeutics to cancer tissue, decreased side effects from off target delivery 
to healthy tissue, and greatly improved clinical outcomes. Targeting to tumor tissue is mediated by 
ligands identified or designed to specifically bind to aberrantly expressed cancer biomarkers.315–318 
Specific targeting using antibodies to CD20 and human epidermal growth factors 1 and 2 (EGFR 
and HER2) has revolutionized clinical treatment of multiple myeloma, colorectal carcinoma, 
lymphoma, and breast cancer,316,319 and nanoparticle therapies targeting the transferrin receptor and 
EGFR have entered clinical trials.315,318,320 Unfortunately, targeted cancer biomarkers are not 
entirely unique to cancer, and low or even comparable levels of expression of the same cancer-
associated receptors can be found on certain healthy tissues.321–323 While targeting can decrease 
nonspecific delivery to most healthy tissue, off-tumor, target-related toxicity can occur through 
delivery to healthy tissue with measurable expression of the targeted receptor, resulting in the 
clinical challenge of mechanism-based toxicity.311,324 As a potential solution to this challenge, dual-
ligand nanoparticle drug delivery is explored here with two goals in mind: first, to effectively 
increase the targeted receptor density on cancer cells by targeting more than one receptor, therefore 
enhancing delivery, and second, to improve selectivity for cells with overexpression of both 
targeted receptors.    
In this investigation, we have created dual-ligand stealth liposomes functionalized with 
peptides targeting the α5β1 and α6β4 integrins. Stealth liposomes represent an effective delivery 
vehicle taking advantage of passive targeting through the enhanced permeability and retention 
effect.325 The polyethylene glycol (PEG) layer that decorates the surface of the stealth liposomes 
provides them with superior serum stability, extended blood circulation kinetics, and immunogenic 
protection, resulting in clinically relevant tumor accumulation and drug delivery.203,326,327 In order 
to exploit these benefits for gene delivery, we have previously developed stealth liposomes 
encapsulating siRNA or plasmid DNA (pDNA), which have demonstrated effective delivery to 
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several cancer cell types (See Chapters 2 and 3).79,272,274,299 The α5β1 and α6β4 integrins were chosen 
as appropriate receptors for dual-ligand targeting because they are upregulated in many of the same 
cancer types including breast,268,323,328–330 colon,331–333 and prostate334–337 and are often associated 
with metastatic development.337–339 Both integrins are internalized and recycled,280,308 a desirable 
characteristic for a drug delivery target.315 The apparently contrasting expression of each of these 
integrins in healthy tissues makes them relevant receptors to appropriately distinguish between 
single-receptor expressing cells and dual-receptor expressing cancer tissue in vivo.323,340 
Peptides are ideal as targeting ligands for delivery applications because they can be designed 
or selected for high target specificity, and elicit low toxicity and immunogenicity.20,198 The use of 
peptide ligands also provides flexibility and control of ligand incorporation into liposomes. Peptide-
amphiphiles can be synthesized to directly participate in liposome self-assembly so that peptide 
valency can be controlled through variation of peptide-amphiphile concentration during assembly. 
A peptide ligand, PR_b, was developed within the Kokkoli group for enhanced specificity for the 
α5β1 integrin.67,70,71  It has been successfully utilized for targeted drug and gene delivery in vitro 
and in vivo for applications to prostate, breast, and colon cancer.69,72,73,75,78,79,206,273 The AG86 
peptide was identified through bead display of laminin derived peptides to bind specifically to the 
α6 integrin, but not the β1 integrin.269   As the α6 integrin is known to heterodimerize with either the 
β1 or β4 integrin,341 it was hypothesized that the AG86 peptide was specific for the α6 integrin or 
the α6β4 integrin pair.  The AG86 peptide was used here for the first time as a targeting ligand, and 
shown to be an effective ligand for drug delivery.    
The potential of dual-ligand functionalized nanoparticles has been explored recently with 
varied levels of success,8,312,342–354 however very few investigations attempted to quantify the 
parameters affecting nanoparticle binding and internalization, which is critical for a systematic 
understanding of future vehicle design. For example, stealth immunoliposomes targeting CD19 and 
CD20 showed additive binding effects when comparing the same total antibody concentration 
between dual- and single-ligand liposomes. However, increasing valency for the dual-ligand 
liposomes decreased uptake, which was suggested to be caused by steric effects.342  A fluorescent 
assay was developed within that study to quantify individual antibody densities but ligand affinities 
and receptor expressions were not addressed.342 Stealth immunoliposomes functionalized with folic 
acid and anti-EGFR antibodies demonstrated an impressive selectivity achieved by combining 
suboptimal single-ligand densities for dual-ligand delivery, however, lack of characterization of 
ligand affinities, receptor expression or internalization rates precludes the development of 
generalizable design parameters from these results.312   
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Dual-ligand nanoparticles have also been explored for gene delivery as a virus-mimetic 
delivery scheme. Polyethylenimine (PEI) polyplexes functionalized with native ligands targeting 
the transferrin receptor and EGFR improved transfection compared to single-targeted 
polyplexes.344  Discussion of ligand affinities or quantitative receptor expressions were absent. 
Functionalizing PEI with targeting ligands presents a challenge to ligand valency estimation 
because polyplex formation results in a large proportion of free PEI,249 and no further ligand 
quantification was provided outside of initial ligand concentration.344  Polyplexes targeted to 
choroidal neovascularization via transferrin and RGD (to target the transferrin receptor and the αvβ3 
integrin) and delivered in vivo achieved less efficient delivery than single-targeted RGD 
polyplexes. Expression levels for the two receptors were not confirmed in the target tissue, and 
delivery localization suggested that the two ligands had targeted two distinct tissues, rather than 
simultaneously targeting the same cells.345  PEI polyplexes functionalized with two peptides 
targeting the transferrin receptor and the αvβ3 integrin showed improved in vitro transfection in 
prostate cancer cells when compared to single-ligand polyplexes with half the overall peptide 
density.8 Internalization and blocking observations of the dual- and single-ligand polyplexes led to 
the hypothesis that each ligand provided a unique delivery mechanism, binding via αvβ3 and 
internalization via the transferrin receptor.8   
Stealth liposomes targeted to αvβ3 and galectin-1 for magnetic resonance imaging of tumor 
angiogenesis showed enhanced uptake in vitro when compared to single-ligand liposomes with the 
same individual peptide density but lower overall peptide density. Dual-ligand liposomes also 
demonstrated enhanced uptake compared to combinations of single-ligand liposomes delivered 
simultaneously.346  In vivo delivery of these liposomes resulted in similar tumor accumulation 
between dual- and single-ligand liposomes, but dual-ligand liposomes mediated endothelium 
localization while RGD liposomes remained in the lumen.347  The effect of ligand and receptor 
density and ratio, as well as mobility on binding of dual-targeted immunoliposomes was also 
explored. NonPEGylated immunoliposomes targeted to ICAM and E-selectin were produced with 
constant overall antibody densities but varying antibody ratios. When delivered to cells with similar 
upregulated expression of both receptors, dual-ligand immunoliposomes with equal antibody 
valency achieved superior delivery.348–350 The effect of membrane fluidity and lipid raft formation 
was also explored using liposomes with immobile surfaces and cells with disrupted lipid rafts. 
Effective delivery was only achieved in the presence of lipid rafts and fluid liposome surfaces 
suggesting that clustering effects from both the ligand and the receptor are critical for dual-ligand 
binding of immunoliposomes.348  These studies highlight the complex design criteria significant for 
dual-ligand binding. More recently, gold nanoparticles targeted to the transferrin receptor and 
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EGFR using peptides with similar affinity and functionalized with a constant number of peptides 
per nanoparticle exhibited higher accumulation in dual- compared to single-expressing cells, and 
compared to single-ligand nanoparticles.354  Similar internalization rates were observed for the two 
receptors, reiterating the importance of characterizing vehicle parameters in heteromultivalent 
systems. These results emphasize the need for understanding and characterization of the key 
parameters that can influence dual-ligand multivalent binding as they can be critical to intelligent 
vehicle design.   
When assessing a multivalent system, there are many parameters which influence the binding 
kinetics and thus the delivery vehicle’s efficiency and selectivity in binding. The affinity of a 
nanoparticle for a cell is determined by the available valency of interaction, which is affected by 
the size of the nanoparticle, the affinity of individual binding events between a ligand-receptor pair, 
the local receptor density, the length of the bound ligand-receptor pair and the local peptide density. 
278,279,355–358 When multiple ligands are attached to the same molecule or vehicle and interact with 
receptors attached to a surface, each additional ligand-receptor pair that participates in a binding 
event contributes to the apparent affinity of the construct. Importantly, it has been observed that an 
increase in ligand-receptor valency contributes more than an additive increase to affinity, and this 
phenomena is referred to as avidity.279,356,357,359–361 The surface density of a receptor therefore has a 
significant effect on the delivery efficiency of targeted nanoparticles, and with the introduction of 
a second ligand to the liposomes, the density of both targeted receptors and the ratios of each 
receptor on a cell will strongly influence nanoparticle binding. The density and ratio of both ligands, 
as well as the comparative affinities of the two interactions become additional controllable 
parameters. This study explores how variations in these parameters affect the efficiency and 
selectivity of a dual-targeting nanoparticle system both in vitro and using a kinetic binding model. 
In order to identify cell lines with a wide range of receptor expression levels and ratios, the 
expression of α6, β4 and α5β1 integrins were quantified on multiple cell lines. A theoretical model 
was developed to explore the effects of cellular receptor expression and liposome ligand density on 
the binding of AG86/PR_b dual-ligand nanoparticles to cancer cells. Guided by the model results, 
in vitro studies were used to explore the actual enhancement to delivery and selectivity achieved 
with dual-ligand nanoparticles to cells with various receptor expression levels. A fluorescent assay 
for quantification of the peptide ratios incorporated in the dual-ligand liposomes is described for 
careful characterization of the peptide ratios. Integrin internalization rates were measured for 
several cell lines. Dual- and single-ligand liposomes were delivered to cells at 4 °C and 37 °C to 
evaluate heteromultivalent nanoparticle binding and internalization, and transfection studies 
demonstrated the potential of dual-ligand liposomal gene delivery.  
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Materials and Methods 
Cell Culture 
A-431, LS 174T, MDA-MB-231, MDA-MB-435, MDA-MB-468, and SK-OV-3 were grown 
in Dulbecco’s Modified Eagle Medium (DMEM) (ThermoFisher Scientific, Grand Island, NY). 
HT-1080, LNCaP, OVCAR-3, PC3-LN4, and  SW 1990 were grown in Roswell Park Memorial 
Institute 1640 medium (RPMI) (ThermoFisher Scientific, Grand Island, NY). HCT116 and HT29 
were grown in McCoy’s 5A medium (ThermoFisher Scientific, Grand Island, NY). DU145, 
HEPG2, and RKO were grown in Minimal Essential Medium (MEM) (ThermoFisher Scientific, 
Grand Island, NY), and BJ-fibroblasts, DLD-1, and MCF7 were grown in DMEM without sodium 
pyruvate (ThermoFisher Scientific, Grand Island, NY). All media were supplemented with 10% 
(v/v) fetal bovine serum (FBS), 100 units/ml penicillin, and 0.1 mg/ml streptomycin (ThermoFisher 
Scientific, Grand Island, NY). Cells were obtained from the American Type Culture Collection and 
A-431, LS 174T, MDA-MB-435, MDA-MB-468, SK-OV-3, HT-1080, PC3-LN4, SW 1990, 
HCT116, and HT29 were a gift from Professor Hackel, University of Minnesota. Cells were 
cultured in T75 flasks in DMEM at 37 °C and 5% CO2  and passaged when they reached 60-80% 
confluence by treatment with TrypLE Express cell dissociation agent (ThermoFisher Scientific, 
Grand Island, NY).   
Receptor Expression Quantification 
Cells were harvested and resuspended in 4 °C PBSA (1 w/v% bovine serum albumin (BSA) in 
phosphate buffered saline (PBS)), and incubated with a 1:100 dilution of MAΒ1969 mouse anti-
human α5β1 antibody (EMD Millipore, Darmstadt, Germany), MAΒ1964 mouse anti-human β4 
(EMD Millipore, Darmstadt, Germany), rat anti-human CD49f/α6 (eBioscience, Inc., San Diego, 
CA), IgG from murine serum (Sigma Aldrich, St. Louis, MO), or purified rat myeloma IgG2a (Life 
Technologies, Grand Island, NY) for 20 min at 4 °C on a rotary shaker. Separate α6 and β4 
antibodies were used because no α6β4 heterodimer antibody was available at the time of this study. 
Cells were pelleted by centrifugation at 500 g for 2.5 min, washed twice with 4 °C PBSA and 
incubated with 1:100 dilution of Alexa Fluor 488 goat anti-mouse IgG or Alexa Fluor 488 donkey 
anti-rat IgG (Life Technologies, Grand Island, NY) for 15 min at 4 °C on a rotary shaker. Following 
incubation, cells were pelleted by centrifugation, washed twice with 4 °C PBSA and analyzed 
immediately on a BD Accuri C6 flow cytometer (Masonic Cancer Center, University of 
Minnesota). Fluorescence intensity from isotype labeled controls were subtracted as background.  
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To determine the number of cell surface receptors from fluorescence intensity data, antibody 
binding capacities were compared with a standardized microbead calibration plot using Quantum 
Simply Cellular Bead standards (Bangs Laboratories, Inc., Fishers, IN) that were stained and 
measured in the same manner as the cells. 
Heteromultivalent Kinetic Model Development 
The kinetics of monovalent binding where one ligand binds to one receptor to form a complex, 
with forward and reverse reaction rates kf and kr, is well established, and has frequently been 
extended to multivalent binding.355,356,358–360,362 Complexes in multivalent interactions can be 
formed between n ligands and receptors to form a multivalent complex (Cn), with a forward reaction 
rate kx governing an additional ligand binding to produce Cn+1, and a reverse reaction rate k-x 
governing the dissocation of one ligand to produce Cn-1 (Equation 11).  
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In the case of multivalent binding of two distinct ligand receptor pairs (ligand a-receptor a and 
ligand b-receptor b), we must track which pair participates in each binding event. For example, 
consider nanoparticle L with ligands a and b which can bind to receptors a and b. From the state 
represented by C1a1b in Scheme 1 (where one a and one b ligands are bound), four different events 
can proceed: a second ligand a can bind at a forward rate of kxa to produce C2a1b, a second ligand b 
can bind at a forward rate of kxb to produce C1a2b, ligand a can dissociate at a reverse rate of kra to 
produce C1b, or ligand b can dissociate at a reverse rate of kra to produce C1a. Each of these events 
contribute to the accumulation of bound nanoparticles at that particular binding state, defining the 
rate equation for C1a1b.  Using this general scheme, Caplan and Rosca362 developed a heterovalent 
binding model for multiligand molecules containing two of each or three of each ligand. We 
expanded this model here to incorporate the additional valencies (up to a total valency of 8 for the 
ligand-receptor pairs) and combinations of valencies encountered between a dual-ligand 
multivalent nanoparticle and a cell.  Scheme 1 represents a nanoparticle with a total valency of 4 
and individual ligand valency of 2 for each ligand-receptor pair.   
Nanoparticle binding was modeled simultaneously for three representative cell lines; one with 
receptor expression similar to the high dual-receptor expressing SK-OV-3 cells (Ra=200,000, 
Rb=200,000), one with higher expression of receptor a (Ra=200,000, Rb=25,000) and one with 
higher expression of receptor b (Ra=25,000, Rb=200,000).  The kinetic parameters used in the 
(11) 
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model, including kr, kf, kx, k-x, and Kd for ligands a and b, were verified previously,362 with the 
assumptions that the reverse reaction rate for binding events occuring after the initial binding of 
the free nanoparticle is equal to the monovalent reverse reaction rate (k-x=kr), and that the forward 
reaction rate for events after the initial binding rate is proportional to the monovalent forward 
reaction rate adjusted by multiplying by the comparative height between the media in a well hwell 
and the ligand-receptor interaction length hbound (kxa=kfa*hwell/hbound), which was shown to be an 
appropriate estimation to model monovalent, divalent and trivalent binding to cells.362 hwell was 
calculated as the height of 200 µL of binding volume in a 6.4 mm diameter well. The fully extended 
length of an integrin as determined by electron microscopy is 20 nm,363,364 and the extended peptide 
length was measured at 2-3 nm,70 resulting in an hbound of approximately 23 nm.  The affinities of 
the two ligands were assumed to be equal. Equations and corresponding Matlab code can be found 
in Appendix A.  
 
Scheme 1. Representative schematic of the binding model of heteromultivalent nanoparticle binding. 
A nanoparticle L functionalized with two distinct ligands, each with an available valency of two, can interact 
with a multivalent surface in 8 unique ways. A free nanoparticle can bind via ligand a with a forward reaction 
rate of kfa and via ligand b with a forward reaction rate kfb. From each bound state, any unbound ligand has 
the potential to associate with a forward reaction rate of kxa or kxb, and each bound ligand has the potential to 
dissociate with a reverse reaction of kra or krb. Adapted from Caplan and Rosca.362   
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Peptide-Receptor Binding Affinity Analysis  
Cells were harvested and fixed in 4% paraformaldehyde in PBS for 10 min at room 
temperature, washed twice in PBS via centrifugation at 500 g for 2.5 min and resuspended into 
PBSA++ (1 w/v% BSA, 0.9 mM CaCl2, 0.5 mM MgCl26H20 in PBS buffer). A constant 
concentration of the labeled free PR_b or AG86 peptide was mixed with varying concentrations of 
unlabeled form of the peptide and incubated with cells for 3 h on an orbital shaker at 4 °C. PR_b 
(KSSPHSRNSGSGSGSGSGRGDSP) and AG86 (KSSLGGLPSHYRARNI) peptides (unlabeled 
and with N-terminus conjugated FITC) were purchased from United Biosystems (Herndon, VA). 
Cells were pelleted by centrifugation at 500 g for 2.5 min, washed twice with 4 °C PBSA++ and 
analyzed immediately on a BD Accuri C6 flow cytometer (Masonic Cancer Center, University of 
Minnesota). Nonlinear regression was used to fit binding curves to the fluorescence intensities to 
determine IC50 and Kd using Equations 12 and 13,365 
1 − 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑏𝑜𝑢𝑛𝑑 =
𝐿0
𝐿0 + 𝐼𝐶50
 
𝐾𝑑 = 𝐼𝐶50 − 𝐿0 
where 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑏𝑜𝑢𝑛𝑑 of the labeled ligand is measured as the fluorescence intensity of the 
sample divided by the maximum fluorescence intensity, and 𝐿0 is the initial concentration of 
unlabeled ligand. 
Fluorescent Liposome Preparation and Characterization 
Fluorescent liposomes were prepared as previously described.76 1,2- Dipalmitoyl-sn-glycero-
3-phosphocholine (DPPC), 1,2-dipalmitoyl-sn- glycero-3-phosphoethanolamine-N-
[methoxy(poly(ethylene glycol))-2000] (ammonium salt) (PEG2000), and cholesterol were 
purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). Peptide-amphiphiles with C16 dialkyl 
tails were made as described previously.67 5 µmol of 60-x mol % DPPC, 35 mol % cholesterol, 5 
mol % DPPE-PEG2000 and x mol % peptide-amphiphile dissolved in chloroform were combined 
in a round-bottom flask and dried under argon at 60 °C. The lipid film was hydrated with 2 mM 
calcein (Sigma-Aldrich, St. Louis, MO) in TNE buffer (10mM Tris, 150 mM NaCl, 1 mM EDTA) 
at 55 °C for 90 min. Liposomes were extruded 11 times using a manual extruder (Avestin, Ottowa, 
ON) through 200 nm membranes, and purified over a Sepharose CL-4B gel filtration column. Lipid 
concentration was measured using a phosphorus assay as described elsewhere.237,366 Peptide 
concentration in the liposomes was determined by the BCA protein assay (Thermo Scientific, 
Waltham, MA) following the manufacturer’s protocol. Peptide concentration is expressed as a mole 
(12) 
(13) 
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percentage of total lipid. Liposome size and charge were measured using dynamic light scattering 
and zeta potential analysis (Brookhaven Instruments Corporation, Holtsville, NY).  
Peptide Ratio Quantification 
PR_b and AG86 peptides were purchased from United Biosystems (Herndon, VA) with a C-
terminal cysteine (PR_b-C and AG86-C) and used to synthesize peptide-amphiphiles as described 
previously.67 Maleimide functionalized tetramethylrhodamine-5-maleimide (TAMRA) (Sigma-
Aldrich, St. Louis, MO) and N-(7-dimethylamino-4-methylcoumarin-3-yl)) maleimide (DACM) 
(Life Technologies, Grand Island, NY) were covalently attached to the PR_b-C and AG86-C 
peptide-amphiphiles respectively using maleimide thiol chemistry367 and purified using high 
performance liquid chromatography. The fluorophores were chosen for their non-overlapping 
excitation emission spectra, small size and neutral charge in order to easily discriminate between 
the fluorescent signals and minimize the effect of the fluorophore on self-assembly. Fluorophore-
functionalized peptide-amphiphiles were used to produce single-ligand liposomes at various 
peptide densities. Fluorescence intensities of DACM and TAMRA, normalized to lipid content, 
were measured at 405/450 and 561/582 nm respectively using a Synergy H1 multi-mode reader 
(Biotek, Winooski, VT), and used to create a peptide density standard. Fluorophore-functionalized 
peptide-amphiphiles were used to produce 75:25, 50:50 and 25:75 PR_b:AG86 functionalized 
stealth liposomes and fluorescence intensity was used to measure the density of each peptide to 
verify the final peptide ratio of the dual-ligand formulations. Nontargeted, single-ligand, and dual-
ligand liposomes were analyzed on a BD LSR II/Fortessa flow cytometer (Masonic Cancer Center, 
University of Minnesota) to verify incorporation of both ligands on individual liposomes.   
Antibody Blocking of Fluorescent Liposome Binding 
SK-OV-3 cells were fixed by incubation in 4% paraformaldehyde (Sigma, St. Louis, MO) for 
10 min at 25 °C, and aliquoted in 4 °C PBSA++. Cells were incubated with 1:100 dilution of 
MAΒ1969 mouse anti-human α5β1 antibody (EMD Millipore, Darmstadt, Germany), 1:100 dilution 
of rat anti-human CD49f/α6 (eBioscience, Inc., San Diego, CA), or 1:100 dilution of MAΒ1964 
mouse anti-human β4 (EMD  Millipore, Darmstadt, Germany) at 4 °C for 30 min. 10 µM PR_b- or 
AG86-functionalized stealth liposomes were added to the cells blocked with α5β1 or α6/β4 antibodies 
respectively and incubated at 4 °C for 1 hr, then washed twice with 4 °C PBS and analyzed 
immediately on a BD Accuri C6 flow cytometer (Masonic Cancer Center, University of 
Minnesota). 
Preparation and Characterization of Liposomes Encapsulating pDNA  
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Condensed plasmid DNA (pDNA) particles were prepared for encapsulation from 95% 
unlabeled pmaxGFP pDNA (gift from Prof. Hu, University of Minnesota) and 5% Cy5-labeled 
pmaxGFP for pDNA quantification as described previously.272  Labeled pDNA was prepared using 
Cy5 Label-IT tracker (Mirus, Madison, WI) according to the manufacturer’s protocol. 20 μg of 
pDNA were dissolved in water and an equal volume of 25 kDa branched polyethyleneimine (bPEI) 
(Sigma-Aldrich, St. Louis, MO) in water was added to the pDNA solution at an amine to phosphate 
(N:P) ratio of 8, vortexed for 5 min, and incubated at room temperature for 30 min. The N:P ratio 
was chosen for optimal size for subsequent encapsulation, and has demonstrated effective 
transfection within targeted stealth liposomes.79  Lipid films were prepared as above, and hydrated 
with the condensed pDNA particles at 45 °C for 90 min. The liposomes were then extruded 11 
times using a manual extruder (Avestin, Ottowa, ON) through 400 nm membranes, and the 
unencapsulated pDNA was removed with overnight dialysis purification through a 1000 kDa 
MWCO membrane (Spectrum Laboratories, Rancho Dominguez, CA).79,272  Final pDNA 
concentration in the liposomes was determined as described elsewhere using a concentration 
standard curve.272 Lipid and peptide concentration, and liposome size and charge were measured 
as described for fluorescent liposome preparation.   
Receptor Internalization  
Receptor internalization analysis was performed as reported previously.368  Cells were plated 
at 100,000 cells/well in 12 well plates and allowed to adhere overnight. Cells were incubated for 3 
h on an orbital shaker at 4 °C in PBSA++ with 100 µM fluorescein isothiocyanate (FITC)-labeled 
free AG86 or PR_b peptides to allow for binding to surface receptors. Cells were washed twice in 
PBSA++ and incubated for various times in prewarmed media and 0.6 µM primaquine (to prevent 
receptor recycling)369 at 37 °C.  Cells were washed twice in PBSA++ and incubated in acid stripping 
buffer (MEM adjusted to pH 3.5) three times for 5 min each time to remove surface proteins and 
surface bound fluorescent peptides. Cells were then washed twice in PBSA++ and harvested with 
TrypleE Express cell dissociation agent (ThermoFisher Scientific, Grand Island, NY). Cells were 
pelleted by centrifugation at 500 g for 2.5 min, washed twice with cold PBSA++ and analyzed 
immediately on a BD Accuri C6 flow cytometer (Masonic Cancer Center, University of 
Minnesota). 
Liposome Binding 
Cells were harvested and resuspended in PBSA++ at 0.5 x 106 cells/mL. Calcein-loaded 
liposomes were added at a final concentration of 10 µM lipids. Liposomes were incubated with 
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cells for 24 h on an orbital shaker at 4 °C to minimize internalization.370 Cells were then pelleted 
by centrifugation at 500 g for 2.5 min, washed twice with 4 °C PBSA++ and analyzed immediately 
by flow cytometry on a BD Accuri C6 flow cytometer (Masonic Cancer Center, University of 
Minnesota).  To determine fraction bound for time course experiments, fluorescence intensity was 
normalized to the maximum intensity measured for each liposome formulation.   
Liposome Binding and Internalization 
Cells were plated at 25,000 cells/well in 24 well plates and allowed to adhere overnight. 
Calcein-loaded liposomes were added at a final concentration of 10 µM lipids. Liposomes were 
incubated with cells for 24 h at 37 °C. Cells were then harvested with TrypleE Express cell 
dissociation agent (ThermoFisher Scientific, Grand Island, NY), pelleted by centrifugation at 500 
g for 2.5 min, washed twice with 4 °C PBS and analyzed immediately on a BD Accuri C6 flow 
cytometer (Masonic Cancer Center, University of Minnesota). 
Transfection Using Liposomes Encapsulating pDNA 
Cells were plated at 25,000 cells/well in 24 well plates and allowed to adhere overnight. They 
were transfected with liposomes encapsulating condensed pDNA at various DNA concentrations 
for 48 h at 37 °C. Cells were then harvested with TrypleE Express cell dissociation agent 
(ThermoFisher Scientific, Grand Island, NY), pelleted by centrifugation at 500 g for 2.5 min, 
washed twice with PBS and analyzed immediately on a BD Accuri C6 flow cytometer (Masonic 
Cancer Center, University of Minnesota). 
Statistics  
ANOVA analysis and Tukey Kramer honest significant difference (HSD) test were performed 
to calculate p-values and determine statistical significance between means unless otherwise 
indicated. 
Results 
Receptor Expression Analysis of Common Cancer Cell Lines 
The expression of α6, β4 and α5β1 integrins were quantified on 20 commonly investigated cell 
lines (Table 3 and Figure 31). The quantitative report of receptor expression on several cell lines 
of various origin allows for direct comparison of expression in different tissues.268,328,331,333–335 From 
the characterization of integrin receptor expression levels and relative α5β1:α6 and α5β1:β4 
expression, six cell lines were chosen for further investigation (Figure 31). The ratio of α5β1 to α6β4 
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expression was close to unity for MCF7 and SK-OV-3 cells, and the expression levels on SK-OV-
3 cells were 100 fold higher than on MCF7 cells, suggesting SK-OV-3 cells would function as an 
appropriate model for a high dual-receptor expressing cell line. MCF7 cells express 103-104 
receptors/cell, consistent with cancer biomarker expression levels measured on healthy model cells 
or tissues,371–373 suggesting MCF7 cells are appropriate as a low receptor expressing or “healthy” 
cell line.  
Four other cell lines were chosen with differential levels of integrin expression. RKO and HT-
1080 cells have higher α5β1 than α6β4 expression levels, with RKO exhibiting a higher ratio of 
α5β1:α6β4 expression, but lower overall expression than HT-1080 cells. LS 174T and SW 1990 cells 
have higher α6β4 than α5β1 expression, with LS 174T cells exhibiting a higher ratio of α6β4:α5β1 
expression and higher expression levels than SW 1990, and both cell lines express higher α6β4 
levels than the dual-receptor expressing SK-OV-3 cells. Note that all cells have measurable 
expression of both receptors. 
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Table 3. Expression levels of α5β1, α6 and β4 integrins on several cell lines.  
Many commercially available cancer cell lines, and one embryonic fibroblast line, were analyzed for α6, β4, 
and α5β1 expression levels using flow cytometry. Quantitative receptor expression levels were calculated by 
subtracting isotype controls as background and comparing fluorescent intensities to a bead calibration curve. 
Data are presented as the mean ± SE (n = 3-4 of longitudinal samples).   
 
Cell Line Cell Type 
α5β1   
(103 Receptors/Cell) 
α6   
(103  Receptors/Cell) 
β4   
(103  Receptors/Cell) 
A-431 
Skin Epidermoid 
Carcinoma 
164 ± 25 300 ± 56 356 ± 40 
BJ 
Embryonic 
Foreskin Fibroblast 
280 ± 65 92 ± 46 4.9 ± 0.5 
DLD-1 
Colorectal 
Adenocarcinoma 
40 ± 8 226 ± 20 165 ± 5.5 
DU 145 
Prostate 
Carcinoma 
174 ± 36 213 ± 13 58 ± 7.4 
HCT 116 
Colorectal 
Carcinoma 
99 ± 18 202 ± 10 165 ± 3.0 
HeLa 
Cervical 
Adenocarcinoma 
313 ± 28 279 ± 39 80 ± 16 
Hep G2 
Hepatocellular 
Carcinoma 
0.1 ± 0.8 102 ±16 5.4 ± 2.2 
HT-1080 
Connective Tissue 
Fibrosarcoma 
240±12 127 ± 21 1.6 ± 1.2 
HT-29 
Colorectal 
Adenocarcinoma 
36 ± 21 486 ± 23 375 ± 81 
LNCaP 
Prostate 
Carcinoma 
83 ± 21 77 ± 1.5 1.4 ± 2.3 
LS 174T 
Colorectal 
Adenocarcinoma 
11 ± 7 3050 ± 1710 1240 ± 647 
MCF7 
Breast 
Adenocarcinoma 
9.7 ± 3.5 10 ± 2.5 5.8 ± 2.3 
MDA-MB-231 
Breast 
Adenocarcinoma 
116 ± 49 245 ± 38 189 ± 69 
MDA-MB-435 Melanoma 55 ± 6 65 ± 29 0.3 ± 0.5 
MDA-MB-468 
Breast 
Adenocarcinoma 
4.1 ± 1.9 79 ± 18 36  ± 3.9 
OVCAR-3 
Ovarian 
Adenocarcinoma 
9.7 ± 1.2 20 ± 1.5 15 ± 2.8 
PC3-LN4 
Prostate 
Carcinoma 
(artificial lymph 
node metastasis) 
48 ± 0.1 208 ± 24 121 ± 3.6 
RKO Colon Carcinoma 33 ± 9.7 2.9 ± 1.1 0.03 ± 0.4 
SK-OV-3 
Ovarian 
Adenocarcinoma 
193 ± 12 359 ± 20 202  ± 21 
SW 1990 
Pancreatic 
Adenocarcinoma 
73 ± 38 505 ± 127 648 ± 163 
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Figure 31. Integrin expression levels of cancer cell lines.   
RKO, HT-1080, SK-OV-3, SW 1990, LS 174T and MCF7 were chosen as representative cell lines for in 
vitro investigation of dual-ligand nanoparticles based on their α6, β4 and α5β1 expression characterized with 
flow cytometry. Quantitative receptor expression levels were calculated by subtracting isotype controls as 
background and comparing fluorescent intensities to a bead calibration curve. Data are presented as the mean 
± SE (n = 3-4). Numerical values are also listed in Table 3. 
 
Heteromultivalent Kinetic Model 
With an initial nanoparticle concentration of 2.5x10-14 M, calculated as described previously,272 
which corresponds to a lipid concentration of 10 µM, the number of liposomes bound to each cell 
was calculated using the heteromultivalent model for nanoparticles with varying valencies from 0-
8 for each ligand and varying ratios of valencies. Selectivity was also calculated for each valency 
state as the ratio of the total number of nanoparticles bound to the cells with equal receptor 
concentrations (Figure 32A) to the total number of nanoparticles on whichever of the two other cell 
types showed greater binding (Figures 32B and 32C). Nanoparticles with higher valencies of ligand 
a were calculated to bind at higher levels to cells with higher expression of receptor a (Figure 32B), 
and nanoparticles with higher valencies of ligand b bound at higher levels to cells with higher 
expression of receptor b (Figure 32C).   
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Figure 32. Theoretical binding of heteromultivalent nanoparticles to three cell types. 
The heteromultivalent kinetic binding model was used to calculate nanoparticles bound to cells with high 
expression of both receptors (Ra=200,000, Rb=200,000) (A), higher expression of receptor a (Ra=200,000, 
Rb=25,000) (B), or higher expression of receptor b (Ra=25,000, Rb=200,000) (C). Valency of ligand a and b 
was varied from 0 to 8 and binding to each cell was measured, as well as selectivity (D) of (A) compared to 
(B) and (C). L = 2.5x10-14 nanoparticles, Kda= Kdb = 3.3x10-6 M, kfa = kfb = 300 M-1s-1, kra = krb = Kda x kfa, k-xa 
= k-xb = kra, kxa = kxb = 9.3x108 M-1s-1.  
 
Nanoparticles with equal valencies between ligand a and b bound at higher levels to the cells 
with equal receptor expression compared to other nanoparticle valencies (Figure 32A). This 
resulted in the highest selectivity of nanoparticles with equal a and b ligand valency for the dual-
receptor expressing cells compared to the other cell types (Figure 32D).  There also appears to be 
an optimum overall valency of 3 for each ligand-receptor pair, above which binding to the dual-
receptor expressing cells decreases, decreasing the selectivity.  Notably, the best valency for 
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targeting cells that expressed higher levels of one receptor is not the best valency to target the dual-
receptor expressing cell.   
Dual- and Single-Ligand Nanoparticle Delivery 
The results of the kinetic binding model suggest that for ligands of similar affinity for their 
targets, a 50:50 ratio of ligands on a nanoparticle surface will bind most effectively and most 
selectively to cells with a high and equal level of targeted receptor expression. With a basic 
theoretical understanding of the effect of valency on dual-targeted nanoparticle binding, this 
concept was explored in vitro. Single-ligand liposomes containing either PR_b or AG86, and dual-
ligand liposomes containing 75:25, 50:50 and 25:75 ratios of PR_b:AG86 were produced with 
similar overall peptide content in order to isolate synergy effects of dual-ligand binding from 
single-ligand avidity effects. Liposome size and zeta potential for each formulation are reported in 
Table 4. The ability to achieve the desired peptide ratios in the final dual-targeted liposomes 
compared to the initial peptide ratio during liposome formation was verified using fluorescently 
labeled peptide-amphiphiles. PR_b was labeled with TAMRA, and AG86 was labeled with DACM. 
As shown in Figure 33A, standards were created using single-ligand liposomes, and fluorescence 
intensity was used to measure peptide ratios in dual-ligand liposomes. A linear fluorescence-
concentration response excludes the possibility of fluorescence self-quenching within the 
investigated concentrations. Final peptide ratios for liposomes initially prepared with 75:25, 50:50 
and 25:75 ratios are shown in Figure 33B, and final peptide ratios for 50:50 and 25:75 formulations 
were not statistically different from initial ratios. Liposomes were also analyzed using flow 
cytometry to establish the presence of both peptides on individual liposomes. Nontargeted 
liposomes (Figure 33C) exhibit background fluorescence at both 561/582 (TAMRA) and 405/450 
(DACM) excitation/emission wavelengths. Functionalization with PR_b-TAMRA (Figure 33E) 
increases the TAMRA-positive population measured at 561/582 nm and functionalization with 
AG86-DACM (Figure 33F) increases the fluorescence intensity measured at 405/450 nm. 
Liposomes functionalized with both fluorescently labeled peptide-amphiphiles (Figure 33D) 
exhibit a simultaneous increase in fluorescence intensity measured at both sets of wavelengths, 
confirming the presence of both peptides on individual liposomes.  
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Table 4. Size and zeta potential of targeted stealth liposome formulations for delivery. 
Data are presented as mean ± SE (n = 5).  
Liposome Formulation Size (nm) 
Zeta Potential 
(mV) 
100% PR_b 181±14 -3.5±5.6 
75:25 PR_b:AG86 169±15 2.5±4.0 
50:50 PR_b:AG86 170±13 -1.8±2.6 
25:75 PR_b:AG86 168±15 -5.4±4.0 
100% AG86 178±5 8.0±2.6 
 
Binding affinity of PR_b and AG86 for their respective receptors was measured using a 
competition cellular assay (Figure 34). The affinities of both ligand-receptor pairs were similar, 
resulting in a Kd of 5.0 ± 3.8 µM and 2.6 ± 0.9 µM for PR_b and AG86 respectively. Similar ligand-
receptor affinities allow subsequent binding analysis to focus solely on valency effects. The Kd of 
PR_b for the α5β1 integrin was previously identified using an ELISA as 76.3 nM.68 Differences in 
measured Kd using different assays has been observed for other peptide binders,374 emphasizing the 
value of cellular Kd measurements for targeting ligand characterization.   
The specificity of the PR_b peptide for the α5β1 integrin has been characterized on endothelial 
and colon cancer cell lines,67,375 however the target specificity of the AG86 peptide is less well 
characterized. The AG86 peptide was initially identified to bind to the α6 integrin, with little 
interaction with the β1 integrin, suggesting an α6 or α6β4 specific binding interaction, as α6 can 
associate only with β1 or β4.269,341 In order to verify the specificity of the PR_b and AG86 liposomes 
for the α5β1 and α6β4 integrins respectively, single targeted liposomes were delivered to SK-OV-3 
cells in the presence and absence of antibodies to block access to the cell surface integrins. The 
presence of the anti-α5β1 antibodies decreased the PR_b liposome binding by 65%, verifying the 
specificity of PR_b for the α5β1 on SK-OV-3 cells (Figure 35A). The presence of the anti-α6 and 
anti-β4 antibodies decreased the AG86 liposome binding to SK-OV-3 cells by 79.7% and 70.6% 
respectively, demonstrating specificity of AG86 peptide binding to the α6β4 heterodimer (Figure 
35B).   
Single-ligand liposomes were first delivered to cells at 4 °C for 2-24 h to identify a sufficient 
incubation time for subsequent experiments in this study. 24 h was chosen as a sufficient time point 
as liposome binding appears to reach saturation before this point (Figure 36).  
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Figure 33. Characterization of peptide ratios in dual-ligand stealth liposomes.   
Single-ligand stealth liposomes were prepared with fluorescently labeled peptide-amphiphiles and used to 
produce a fluorescent concentration standard (A). Dual-ligand stealth liposomes were prepared with 4.5-5.5 
mol% of 75:25, 50:50 and 25:75 initial molar ratios of PR_b-TAMRA:AG86-DACM and final peptide 
percentages were calculated using the single-ligand standards (B). Peptide percentage data are presented as 
the mean ± SE (n = 3). Z test statistical analysis was performed comparing final to initial peptide contents. † 
p > 0.05. Nontargeted (C), 50:50 dual-ligand (D), 100% PR_b (E), and 100% AG86 (F) stealth liposomes 
were analyzed using flow cytometry to verify the presence of both fluorescently labeled peptide-amphiphiles 
in individual cytometry events.   
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Figure 34. Competition binding curves for PR_b-α5β1 and AG86-α6β4.   
Affinity of PR_b for the α5β1 integrin (A) and AG86 for the α6β4 integrin (B) were calculated from 
competition binding curves generated from delivery of 100 nM of FITC-labeled peptide and varying 
concentrations of unlabeled peptide to SK-OV-3 cells at 4 °C for 3 h.  
 
 
Figure 35. Antibody blocking of liposome binding. 
10 µM single-ligand calcein-loaded stealth liposomes were incubated with SK-OV-3 cells at 4 °C for 1 hr in 
the presence and absence of blocking antibodies, and binding was measured with flow cytometry. (A) PR_b 
stealth liposomes (5.0 mol% PR_b), blue, blocked with 1:50 anti-α5β1 antibody, purple, and (B) AG86 stealth 
liposomes (5.9 mol% AG86), yellow, blocked with 1:100 anti-α6, orange, or anti-β4, brown, antibody. 
Untreated cells were measured for background fluorescence (grey).  
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Figure 36. Effect of delivery time on liposome binding.   
10 µM of lipids of single-ligand stealth liposomes loaded with calcein and functionalized with 6.5 ± 2.5 
mol% PR_b or 6.3 ± 0.9 mol% AG86 peptide-amphiphiles were incubated with SW 1990 cells for various 
times and liposome binding was determined via flow cytometry. Fraction bound was calculated as 
fluorescence intensity/maximum intensity. Data are presented as the mean ± SE (n = 4).  
 
Single- and dual-targeted stealth liposomes with 5 mol% total peptide were incubated with 
several cells, with various receptor concentrations and ratios, for 24 h at 4 °C, to prevent 
internalization (Figure 37A). Two important observations emerge from the results shown in Figure 
37A: First, the 50:50 liposome formulation binds much more efficiently to SK-OV-3 cells, the high 
dual-receptor expressing cell line, than any of the other liposome formulations, achieving at least 
5 fold better binding than either of the single-ligand formulations. Second, the 50:50 formulation 
binds significantly more efficiently to SK-OV-3 cells than to any other cell, achieving 27 fold 
selectivity for SK-OV-3 cells compared to MCF7, a low dual-expressing cell line (a cell line with 
balanced but lower receptor expression), and 8-10 fold selectivity for SK-OV-3 cells compared to 
cells with unbalanced receptor ratios. Additionally, single- and dual-targeted stealth liposomes 
were delivered to the same cell lines at 37 °C to allow for binding and internalization (Figure 37B). 
Similar trends were observed for SK-OV-3 cells with liposome delivery at physiological 
conditions. 50:50 liposomes bound and internalized 2-3 fold more in SK-OV-3 cells than any other 
liposome formulation. They also bound and internalized to a higher extent in SK-OV-3 cells 
compared to RKO, SW 1990, LS 174T and MCF7 cells, however these differences were not 
statistically significant. Interestingly, in HT-1080 cells, 50:50 liposomes bound and internalized 
more efficiently compared to all other cells (there was no statistically significant difference between 
50:50 liposome binding to SK-OV-3 and HT-1080 cells), which was not the case when considering 
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binding alone. Differences in α5β1 and α6β4 internalization rates between cells were hypothesized 
to play some role in differences observed between binding (Figure 37A) and binding with 
internalization (Figure 37B) and were measured for each cell line (Figure 38). Figure 38 shows that 
the internalization of α5β1 and α6β4 integrins was similar for each cell. In general, internalization of 
both integrins was very rapid in HT-1080, SK-OV-3 and SW 1990 cells, with almost all integrins 
initially present at the surface internalized after 45 min. Integrin internalization was relatively 
slower in RKO, LS 174T and MCF7 cells, with only 30-60% of integrins internalized after 45 min 
of incubation at 37 °C.  
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Receptors/cell (103) 
 RKO HT-1080 SK-OV-3 SW 1990 LS 174T MCF7 
α5β1 33±10 240±12 190±12 73±38 11±6.6 10±4 
α6 2.9±1.1 127±21 360±20 510±1130 3100±1700 10±3 
β4 0.03±0.4 1.6±1.2 200±21 650±160 1200±650 6±2 
 
Figure 37. Dual- and single-targeted stealth liposome delivery to cells with varying receptor density.   
Stealth liposomes loaded with calcein and functionalized with 100% PR_b, 75% PR_b:25% AG86, 50% 
PR_b:50% AG86, 25% PR_b:75% AG86, or 100% AG86, were delivered to RKO, HT-1080, SK-OV-3, SW 
1990, LS 174T, and MCF7 cells for 24 h at 4 °C (A) to measure liposome binding, or 37 °C (B) to allow for 
binding and internalization. Total peptide concentration, shown in the legend for each formulation, was kept 
constant to keep total valency constant across samples. Data are presented as mean ± SE (n = 5). Fluorescence 
intensity of bound and internalized liposomes was measured using flow cytometry. * in (A) p < 0.05 
compared to all other samples. * in (B) shows significant statistical difference (p < 0.05) between the 50:50 
formulation with the HT-1080 cells and the formulations covered under the horizontal lines. The table shows 
the integrin expression levels measured for the cell lines. There was no significant statistical difference for 
pairs without brackets. 
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Figure 38. Internalization of α5β1 and α6β4 integrins.   
FITC-labeled PR_b and AG86 were allowed to bind for 3 h at 4 °C to α5β1 integrin and α6β4 integrin, 
respectively, on RKO (A), HT-1080 (B), SK-OV-3 (C), SW 1990 (D), LS 174T (E), and MCF7 (F) cells. 
Integrin bound peptides were allowed to internalize for 5-45 min at 37 °C in the presence of primaquine 
before surface bound peptide was removed via acid stripping. Internalized peptide was quantified via flow 
cytometry. Receptor internalization (%) was calculated as fluorescence intensity/fluorescence intensity in the 
absence of acid stripping. Data are presented as mean ± SE (n = 3). 
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Transfection with Single- and Dual-Ligand Liposomes 
For a cell line with comparable high levels of expression of two targeted receptors, the best 
binding and selectivity was achieved using dual-ligand liposomes with equal composition of the 
two ligands (Figure 32A, D and 37A). This concept was further explored with the delivery of a 
GFP reporter plasmid to the high dual-receptor expressing SK-OV-3 cells. RKO and LS 174T cells 
were also used as cells with much higher levels of expression of one receptor, and MCF7 cells were 
included as low dual-receptor expressing cells. Condensed pDNA was fully encapsulated79,272 (see 
Chapter 2) within PR_b or AG86 single-ligand stealth liposomes, or 50:50 dual-ligand stealth 
liposomes, and delivered to cells for 48 h, before GFP fluorescence and Cy5-labeled pDNA 
fluorescence were measured to determine transfection efficiency and internalization, respectively.  
Even with the additional barriers that exist between internalization and transfection, the dual-ligand 
stealth liposomes were more effective at transfecting the SK-OV-3 high dual-receptor expressing 
cells than single-ligand stealth liposomes (Figure 39A). Dual-ligand liposomes also mediated 
selective delivery to SK-OV-3 compared to RKO, LS 174T and MCF7 cells which was observed 
both in pDNA internalization and transfection (Figure 39A and 39B). Increasing the amount of 
pDNA delivered to SK-OV-3 cells with the dual-ligand stealth liposomes increased both pDNA 
internalization and transfection nonlinearly (Figure 40).   
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Figure 39. Gene delivery and transfection with dual- and single-targeted stealth liposomes.   
Stealth liposomes encapsulating condensed pDNA/PEI, where the pDNA was fluorescently labeled with Cy5, 
were functionalized with 100% PR_b, 50% PR_b:50% AG86, or 100% AG86 and used to deliver 500 ng of 
GFP plasmid to RKO, SK-OV-3, LS 174T or MCF7 cells. Total peptide concentration, shown in the legend 
for each formulation, was kept constant. The liposomes were incubated with the cells for 48 h at 37 °C. (A) 
Transfection was measured via GFP fluorescence and (B) pDNA internalization was measured via Cy5 
fluorescence using flow cytometry. Data are presented as mean ± SE (n = 3). * in (A) p  < 0.05 compared to 
all other samples. * in (B) p  < 0.05. There was no significant statistical difference for pairs without brackets 
in (B). 
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Figure 40. Gene delivery and transfection with dual-targeted stealth liposomes at various concentrations. 
Stealth liposomes functionalized with 50% PR_b:50% AG86 (total peptide 6.2 ± 0.8 mol%) encapsulating 
Cy5-labeled condensed pDNA were used to deliver 0.1-1.0 µg GFP pDNA to SK-OV-3 cells for 48 h at 37 
°C. Transfection was measured via GFP fluorescence and internalization was measured via Cy5 fluorescence. 
Data are presented as mean ± SE (n = 3). * p < 0.05. There was no significant statistical difference for pairs 
without brackets. 
 
Discussion 
The concept of functionalizing nanoparticles with dual multivalent ligands for improved 
delivery of chemotherapy has only recently been pursued,8,312,342,344,345,349,350,354 and with each 
success, the accompanying challenges emphasize the need for systematic understanding of relevant 
vehicle parameters and their effect on delivery to guide the design of efficient delivery vehicles.   
As delivery schemes become more sophisticated, the experiments necessary to fully characterize 
their cellular interactions become combinatorially complex, and the experimental load becomes 
unmanageable. Therefore, developing even basic models to establish critical parameters and 
general trends can guide more strategic experiment design.   
Anticipated to significantly contribute to dual-ligand nanoparticle delivery efficiency, receptor 
expression was quantified for several cancer cell lines. Some general integrin expression trends can 
be elucidated where multiple cell lines from the same cancer type were characterized. The α5β1 
integrin is normally associated with ovarian cancer development and metastasis,376 however there 
is conflicting evidence of the involvement of α6β4 in ovarian cancer progression.377,378  The ovarian 
cancer cells characterized here (SK-OV-3 and OVCAR-3) both have moderate to high levels of 
expression of the two integrins, with α5β1:α6β4 expression ratios close to unity, corroborating the 
evidence that both integrins are associated with ovarian cancer development. Upregulated α5β1 
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expression has also been observed in breast cancer,323,330 and poor prognosis329,379 and metastases328 
in breast cancer patients is commonly associated with high levels of α6β4 expression, particularly 
in triple negative breast cancer (an especially aggressive and hard to treat type of breast cancer).  
MDA-MB-231 and MDA-MB-468 cell lines, which have been identified as triple negative breast 
cancer cell lines,380 express moderate to high levels of α6β4 integrin (104-105 receptors/cell) and 
MDA-MB-231 also expresses high levels of α5β1 (>105 receptors/cell). However, MCF7 cells, a 
breast cancer cell line that is not triple negative, expressed low levels of both integrins. High levels 
of α6β4 and α5β1 expression also facilitates invasive malignancy in colorectal cancer.322,331 With the 
exception of RKO cells which have previously demonstrated negligible α6β4 expression,331 the 
characterized colorectal carcinoma cell lines expressed low to moderate levels of α5β1 integrin 
(<105 receptors/cell) and high levels of α6β4 expression (>105 receptors/cell). DU145 and PC3-LN4 
cells, which are prostate carcinoma cell lines, exhibited α5β1:α6β4 expression ratios that were closer 
to unity than the colorectal cancer or breast cancer cell lines, with similar overall expression levels. 
LNCaP cells, another prostate carcinoma cell line, however, had almost 100 fold lower β4 
expression than α5β1 and α6 expression. While in vitro cellular expression analysis cannot always 
be extrapolated to in vivo environments, the characterization of cellular expression reported here of 
integrins which have been identified as cancer biomarkers highlights the subtleties usually 
neglected when receptor expression is reported qualitatively. In particular, quantification of 
receptor expression is critical in nanoparticle drug delivery when designing a vehicle with more 
than one type of ligand. Biomarker quantification of model tissues in preclinical studies provides 
correlation between treatment effectiveness and biomarker levels which can lead to accurate 
prediction of treatment outcomes for personalized medicine strategies.   
In pursuit of a paradigm for dual-ligand vehicle design, a kinetic model was created to explore 
the effect of ligand valency and ratio, and receptor density and ratio on nanoparticle delivery. 
Implicit within the model are two assumptions. First is the assumption that ligands and receptors 
are homogenously distributed within the binding area. Peptide-amphiphiles have been observed to 
mix with PEGylated lipids at peptide-amphiphile concentrations below 10 mol% and above 35 
mol%, while they phase separated at 10-35 mol%,381 but it is unclear how the two ligands would 
distribute in relation to each other. The assumption of homogenous ligand distribution may 
therefore underestimate local ligand density, and evaluation of ligand distribution could improve 
the estimates of available ligand density. The assumption of homogenous distribution of receptors 
is a clear simplification of cellular biology, as receptor clustering into and out of focal adhesions 
and hemidesmosomes is well known integrin behavior,280,382–384 which could be accounted for in 
the future with a previously developed model of receptor clustering.356,385,386 Second is the 
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assumption that kr is equivalent for every dissociation event and every kx is proportional to the free 
nanoparticle kf. It is difficult to directly measure differences in forward and reverse reaction rates 
for multivalent binding events, however when multivalent kinetic equations were fit to bivalent and 
trivalent experimental binding data, the reverse reaction rates for multivalent binding were 
calculated to be up to 100 fold slower than the kr for the first ligand to bind, while the forward 
reaction rates were rarely more than 10 fold slower or faster,358,387 suggesting that this assumption 
may be unrealistic. Despite the biological simplifications introduced by these assumptions, the 
model was able to predict the delivery enhancements achieved with optimal valency ratios for dual 
ligand nanoparticles targeting dual-receptor expressing cells. 
Sensitivity analysis was performed for the input parameters chosen to generate Figure 32. The 
results varied little with changes in ligand-receptor kf, however decreases in Kd (increases in 
affinity) decrease the optimal valency calculated for a dual-ligand nanoparticle binding to a dual-
receptor expressing cell, while the potential selectivity reaches a maximum at a Kd of 2 x 10-5 M 
(Appendix B1), above which increasing affinity decreases binding. Similar results were observed 
when varying the receptor expression of the dual-receptor expressing cell; higher levels of receptor 
expression decreased the optimum valency of a dual-ligand nanoparticle, while the selectivity 
reaches a maximum around 3 x 104 receptors per cell (Appendix B2). The appearance of a 
maximum selectivity with variations in ligand density, Kd, and receptor expression suggests that 
increasing valency and affinity of ligand-receptor pairs will increase selectivity to an extent, but 
this selectivity can be inhibited by high valency or affinity interactions. The dependence of the 
selectivity on the comparative ligand-receptor affinities was also explored (Appendix B3). Notably, 
for up to a 9 fold difference in Kd between the two ligand-receptor pairs, the overall selectivity 
decreased, but maximum selectivity was still achieved with dual-ligand nanoparticles of equal 
valency. While this result hasn’t been verified in vitro, it suggests that balancing ligand valency 
may be more significant to successful delivery than choosing ligands with equal affinities for their 
targets, and a dual targeted vehicle with a 50:50 ratio of ligands should bind with higher efficiency 
and selectivity to dual-receptor expressing cells as long as the affinities of the two ligands are within 
an order of magnitude of each other. The heteromultivalent kinetic model addresses the need for 
better understanding of the effect of binding parameters on delivery by identifying the ratio of 
valencies as an extremely critical design constraint. In addition, it revealed the existence of an 
optimum ligand density and receptor density, indicating that single-ligand delivery optimization is 
not applicable to dual-ligand construction.   
Two important trends emerged from the model and the binding data. For dual-ligand 
nanoparticles with equal ligand valencies (50:50) delivered to dual-receptor expressing cells with 
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equal and high receptor expression levels: delivery is enhanced compared to single-ligand 
liposomes and selectivity for dual-receptor expressing cells is achieved compared to single-receptor 
expressing cells. The elucidation of these trends effectively guided the design of an efficient and 
specific gene delivery vehicle targeted to SK-OV-3 cells. Previous studies have identified 5 mol% 
PR_b as a sufficient concentration for single targeting applications.74,79  In the 5 mol% 50:50 stealth 
liposome formulation used here, PR_b and AG86 are present at approximately 2.5 mol% each. The 
use of a substandard individual ligand concentration for effective dual-ligand targeting is consistent 
with the conclusion from the model that the optimal dual-ligand density is less than the optimal 
single-ligand density. Interestingly, when stealth liposomes were allowed to bind and internalize 
within cells with various receptor densities, the 50:50 dual-ligand stealth liposomes interacted more 
selectively with HT-1080 cells compared to all other cells, and there was no statistical difference 
between the liposomes that bound and internalized in HT-1080 and SK-OV-3 cells. HT-1080 cells 
express higher levels of α5β1 than α6β4, however, the ratio of α5β1:α6β4 expression is much smaller 
(1.9 fold) than the other cells with higher expression of one receptor out of the two targeted. The 
unexpected efficiency of dual-ligand liposome delivery to HT-1080 cells emphasizes the need for 
a more quantitative understanding of the parameter space governing multivalent delivery, perhaps 
suggesting a threshold of expression level and receptor ratio necessary for effective dual-ligand 
binding and internalization.  
Liposome delivery for all formulations in Figure 37B is more efficient in HT-1080 cells 
compared to SK-OV-3 cells, which can’t simply be explained by expression levels. In addition, 
binding and internalization within the LS174T cells was surprisingly low considering the 
expression levels measured for these cells. The high integrin internalization rates for the HT-1080 
cells may partially account for the increased binding and internalization of the 50:50 formulation 
compared to binding for these cells. However, clustering, recycling and trafficking of integrins 
were not examined and may likely play a significant role as well. Integrin clustering is a significant 
regulator of extracellular matrix adhesion and cell signalling processes.280,308,383,384,388  
Approximately 20% of surface integrins have been observed in clusters,382 and of these, integrins 
can exist in nascent or mature clusters with integrin densities of 365 and 875 integrins/µm2 
respectively, while the density of homogenously distributed receptors would be approximately 200 
integrins/µm2 which is a clear underestimation of available receptor valency.389 These 
measurements, however, have only been performed in one cell type, and could vary significantly 
from cell to cell.  The integrin mobility, and therefore ability to cluster, significantly increases with 
increasing temperature,390 which could also contribute to unexpected increases in binding for 
certain cell types when nanoparticles were delivered at 37 °C compared to 4 °C.  Intracellular 
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trafficking of integrins can also vary with cell type.  For example, α5β1 internalization is clathrin 
dependant in fibrosarcoma cells,388 and caveolin mediated in ovarian and colorectal cancer 
cells.274,391  Internalization of active and inactive forms of α5β1 integrin can be regulated via 
different pathways,280,388 and internalization of other integrins can even influence internalization 
rates and pathways of certain integrins.388 Once internalized, α5β1 and α6β4 are either degraded, or 
recycled through long-loop recycling, which involves trafficking through early endosomes to the 
perinuclear recycling complex, and a Rab11 GTPase dependent return to the cell surface.280,308 The 
decision between integrin degradation or recycling may depend on integrin activation state 
mediated by native, and potentially synthetic, ligand binding.280,308  Further elucidation of integrin 
biology is therefore required for accurate predictions of nanoparticle-cell interactions for different 
cell types. The current kinetic model used in this study only addresses binding, however the in vitro 
results at 37 °C suggest that internalization and integrin biology are not negligible in delivery 
considerations, and a more extensive guide for vehicle design should include these effects.   
Though the cells investigated here are cancer cell lines, the comparative receptor expression 
levels may also be used as a model for tissue types encountered in vivo: the high dual-receptor 
expressing SK-OV-3 cells represent cancer tissue with high levels of expression of both receptors. 
MCF7 cells have expression levels comparable to levels observed for common cancer biomarkers 
such as EGFR and VEGFR in healthy cells,371,372 and therefore represent healthy tissue with much 
lower expression of both receptors. The cell lines with differential expression levels of the two 
integrins (RKO, HT-1080, LS 174T and SW 1990) model any healthy tissue with high levels of 
expression of only one of the cancer biomarkers, which would be the site of toxicity when 
mechanism based toxicity is encountered in healthy sites. With this potential model of tissue in 
mind, the work here demonstrates the ability to design an efficient delivery vehicle that may 
selectively target dual-receptor expressing cancer tissue, while minimizing binding to healthy tissue 
unintentionally reached by conventional targeted therapies.    
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Chapter 5 Concluding Remarks and Future 
Directions 
This thesis addresses the delivery challenges currently limiting the field of cancer gene therapy. 
Many advances have been made throughout the years, as discussed at great length in Chapter 1, 
however gene therapy solutions for cancer are still largely absent from clinical treatments. Gene 
therapy faces several significant hurdles between systemic administration and intracellular 
expression, and in an attempt to overcome these hurdles, an established small molecule delivery 
technology, the stealth liposome, was translated for encapsulation and delivery of nucleic acids. 
Stealth liposome technology is an ideal choice to protect nucleic acids from degradation, clearance 
and immunogenicity, and the addition of targeting ligands integrates the passive and active 
targeting effects that can facilitate tumor accumulation, while a combination of the targeting and 
the nucleic acid-polymer complex contributes to cellular internalization and cytosolic or nuclear 
delivery of nucleic acids. A major objective throughout the development of this vehicle was the 
establishment of general design criteria for further vehicle development, and to that end, each layer 
of vehicle construction was systematically investigated for its significance to vehicle properties and 
delivery capacity.   
As outlined in Chapter 2, stealth liposomes were first developed for plasmid DNA 
encapsulation. In order to encapsulate plasmid DNA, which is much larger than the small molecules 
typically encapsulated in stealth liposomes, DNA was first condensed into nanoparticles using PEI. 
The complex vehicle design required the development and verification of a new quantification tool. 
General guidelines were then outlined for the encapsulation process, and through exploration of 
material composition, the ability to tune DNA yield and liposome loading fraction was 
demonstrated through variations in lipid:DNA ratios. Higher lipid:DNA ratios favor higher yields, 
while lower ratios favor liposome loading.   
With the tools developed for DNA encapsulation, stealth liposome technology was readily 
translated for siRNA applications in Chapter 3. A lower lipid:nucleic acid ratio was employed to 
enhance loaded liposome fraction, since targeting was introduced for this vehicle. Another aspect 
of vehicle design was explored with the goal of addressing the critical gene delivery barrier of 
appropriate intracellular localization upon delivery. Complexation with PEI, a cationic polymer 
with high buffering capacity, was necessary for siRNA-mediated gene silencing via targeted stealth 
liposomes, and the identification of the optimal siRNA:polymer ratio was clearly important to 
successful transfection.   
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The next aspect of the gene delivery scheme that was explored was the ability to effectively 
and selectively target disease tissue through dual-ligand targeting. The addition of a second 
targeting ligand significantly increased the design complexity which warranted the development of 
a kinetic model to inform experimental choices and verify experimental trends. With the intention 
of elucidating design criteria, several aspects of the targeting parameter space were characterized. 
Optimal delivery and selectivity was described for dual-ligand stealth liposomes targeting dual-
receptor expressing cells. By characterizing and varying receptor expression and ratio, and ligand 
density and ratio, the importance of these parameters in targeting design was demonstrated. 
Combining the optimal dual targeting formulation with the previously developed nucleic acid 
encapsulation tools produced a highly efficient and cell line selective gene delivery vehicle for 
cancer gene therapy applications.   
Future Directions 
PEI exhibited an important role in targeted stealth liposomes transfection of siRNA, perhaps 
synergistically with α6β4 targeting, however, the mechanism of transfection enhancement remains 
elusive. The internalization pathway mediated by the targeting ligand could be identified through 
pathway disruption, and intracellular localization and cytosolic release could be investigated 
through confocal imaging and pH sensitive fluorescent probes. Elucidation of the intracellular 
pathways utilized by the optimized siRNA delivery vehicle could direct targeting ligand choice 
towards those that rely on similar internalization pathways. PEI can elicit toxicity at high 
concentrations,392,393 and although no toxicity was observed with the vehicle concentrations 
explored in Chapter 2, it may be beneficial to replace PEI with a more biocompatible polymer. PEI 
could be substituted within the liposomes with other polymers with a broad range of buffering 
capacity, with the goal of identifying an optimal buffering capacity to inform property 
characterization for novel polymer design.   
Chapter 4 focuses on the influence of variations in receptor and ligand ratios on nanoparticle 
binding, however, several other vehicle parameters with potential delivery impact are easily 
modifiable for further characterization of the dual-ligand delivery parameter space.  Ligand and 
receptor mobility proved significant for immunoliposome targeting of ICAM and ELAM,349 and 
the impact of mobility on the delivery scheme designed here could be explored using cellular 
fixation or lipids with various bilayer packing properties. The model revealed the theoretical 
existence of an optimal overall ligand density above which no further benefit to binding is gained, 
and also suggested that nanoparticle binding was relatively tolerant to differences in ligand-receptor 
pair affinities. These concepts could be verified in vitro, by comparing dual-ligand liposome 
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formulations with various overall ligand densities, and by tuning the affinity of one of the ligands. 
Additional receptors could also be targeted to explore the effect of receptor biology, such as 
clustering, mobility, internalization pathway and rates, on nanoparticle delivery.   
The final goal of the development of targeted gene delivery for cancer therapy is to surmount 
the in vivo barriers to effective gene therapy in order to take advantage of the cellular level benefits 
demonstrated by this vehicle. Each delivery barrier presents distinct challenges and warrants unique 
improvements to further vehicle design. It will therefore be important to identify any additional 
obstacle to delivery effectiveness by assessing biodistribution with in vivo and ex vivo imaging 
techniques, intratumoral and intracellular localization with immunohistochemistry, and function 
using an easily measurable transfection outcome such as fluorescence or luminescence.    
Final Words 
As our understanding of the mechanisms driving and characterizing cancer becomes more 
sophisticated, so will our delivery vehicles.  The objective in developing targeted stealth liposomes 
encapsulating gene therapy is therefore not only to achieve superior delivery and transfection, but 
to contribute to the establishment of a paradigm to guide more intelligent vehicle design.  Using 
modular vehicles, consisting of nucleic acid complexation, stealth liposome encapsulation and one 
or more targeting moieties, provides extra flexibility in tuning vehicle characteristics to address 
specific challenges.  The concepts presented in this work can be used as a platform upon which to 
build delivery schemes for innumerable applications.   
 106 
 
Bibiography 
 
1. Luo, D. & Saltzman, W. M. Synthetic DNA delivery systems. Nat. Biotechnol. 18, 33–37 
(2000). 
2. Cichon, G. et al. Intravenous administration of recombinant adenoviruses causes 
thrombocytopenia, anemia and erythroblastosis in rabbits. J. Gene Med. 1, 360–71 (1999). 
3. Muruve, D. A., Barnes, M. J., Stillman, I. E. & Libermann, T. A. Adenoviral gene therapy 
leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic 
injury in vivo. Hum. Gene Ther. 10, 965–976 (1999). 
4. Buckley, R. H. Gene therapy for SCID - a complication after remarkable progress. Lancet 
360, 1185–1186 (2002). 
5. Marshall, E. Clinical research - Gene therapy a suspect in leukemia-like disease. Science 
298, 34–35 (2002). 
6. Pack, D. W., Hoffman, A. S., Pun, S. & Stayton, P. S. Design and development of polymers 
for gene delivery. Nat. Rev. Drug Discov. 4, 581–593 (2005). 
7. Suk, J. S. et al. Gene delivery to differentiated neurotypic cells with RGD and HIV Tat 
peptide functionalized polymeric nanoparticles. Biomaterials 27, 5143–50 (2006). 
8. Nie, Y. et al. Dual-targeted polyplexes: one step towards a synthetic virus for cancer gene 
therapy. J. Control. Release 152, 127–134 (2011). 
9. Medina-Kauwe, L. K., Maguire, M., Kasahara, N. & Kedes, L. Nonviral gene delivery to 
human breast cancer cells by targeted Ad5 penton proteins. Gene Ther. 8, 1753–61 (2001). 
10. Perez-Martinez, F. C. et al. Barriers to Non-Viral Vector-Mediated Gene Delivery in the 
Nervous System. Pharm. Res. 28, 1843–58 (2011). 
11. Xiong, X.-B. B., Uludag, H., Lavasanifar, A., Uludağ, H. & Lavasanifar, A. Virus-mimetic 
polymeric micelles for targeted siRNA delivery. Biomaterials 31, 5886–93 (2010). 
12. Zuber, G., Dontenwill, M. & Behr, J. P. Synthetic viruslike particles for targeted gene 
delivery to alphavbeta3 integrin-presenting endothelial cells. Mol. Pharm. 6, 1544–1552 
(2009). 
13. Andreu, A., Fairweather, N. & Miller, A. D. Clostridium neurotoxin fragments as potential 
targeting moieties for liposomal gene delivery to the CNS. Chembiochem 9, 219–231 
(2008). 
14. Talsma, S. S., Babensee, J. E., Murthy, N. & Williams, I. R. Development and in vitro 
validation of a targeted delivery vehicle for DNA vaccines. J. Control. Release 112, 271–9 
(2006). 
15. Ferrer-Miralles, N., Vázquez, E., Villaverde, A., Vazquez, E. & Villaverde, A. Membrane-
active peptides for non-viral gene therapy: making the safest easier. Trends Biotechnol. 26, 
267–75 (2008). 
16. Duan, Y. J. et al. Poly(ethylene glycol)-Grafted Polyethylenimine Modified with G250 
Monoclonal Antibody for Tumor Gene Therapy. Hum. Gene Ther. 21, 191–198 (2010). 
17. Martin-Herranz, A. et al. Surface functionalized cationic lipid-DNA complexes for gene 
delivery: PEGylated lamellar complexes exhibit distinct DNA-DNA interaction regimes. 
Biophys. J. 86, 1160–1168 (2004). 
18. Pearce, T. R., Shroff, K. & Kokkoli, E. Peptide Targeted Lipid Nanoparticles for Anti-
Cancer Drug Delivery. Adv. Mater. 24, 3803–3822 (2012). 
19. Khalil, I. A., Kogure, K., Akita, H. & Harashima, H. Uptake Pathways and Subsequent 
Intracellular Trafficking in Nonviral Gene Delivery. Pharmacol. Rev. 58, 32–45 (2006). 
20. Pangburn, T. O., Petersen, M. A., Waybrant, B., Adil, M. M. & Kokkoli, E. Peptide- and 
 107 
 
aptamer-functionalized nanovectors for targeted delivery of therapeutics. J. Biomech. Eng. 
131, 074005 (2009). 
21. Chen, K. & Conti, P. S. Target-specific delivery of peptide-based probes for PET imaging. 
Adv. Drug Deliv. Rev. 62, 1005–22 (2010). 
22. Khan, J. et al. Classification and diagnostic prediction of cancers using gene expression 
profiling and artificial neural networks. Nat. Med. 7, 673–9 (2001). 
23. Wen, S. F. et al. Assessment of p53 gene transfer and biological activities in a clinical study 
of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther. 10, 224–
238 (2003). 
24. Brummelkamp, T. R., Bernards, R. & Agami, R. Stable suppression of tumorigenicity by 
virus-mediated RNA interference. Cancer Cell 2, 243–7 (2002). 
25. Crnkovic-Mertens, I., Hoppe-Seyler, F. & Butz, K. Induction of apoptosis in tumor cells by 
siRNA-mediated silencing of the livin/ML-IAP/KIAP gene. Oncogene 22, 8330–8336 
(2003). 
26. Xu, G. & McLeod, H. L. Strategies for enzyme/prodrug cancer therapy. Clin. Cancer Res. 
7, 3314–3324 (2001). 
27. Westphal, E. M., Ge, J., Catchpole, J. R., Ford, M. & Kenney, S. C. The 
nitroreductase/CB1954 combination in Epstein-Barr virus-positive B-cell lines: induction 
of bystander killing in vitro and in vivo. Cancer Gene Ther. 7, 97 (2000). 
28. Schmitz, V. et al. Treatment of colorectal and hepatocellular carcinomas by adenoviral 
mediated gene transfer of endostatin and angiostatin-like molecule in mice. Gut 53, 561–
567 (2004). 
29. Palmer, D. H., Young, L. S. & Mautner, V. Cancer gene-therapy: clinical trials. Trends 
Biotechnol. 24, 76–82 (2006). 
30. McNeish, I. a, Bell, S. J. & Lemoine, N. R. Gene therapy progress and prospects: cancer 
gene therapy using tumour suppressor genes. Gene Ther. 11, 497–503 (2004). 
31. Chandler, L. A. et al. Prevalent expression of fibroblast growth factor (FGF) receptors and 
FGF2 in human tumor cell lines. Int. J. Cancer 81, 451–458 (1999). 
32. Niu, G. Q., Driessen, W. H. P., Sullivan, S. M. & Hughes, J. A. In Vivo Anti-Tumor Effect 
of Expressing p14ARF-TAT Using a FGF2-Targeted Cationic Lipid Vector. Pharm. Res. 
28, 720–30 (2011). 
33. Maruta, F. et al. Identification of FGF receptor-binding peptides for cancer gene therapy. 
Cancer Gene Ther. 9, 543–52 (2002). 
34. Rao, G. a, Tsai, R., Roura, D. & Hughes, J. A. Evaluation of the transfection property of a 
peptide ligand for the fibroblast growth factor receptor as part of PEGylated 
polyethylenimine polyplex. J. Drug Deliv. 16, 79–89 (2008). 
35. Akinc, A., Thomas, M., Klibanov, A. M. & Langer, R. Exploring polyethylenimine-
mediated DNA transfection and the proton sponge hypothesis. J. Gene Med. 7, 657–663 
(2005). 
36. Li, D. et al. Construction of a Star-Shaped Copolymer as a Vector for FGF Receptor-
Mediated Gene Delivery In Vitro and In Vivo. Biomacromolecules 11, 2221–2229 (2010). 
37. Klapper, L. N. et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function 
solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Natl. Acad. 
Sci. 96, 4995–5000 (1999). 
38. Singh, A. B. & Harris, R. C. Autocrine, paracrine and juxtacrine signaling by EGFR ligands. 
Cell. Signal. 17, 1183–1193 (2005). 
39. Li, Z. H. et al. Identification and characterization of a novel peptide ligand of epidermal 
growth factor receptor for targeted delivery of therapeutics. FASEB J. 19, 1978–85 (2005). 
40. Schäfer,  a et al. Disconnecting the Yin and Yang Relation of Epidermal Growth Factor 
Receptor (EGFR)-Mediated Delivery: A Fully Synthetic, EGFR-Targeted Gene Transfer 
System Avoiding Receptor Activation. Hum. Gene Ther. 22, 1463–73 (2011). 
 108 
 
41. Magadala, P. & Amiji, M. Epidermal growth factor receptor-targeted gelatin-based 
engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer 
cells. AAPS J. 10, 565–76 (2008). 
42. Sun, Y.-X. X. et al. The influence of RGD addition on the gene transfer characteristics of 
disulfide-containing polyethyleneimine/DNA complexes. Biomaterials 29, 4356–65 
(2008). 
43. Ng, Q. K. T. et al. Engineering Clustered Ligand Binding Into Nonviral Vectors: 
alpha(v)beta(3) Targeting as an Example. Mol. Ther. 17, 828–36 (2009). 
44. Zhou, Q.-H. H. et al. Cyclic RGD-targeting of reversibly stabilized DNA nanoparticles 
enhances cell uptake and transfection in vitro. J. Drug Target. 17, 364–373 (2009). 
45. Lee, J. H. et al. All‐ in‐ One Target‐ Cell‐ Specific Magnetic Nanoparticles for 
Simultaneous Molecular Imaging and siRNA Delivery. Angew. Chemie 48, 4174–4179 
(2009). 
46. Katow, H., Yazawa, S. & Sofuku, S. A fibronectin-related synthetic peptide, pro-ala-ser-
ser, inhibits fibronectin binding to the cell-surface, fibronectin-promoted cell-migration in 
vitro, and cell-migration in vivo. Exp. Cell Res. 190, 17–24 (1990). 
47. Yamada, K. M. & Kennedy, D. W. Dualistic nature of adhesive protein function: fibronectin 
and its biologically active peptide fragments can autoinhibit fibronectin function. J. Cell 
Biol. 99, 29–36 (1984). 
48. Parkhouse, S. M., Garnett, M. C. & Chan, W. C. Targeting of polyamidoamine-DNA 
nanoparticles using the Staudinger ligation: attachment of an RGD motif either before or 
after complexation. Bioorg. Med. Chem. 16, 6641–50 (2008). 
49. Haubner, R. et al. Structural and functional aspects of RGD-containing cyclic pentapeptides 
as highly potent and selective integrin alpha(v)beta(3) antagonists. J. Am. Chem. Soc. 118, 
7461–7472 (1996). 
50. Kaneshiro, T. L. & Lu, Z.-R. R. Targeted intracellular codelivery of chemotherapeutics and 
nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials 30, 
5660–6 (2009). 
51. Studeny, M. et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-
beta delivery into tumors. Cancer Res. 62, 3603–3608 (2002). 
52. Sazani, P. & Kole, R. Therapeutic potential of antisense oligonucleotides as modulators of 
alternative splicing. J. Clin. Invest. 112, 481–486 (2003). 
53. Kang, H., Alam, M. R., Dixit, V., Fisher, M. & Juliano, R. L. Cellular delivery and 
biological activity of antisense oligonucleotides conjugated to a targeted protein carrier. 
Bioconjug. Chem. 19, 2182–8 (2008). 
54. Kunath, K. et al. Integrin targeting using RGD-PEI conjugates for in vitro gene transfer. J. 
Gene Med. 5, 588–99 (2003). 
55. Han, H. D. et al. Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles. 
Clin. Cancer Res. 16, 3910–3922 (2010). 
56. Koivunen, E., Wang, B. C. & Ruoslahti, E. Phage libraries displaying cyclic peptides with 
different ring sizes: ligand specificities of the RGD-directed integrins. Nat. Biotechnol. 13, 
265–270 (1995). 
57. Pasqualini, R., Koivunen, E. & Ruoslahti, E. alpha v Integrins as receptors for tumor 
targeting by circulating ligands. Nat. Biotechnol. 15, 542–546 (1997). 
58. Anwer, K., Kao, G., Rolland, A., Driessen, W. H. P. & Sullivan, S. M. Peptide-mediated 
gene transfer of cationic lipid/plasmid DNA complexes to endothelial cells. J. Drug Target. 
12, 215–21 (2004). 
59. Carlisle, R. C., Read, M. L., Wolfert, M. A. & Seymour, L. W. Self-assessing poly(L-
lysine)/DNA complexes capable of integrin-mediated cellular uptake and gene expression. 
Colloids and Surfaces B-Biointerfaces 16, 261–272 (1999). 
60. Parker, A. L. et al. Enhanced gene transfer activity of peptide-targeted gene-delivery 
 109 
 
vectors. J. Drug Target. 13, 39–51 (2005). 
61. Kim, J., Kim, S. W. & Kim, W. J. PEI-g-PEG-RGD/Small Interference RNA Polyplex-
Mediated Silencing of Vascular Endothelial Growth Factor Receptor and Its Potential as an 
Anti-Angiogenic Tumor Therapeutic Strategy. Oligonucleotides 21, 101–7 (2011). 
62. Suh, W., Han, S. O., Yu, L. & Kim, S. W. An angiogenic, endothelial-cell-targeted 
polymeric gene carrier. Mol. Ther. 6, 664–672 (2002). 
63. Harvie, P. et al. Targeting of lipid-protamine-DNA (LPD) lipopolyplexes using RGD 
motifs. J. Liposome Res. 13, 231–247 (2003). 
64. Kim, W. J. et al. Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-
angiogenesis. J. Control. Release 106, 224–34 (2005). 
65. Muschler, J. L. & Horwitz, A. F. Down-regulation of the chicken alpha5beta1 integrin 
fibronectin receptor during development. Development 113, 327–337 (1991). 
66. Hart, S. L. et al. Lipid-mediated enhancement of transfection by a nonviral integrin-
targeting vector. Hum. Gene Ther. 9, 575–585 (1998). 
67. Mardilovich, A., Craig, J., McCammon, M. Q., Garg, A. & Kokkoli, E. Design of a Novel 
Fibronectin-Mimetic Peptide-Amphiphile for Functionalized Biomaterials. Langmuir 22, 
3259–3264 (2006). 
68. Shroff, K., Pearce, T. R. & Kokkoli, E. Enhanced integrin mediated signaling and cell cycle 
progression on fibronectin mimetic peptide amphiphile monolayers. Langmuir 28, 1858–65 
(2012). 
69. Pangburn, T. O., Bates, F. S. & Kokkoli, E. Polymersomes functionalized via ‘click’ 
chemistry with the fibronectin mimetic peptides PR_b and GRGDSP for targeted delivery 
to cells with different levels of α5β1 expression. Soft Matter 8, 4449 (2012). 
70. Craig, J. A., Rexeisen, E. L., Mardilovich, A., Shroff, K. & Kokkoli, E. Effect of linker and 
spacer on the design of a fibronectin-mimetic peptide evaluated via cell studies and AFM 
adhesion forces. Langmuir 24, 10282–10292 (2008). 
71. Mardilovich, A. & Kokkoli, E. Biomimetic peptide-amphiphiles for functional biomaterials: 
The role of GRGDSP and PHSRN. Biomacromolecules 5, 950–957 (2004). 
72. Garg, A. & Kokkoli, E. pH-Sensitive PEGylated liposomes functionalized with a 
fibronectin-mimetic peptide show enhanced intracellular delivery to colon cancer cells. 
Curr. Pharm. Biotechnol. 12, 1135–1143 (2011). 
73. Garg, A., Tisdale, A. W., Haidari, E. & Kokkoli, E. Targeting colon cancer cells using 
PEGylated liposomes modified with a fibronectin-mimetic peptide. Int. J. Pharm. 366, 201–
210 (2009). 
74. Demirgöz, D. et al. PR_b-Targeted PEGylated Liposomes for Prostate Cancer Therapy. 
Langmuir 24, 13518–13524 (2008). 
75. Demirgöz, D. et al. PR_b-targeted delivery of tumor necrosis factor-α by polymersomes for 
the treatment of prostate cancer. Soft Matter 5, 2011 (2009). 
76. Atchison, N. A. et al. Binding of the fibronectin-mimetic peptide, PR_b, to alpha5beta1 on 
pig islet cells increases fibronectin production and facilitates internalization of PR_b 
functionalized liposomes. Langmuir 26, 14081–8 (2010). 
77. Shroff, K. & Kokkoli, E. PEGylated liposomal doxorubicin targeted to α5β1-expressing 
MDA-MB-231 breast cancer cells. Langmuir 28, 4729–4736 (2012). 
78. Pangburn, T. O., Georgiou, K., Bates, F. S. F. & Kokkoli, E. Targeted Polymersome 
Delivery of siRNA Induces Cell Death of Breast Cancer Cells Dependent upon Orai3 
Protein Expression. Langmuir 28, 12816–12830 (2012). 
79. Adil, M. et al. PR_b Functionalized Stealth Liposomes for Targeted Delivery to Metastatic 
Colon Cancer. Biomater. Sci. 1, 393–401 (2013). 
80. Nicklin, S. A., White, S. J., Watkins, S. J., Hawkins, R. E. & Baker, A. H. Selective targeting 
of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. 
Circulation 102, 231–237 (2000). 
 110 
 
81. Oku, N. et al. Anti-neovascular therapy using novel peptides homing to angiogenic vessels. 
Oncogene 21, 2662–2669 (2002). 
82. Oreilly, M. S., Holmgren, L., Chen, C. & Folkman, J. Angiostatin induces and sustains 
dormancy of human primary tumors in mice. Nat. Med. 2, 689–692 (1996). 
83. Lu, Z. X., Liu, L. T. & Qi, X. R. Development of small interfering RNA delivery system 
using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor 
tumor-targeted therapy. Int. J. Nanomedicine 6, 1661–1673 (2011). 
84. Koolpe, M., Dail, M. & Pasquale, E. B. An ephrin mimetic peptide that selectively targets 
the EphA2 receptor. J. Biol. Chem. 277, 46974–46979 (2002). 
85. Blackburn, W. H., Dickerson, E. B., Smith, M. H., McDonald, J. F. & Lyon, L. A. Peptide-
Functionalized Nanogels for Targeted siRNA Delivery. Bioconjug. Chem. 20, 960–8 
(2009). 
86. Dickerson, E. B. et al. Chemosensitization of cancer cells by siRNA using targeted nanogel 
delivery. BMC Cancer 10, 10 (2010). 
87. Porkka, K., Laakkonen, P., Hoffman, J. A., Bernasconi, M. & Ruoslahti, E. A fragment of 
the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. 
Proc. Natl. Acad. Sci. 99, 7444–7449 (2002). 
88. Ginisty, H., Sicard, H., Roger, B. & Bouvet, P. Structure and functions of nucleolin. J. Cell 
Sci. 112, 761–772 (1999). 
89. Hovanessian, A. G. Midkine, a cytokine that inhibits HIV infection by binding to the cell 
surface expressed nucleolin. Cell Res. 16, 174–181 (2006). 
90. Hovanessian, A. G. et al. The cell-surface-expressed nucleolin is associated with the actin 
cytoskeleton. Exp. Cell Res. 261, 312–328 (2000). 
91. Nisole, S., Krust, B. & Hovanessian, A. G. Anchorage of HIV on permissive cells leads to 
coaggregation of viral particles with surface nucleolin at membrane raft microdomains. Exp. 
Cell Res. 276, 155–173 (2002). 
92. Watanabe, T. et al. Nucleolin on the Cell Surface as a New Molecular Target for Gastric 
Cancer Treatment. Biol. Pharm. Bull. 33, 796–803 (2010). 
93. Christian, S. et al. Nucleolin expressed at the cell surface is a marker of endothelial cells in 
angiogenic blood vessels. J. Cell Biol. 163, 871–878 (2003). 
94. Derfus, A. M., Chen, A. A., Min, D.-H. H., Ruoslahti, E. & Bhatia, S. N. Targeted quantum 
dot conjugates for siRNA delivery. Bioconjug. Chem. 18, 1391–6 (2007). 
95. Arap, W., Pasqualini, R. & Ruoslahti, E. Cancer treatment by targeted drug delivery to 
tumor vasculature in a mouse model. Science 279, 377–380 (1998). 
96. Pasqualini, R. et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target 
for inhibiting angiogenesis. Cancer Res. 60, 722–727 (2000). 
97. Chen, Y., Wu, J. J. & Huang, L. Nanoparticles targeted with NGR motif deliver c-myc 
siRNA and doxorubicin for anticancer therapy. Mol. Ther. 18, 828–34 (2010). 
98. Xia, H. B., Anderson, B., Mao, Q. W. & Davidson, B. L. Recombinant human adenovirus: 
Targeting to the human transferrin receptor improves gene transfer to brain microcapillary 
endothelium. J. Virol. 74, 11359–11366 (2000). 
99. Deuel, T. F., Keim, P. S., Farmer, M. & Heinrikson, R. L. Amino-Acid Sequence of Human 
Platelet Factor 4. Proc. Natl. Acad. Sci. 74, 2256–2258 (1977). 
100. Butcher, D. J. et al. A natural motif approach to protein design: A synthetic leucine zipper 
peptide mimics the biological function of the platelet factor 4 protein. FEBS Lett. 409, 183–
187 (1997). 
101. Handin, R. I. & Cohen, H. J. Purification and Binding Properties of Human Platelet Factor 
4. J. Biol. Chem. 251, 4273–4282 (1976). 
102. Liu, S. C. et al. cDNA cloning and expression of HIP, a novel cell surface heparan 
sulfate/heparin-binding protein of human uterine epithelial cells and cell lines. J. Biol. 
Chem. 271, 11817–11823 (1996). 
 111 
 
103. Tylercross, R., Sobel, M., Marques, D. & Harris, R. B. Heparin-Binding Domain Peptides 
of Antithrombin-III - Analysis by Isothermal Titration Calorimetry and Circular-Dichroism 
Spectroscopy. Protein Sci. 3, 620–627 (1994). 
104. TylerCross, R., Sobel, M., McAdory, L. E. & Harris, R. B. Structure-function relations of 
antithrombin III-heparin interactions as assessed by biophysical and biological assays and 
molecular modeling of peptide-pentasaccharide-docked complexes. Arch. Biochem. 
Biophys. 334, 206–213 (1996). 
105. Fichter, K. M., Zhang, L., Kiick, K. L. & Reineke, T. M. Peptide-Functionalized Poly 
(ethylene glycol) Star Polymers : DNA Delivery Vehicles with Multivalent Molecular 
Architecture. Bioconjug. Chem. 19, 76–88 (2008). 
106. Koch  Baram, T., Chobsieng, P. &Fridkin, M., Y. Enzymatic Degradation of Lutenizing 
Hormone-Releasing Hormone (LH-RH) by Hypothalamic Tissue. Biochem. Biophys, Res. 
Commun. 61, (1974). 
107. Coy, D. H., Vilchezmartinez, J. A., Coy, E. J. & Schally, A. V. Analogs of Luteinizing-
Hormone-Releasing Hormone with Increased Biological-Activity Produced by D-Amino-
Acid Substitutions in Position 6. J. Med. Chem. 19, 423–425 (1976). 
108. Koch  Baram, T., Hazum, E. &Fridkin, M., Y. Resistance to Enzymatic Degradation of LH-
RH Analogues Possessing Increased Biological Activity. Biochem. Biophys, Res. Commun. 
74, 488–491 (1977). 
109. Kim, S. H. W. H. W., Jeong, J. H., Lee, S. H., Kim, S. H. W. H. W. & Park, T. G. LHRH 
receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-
assembled from siRNA-PEG-LHRH conjugate and PEI. Bioconjug. Chem. 19, 2156–62 
(2008). 
110. Taratula, O. et al. Surface-engineered targeted PPI dendrimer for efficient intracellular and 
intratumoral siRNA delivery. J. Control. Release 140, 284–93 (2009). 
111. Mandel, R. J. et al. Characterization of intrastriatal recombinant adeno-associated virus-
mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in 
a rat model of Parkinson’s disease. J. Neurosci. 18, 4271–4284 (1998). 
112. Bilang-Bleuel, A. et al. Intrastriatal injection of an adenoviral vector expressing glial-cell-
line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral 
impairment in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. 94, 8818 (1997). 
113. Choi-Lundberg, D. L. et al. Dopaminergic neurons protected from degeneration by GDNF 
gene therapy. Science 275, 838–841 (1997). 
114. Kells, A. P. et al. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a 
model of Huntington disease. Mol. Ther. 9, 682–688 (2004). 
115. Holtzman, D. M. et al. TrkA Expression in the CNS - Evidence for the Existence of Several 
Novel NGF-Responsive CNS Neurons. J. Neurosci. 15, 1567–1576 (1995). 
116. Ibáñez, C. F. Neurotrophic factors: from structure-function studies to designing effective 
therapeutics. Trends Biotechnol. 13, 217–27 (1995). 
117. Wiesmann, C., Ultsch, M. H., Bass, S. H. & de Vos, A. M. Crystal structure of nerve growth 
factor in complex with the ligand-binding domain of the TrkA receptor. Nature 401, 184–8 
(1999). 
118. Zeng, J., Too, H.-P., Ma, Y., Luo, E. S. E. & Wang, S. A synthetic peptide containing loop 
4 of nerve growth factor for targeted gene delivery. J. Gene Med. 6, 1247–56 (2004). 
119. Zeng, J. & Wang, S. Enhanced gene delivery to PC12 cells by a cationic polypeptide. 
Biomaterials 26, 679–86 (2005) 
120. Barrett, G. L., Trieu, J. & Naim, T. The identification of leptin-derived peptides that are 
taken up by the brain. Regul. Pept. 155, 55–61 (2009). 
121. Liu, Y. et al. A leptin derived 30-amino-acid peptide modified pegylated poly-L-lysine 
dendrigraft for brain targeted gene delivery. Biomaterials 31, 5246–57 (2010). 
122. Lentz, T. L., Burrage, T. G., Smith, A. L., Crick, J. & Tignor, G. H. Is the Acetylcholine-
 112 
 
Receptor a Rabies Virus Receptor. Science 215, 182–184 (1982). 
123. Lentz, T. L., Wilson, P. T., Hawrot, E. & Speicher, D. W. Amino-Acid-Sequence Similarity 
Between Rabies Virus Glycoprotein and Snake-Venom Curaremimetic Neurotoxins. 
Science 226, 847–848 (1984). 
124. Karlsson, E. Chemistry of protein toxins in snake venoms. Handb. Exp. Pharmacol. 52, 
159–212 (1979). 
125. Kumar, P. et al. Transvascular delivery of small interfering RNA to the central nervous 
system. Nature 448, 39–43 (2007). 
126. Lentz, T. L., Hawrot, E. & Wilson, P. T. Synthetic Peptides Corresponding to Sequences of 
Snake-Venom Neurotoxins and Rabies Virus Glycoprotein Bind to the Nicotinic 
Acetylcholine-Receptor. Proteins-Structure Funct. Genet. 2, 298–307 (1987). 
127. Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic injection of 
targeted exosomes. Nat. Biotechnol. 29, 341–U179 (2011). 
128. Valadi, H. et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel 
mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654–9 (2007). 
129. Vassar, R. et al. β-secretase cleavage of Alzheimer’s amyloid precursor protein by the 
transmembrane aspartic protease BACE. Science 286, 735–741 (1999). 
130. Gong, C., Li, X., Xu, L. & Zhang, Y.-H. H. Target delivery of a gene into the brain using 
the RVG29-oligoarginine peptide. Biomaterials 33, 3456–63 (2012). 
131. Liu, J. K. et al. A novel peptide defined through phage display for therapeutic protein and 
vector neuronal targeting. Neurobiol. Dis. 19, 407–418 (2005). 
132. Martinez-Fong, D. et al. Neurotensin-SPDP-poly-L-lysine conjugate: a nonviral vector for 
targeted gene delivery to neural cells. Mol. Brain Res. 69, 249–262 (1999). 
133. Park, I.-K. K., Lasiene, J., Chou, Sh.-H. H., Horner, P. J. & Pun, S. H. Neuron-specific 
delivery of nucleic acids mediated by Tet1- modified poly(ethylenimine). J. Gene Med. 9, 
691–702 (2007). 
134. Kwon, E. J., Bergen, J. M., Park, I. K. & Pun, S. H. Peptide-modified vectors for nucleic 
acid delivery to neurons. J. Control. Release 132, 230–5 (2008). 
135. Oliveira, H. et al. Targeted gene delivery into peripheral sensorial neurons mediated by self-
assembled vectors composed of poly(ethylene imine) and tetanus toxin fragment c. J. 
Control. Release 143, 350–8 (2010). 
136. Lalli, G. et al. Functional characterisation of tetanus and botulinum neurotoxins binding 
domains. J. Cell Sci. 112, 2715–2724 (1999). 
137. Fishman, P. S. & Carrigan, D. R. Retrograde transneuronal transfer of the C-fragment of 
tetanus toxin. Brain Res. 406, 275–9 (1987). 
138. Guggino, W. B. & Stanton, B. A. New insights into cystic fibrosis: molecular switches that 
regulate CFTR. Nat. Rev. Mol. Cell Biol. 7, 426–436 (2006). 
139. Babinski, D. & Trawinska-Bartnicka, M. Rhinosinusitis in cystic fibrosis: Not a simple 
story. Int. J. Pediatr. Otorhinolaryngol. 72, 619–624 (2008). 
140. McKay, T. & Huang, L. Secretin-Mediated Gene Delivery, a Specific Targeting Mechanism 
with Potential for Treatment of Biliary and Pancreatic Disease in Cystic Fibrosis. Mol. Ther. 
5, 323–8 (2002). 
141. Hefford, M. A. & Kaplan, H. Chemical-Properties of the Histidine Residue of Secretin- 
Evidence for a Specific Intramolecular Interaction. Biochim. Biophys. Acta 998, 267–270 
(1989). 
142. Yokosaki, Y. et al. Identification of the ligand binding site for the integrin alpha9 beta1 in 
the third fibronectin type III repeat of tenascin-C. J. Biol. Chem. 273, 11423–8 (1998). 
143. Schneider, H. et al. A novel peptide, PLAEIDGIELTY, for the targeting of alpha(9)beta(1)-
integrins. FEBS Lett. 429, 269–273 (1998). 
 
 113 
 
144. Waterhouse, J. E., Jorgensen, M. R., Harbottle, R. P., Kostarelos, K. & Miller, A. D. 
Synthesis and biological evaluation of alpha 9 beta 1 integrin targeted non-viral gene 
delivery system. Mol. Ther. 7, S218–S218 (2003). 
145. Waterhouse, J. E. et al. Synthesis and application of integrin targeting lipopeptides in 
targeted gene delivery. Chembiochem 6, 1212–23 (2005). 
146. Writer, M. J. et al. Targeted gene delivery to human airway epithelial cells with synthetic 
vectors incorporating novel targeting peptides selected by phage display. J. Drug Target. 
12, 185–93 (2004). 
147. Tagalakis, A. D., He, L., Saraiva, L., Gustafsson, K. T. & Hart, S. L. Receptor-targeted 
liposome-peptide nanocomplexes for siRNA delivery. Biomaterials 32, 6302–6315 (2011). 
148. Manunta, M. D. I. et al. Nebulisation of Receptor-Targeted Nanocomplexes for Gene 
Delivery to the Airway Epithelium. PLoS One 6, (2011). 
149. Rayner, S. A., Larkin, D. F. P. & George, A. J. T. TNF receptor secretion after ex vivo 
adenoviral gene transfer to cornea and effect on in vivo graft survival. Invest. Ophthalmol. 
Vis. Sci. 42, 1568–1573 (2001). 
150. Klebe, S., Sykes, P. J., Coster, D. J., Krishnan, R. & Williams, K. A. Prolongation of sheep 
corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10. 
Transplantation 71, 1214–1220 (2001). 
151. Jun, A. S. & Larkin, D. F. P. Prospects for gene therapy in corneal disease. Eye 17, 906–11 
(2003). 
152. Lai, C. M. et al. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a 
rat model of corneal neovascularization. Hum. Gene Ther. 12, 1299–1310 (2001). 
153. Kamata, Y. et al. Adenovirus-mediated gene therapy for corneal clouding in mice with 
mucopolysaccharidosis type VII. Mol. Ther. 4, 307–312 (2001). 
154. Shewring, L. et al. A nonviral vector system for efficient gene transfer to corneal endothelial 
cells via membrane integrin. Transplantation 64, 763–769 (1997). 
155. Collins, L. & Fabre, J. W. A synthetic peptide vector system for optimal gene delivery to 
corneal endothelium. J. Gene Med. 6, 185–94 (2004). 
156. Trippel, S. B., Ghivizzani, S. C. & Nixon, A. J. Gene-based approaches for the repair of 
articular cartilage. Gene Ther. 11, 351–9 (2004). 
157. Santos, J. L. et al. Receptor-Mediated Gene Delivery Using PAMAM Dendrimers 
Conjugated with Peptides Recognized by Mesenchymal Stem Cells. Mol. Pharm. 7, 763–
74 (2010). 
158. Pi, Y. B. et al. Targeted delivery of non-viral vectors to cartilage in vivo using a 
chondrocyte-homing peptide identified by phage display. Biomaterials 32, 6324–32 (2011). 
159. Balian, G. Bone Targeting Peptides. (2004). 
160. Rosenzwajg, M., Canque, B. & Gluckman, J. C. Human dendritic cell differentiation 
pathway from CD34(+) hematopoietic precursor cells. Blood 87, 535–544 (1996). 
161. Moffatt, S. & Cristiano, R. J. Uptake characteristics of NGR-coupled stealth PEI/pDNA 
nanoparticles loaded with PLGA-PEG-PLGA tri-block copolymer for targeted delivery to 
human monocyte-derived dendritic cells. Int. J. Pharm. 321, 143–54 (2006). 
162. Hammes, H. P., Brownlee, M., Jonczyk, A., Sutter, A. & Preissner, K. T. Subcutaneous 
injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal 
neovascularization. Nat. Med. 2, 529–33 (1996). 
163. Bryant, D. M., Wylie, F. G. & Stow, J. L. Regulation of Endocytosis , Nuclear Translocation 
, and Signaling of Fibroblast Growth Factor Receptor 1 by E-Cadherin. 16, 14–23 (2005). 
164. Wang, Y.-N., Yamaguchi, H., Hsu, J.-M. & Hung, M.-C. Nuclear trafficking of the 
epidermal growth factor receptor family membrane proteins. Oncogene 29, 3997–4006 
(2010). 
165. Bergen, J. M., Park, I.-K. K., Horner, P. J. & Pun, S. H. Nonviral approaches for neuronal 
delivery of nucleic acids. Pharm. Res. 25, 983–98 (2008). 
 114 
 
166. Pardridge, W. M. Drug and gene targeting to the brain with molecular Trojan horses. Nat. 
Rev. Drug Discov. 1, 131–9 (2002). 
167. Fairweather, N. F., Lyness, V. A., Pickard, D. J., Allen, G. & Thomson, R. O. Cloning, 
nucleotide sequencing, and expression of tetanus toxin fragment C in Escherichia coli. J. 
Bacteriol. 165, 21–7 (1986). 
168. Lalli, G. & Schiavo, G. Analysis of retrograde transport in motor neurons reveals common 
endocytic carriers for tetanus toxin and neurotrophin receptor p75NTR. J. Cell Biol. 156, 
233–9 (2002). 
169. Carlisle, R. C. et al. Polymer-coated polyethylenimine/DNA complexes designed for 
triggered activation by intracellular reduction. J. Gene Med. 6, 337–44 (2004). 
170. Thibault, M., Nimesh, S., Lavertu, M. & Buschmann, M. D. Intracellular trafficking and 
decondensation kinetics of chitosan-pDNA polyplexes. Mol. Ther. 18, 1787–95 (2010). 
171. Vandenbulcke, F., Nouel, D., Vincent, J. P., Mazella, J. & Beaudet, A. Ligand-induced 
internalization of neurotensin in transfected COS-7 cells: differential intracellular 
trafficking of ligand and receptor. J. Cell Sci. 113 ( Pt 1, 2963–75 (2000). 
172. Belouzard, S. & Rouillé, Y. Ubiquitylation of leptin receptor OB-Ra regulates its clathrin-
mediated endocytosis. EMBO J. 25, 932–42 (2006). 
173. Howe, C. L. A Cbl:clathrin complex involved in NGF signaling for neurite outgrowth. 
Neurosci. Res. Commun. 33, 86–98 (2003). 
174. Miki, T. et al. The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) 
interacts with membrane type 1 matrix metalloproteinase and CD13/aminopeptidase N and 
modulates their endocytic pathways. J. Biol. Chem. 282, 12341–52 (2007). 
175. Nesterov, A., Carter, R. E., Sorkina, T., Gill, G. N. & Sorkin, A. Inhibition of the receptor-
binding function of clathrin adaptor protein AP-2 by dominant-negative mutant mu2 subunit 
and its effects on endocytosis. EMBO J. 18, 2489–99 (1999). 
176. Kagaya, H. et al. Impact of polyplex micelles installed with cyclic RGD peptide as ligand 
on gene delivery to vascular lesions. Gene Ther. 19, 61–9 (2012). 
177. Goh, L. K., Huang, F., Kim, W., Gygi, S. & Sorkin, A. Multiple mechanisms collectively 
regulate clathrin-mediated endocytosis of the epidermal growth factor receptor. J. Cell Biol. 
189, 871–83 (2010). 
178. Haugsten, E. M., Malecki, J., Bjørklund, S. M. S., Olsnes, S. & Wesche, J. Ubiquitination 
of fibroblast growth factor receptor 1 is required for its intracellular sorting but not for its 
endocytosis. Mol. Biol. Cell 19, 3390–403 (2008). 
179. Le Roy, C. & Wrana, J. L. Clathrin- and non-clathrin-mediated endocytic regulation of cell 
signalling. Nat. Rev. Mol. Cell Biol. 6, 112–26 (2005). 
180. Legrand, D. et al. Surface nucleolin participates in both the binding and endocytosis of 
lactoferrin in target cells. Eur. J. Biochem. 271, 303–317 (2004). 
181. Huang, F., Khvorova, A., Marshall, W. & Sorkin, A. Analysis of clathrin-mediated 
endocytosis of epidermal growth factor receptor by RNA interference. J. Biol. Chem. 279, 
16657–61 (2004). 
182. Vrecl, M. et al. Agonist-induced endocytosis and recycling of the gonadotropin-releasing 
hormone receptor: effect of beta-arrestin on internalization kinetics. Mol. Endocrinol. 12, 
1818–29 (1998). 
183. Grimes, M. L., Beattie, E. & Mobley, W. C. A signaling organelle containing the nerve 
growth factor-activated receptor tyrosine kinase, TrkA. Proc. Natl. Acad. Sci. 94, 9909–14 
(1997). 
184. Cammisotto, P. G. et al. Receptor-Mediated Transcytosis of Leptin through Human 
Intestinal Cells In Vitro. Int. J. Cell Biol. 2010, 928169 (2010). 
185. Savdie, C., Ferguson, S. S. G., Vincent, J.-P., Beaudet, A. & Stroh, T. Cell-type-specific 
pathways of neurotensin endocytosis. Cell Tissue Res. 324, 69–85 (2006). 
186. Deinhardt, K., Berninghausen, O., Willison, H. J., Hopkins, C. R. & Schiavo, G. Tetanus 
 115 
 
toxin is internalized by a sequential clathrin-dependent mechanism initiated within lipid 
microdomains and independent of epsin1. J. Cell Biol. 174, 459–71 (2006). 
187. Melkebeek, V. et al. Targeting aminopeptidase N, a newly identified receptor for F4ac 
fimbriae, enhances the intestinal mucosal immune response. Mucosal Immunol. 5, 635–45 
(2012). 
188. Song, N. et al. The nuclear translocation of endostatin is mediated by its receptor nucleolin 
in endothelial cells. Angiogenesis 15, 697–711 (2012). 
189. Marchese, C. et al. Receptor-mediated endocytosis of keratinocyte growth factor. J. Cell 
Sci. 111, 3517–27 (1998). 
190. Pawson,  a. J. Multiple Determinants for Rapid Agonist-Induced Internalization of a 
Nonmammalian Gonadotropin-Releasing Hormone Receptor: A Putative Palmitoylation 
Site and Threonine Doublet within the Carboxyl-Terminal Tail Are Critical. Endocrinology 
144, 3860–3871 (2003). 
191. Zhuang, G., Hunter, S., Hwang, Y. & Chen, J. Regulation of EphA2 receptor endocytosis 
by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation. 
J. Biol. Chem. 282, 2683–94 (2007). 
192. Roseberry, A. G. & Hosey, M. M. Internalization of the M2 muscarinic acetylcholine 
receptor proceeds through an atypical pathway in HEK293 cells that is independent of 
clathrin and caveolae. J. Cell Sci. 114, 739–46 (2001). 
193. Walker, J. K., Premont, R. T., Barak, L. S., Caron, M. G. & Shetzline, M. A. Properties of 
secretin receptor internalization differ from those of the beta(2)-adrenergic receptor. J. Biol. 
Chem. 274, 31515–23 (1999). 
194. Muro, S. et al. A novel endocytic pathway induced by clustering endothelial ICAM-1 or 
PECAM-1. J. Cell Sci. 116, 1599–609 (2003). 
195. Rejman, J., Bragonzi, A. & Conese, M. Role of clathrin- and caveolae-mediated endocytosis 
in gene transfer mediated by lipo- and polyplexes. Mol. Ther. 12, 468–74 (2005). 
196. Ziello, J. E., Huang, Y. & Jovin, I. S. Cellular endocytosis and gene delivery. Mol. Med. 16, 
222–229 
197. Seow, Y. & Wood, M. J. Biological Gene Delivery Vehicles: Beyond Viral Vectors. Mol. 
Ther. 17, 767–777 (2009). 
198. Levine, R. M., Scott, C. M. & Kokkoli, E. Peptide Functionalized Nanoparticles for 
Nonviral Gene Delivery. Soft Matter 9, 985–1004 (2013). 
199. Zhang, J.-S., Liu, F. & Huang, L. Implications of Pharmacokinetic Behavior of Lipoplex 
for its Inflammatory Toxicity. Adv. Drug Deliv. Rev. 57, 689–698 (2005). 
200. Balazs, D. & Godbey, W. Liposomes for use in gene delivery. J. Drug Deliv. 2011, (2011). 
201. Simões, S., Filipe, A. & Faneca, H. Cationic liposomes for gene delivery. Expert Opin. Drug 
Deliv. 2, 237–254 (2005). 
202. Zhao, W., Zhuang, S. & Qi, X.-R. Comparative study of the in vitro and in vivo 
characteristics of cationic and neutral liposomes. Int. J. Nanomedicine 6, 3087–3098 (2011). 
203. Immordino, M. L., Dosio, F. & Cattel, L. Stealth Liposomes: Review of the Basic Science, 
Rationale, and Clinical Applications, Existing and Potential. Int. J. Nanomedicine 1, 297–
315 (2006). 
204. Fields, A. L. & Runowicz, C. D. Current Therapies in Ovarian Cancer. Cancer Invest. 21, 
148–156 (2003). 
205. Brown, S. & Khan, D. R. The Treatment of Breast Cancer Using Liposome Technology. J. 
Drug Deliv. 2012, (2012). 
206. Demirgöz, D., Garg, A. & Kokkoli, E. PR_b-targeted PEGylated liposomes for prostate 
cancer therapy. Langmuir 24, 13518–13524 (2008). 
207. Tros de Ilarduya, C., Sun, Y. & Düzgüneş, N. Gene delivery by lipoplexes and polyplexes. 
Eur. J. Pharm. Sci. 40, 159–170 (2010). 
208. Preuss, M., Tecle, M., Shah, I., Matthews, D. a & Miller, A. D. Comparison between the 
 116 
 
interactions of adenovirus-derived peptides with plasmid DNA and their role in gene 
delivery mediated by liposome-peptide-DNA virus-like nanoparticles. Org. Biomol. Chem. 
1, 2430–2438 (2003). 
209. Herringson, T. P. P., Patlolla, R. R. R. & Altin, J. G. G. Targeting of plasmid DNA-
lipoplexes to cells with molecules anchored via a metal chelator lipid. J. Gene Med. 11, 
1048–1063 (2009). 
210. Legendre, J.-Y. & Szoka Jr., F. C. Delivery of Plasmid DNA into mammalian cells using 
pH-sensitive liposomes. Pharm. Res. 9, 1235–1242 (1992). 
211. Vonarbourg, A. et al. The encapsulation of DNA molecules within biomimetic lipid 
nanocapsules. Biomaterials 30, 3197–3204 (2009). 
212. Lee, L. K. et al. Biophysical characterization of an integrin-targeted non-viral vector. Med. 
Sci. Monit. 9, BR54–61 (2003). 
213. Jeffs, L. B. et al. A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation 
of Plasmid DNA. Pharm. Res. 22, 362–372 (2005). 
214. Holden, M. J. et al. Factors affecting quantification of total DNA by UV spectroscopy and 
PicoGreen fluorescence. J. Agric. Food Chem. 57, 7221–7226 (2009). 
215. Bhat, S. et al. Comparison of methods for accurate quantification of DNA mass 
concentration with traceability to the international system of units. Anal. Chem. 82, 7185–
7192 (2010). 
216. Tagawa, T. et al. Characterisation of LMD virus-like nanoparticles self-assembled from 
cationic liposomes, adenovirus core peptide mu and plasmid DNA. Gene Ther. 9, 564–576 
(2002). 
217. Holladay, C. et al. A reliable method for detecting complexed DNA in vitro. Nanoscale 2, 
2718–2723 (2010). 
218. Wacker, M. & Schubert, R. From mixed micelles to liposomes: Critical steps during 
detergent removal by membrane dialysis. Int. J. Pharm. 162, 171–175 (1998). 
219. Madani, F., Perálvarez-Marín, A. & Gräslund, A. Liposome Model Systems to Study the 
Endosomal Escape of Cell-Penetrating Peptides: Transport across Phospholipid Membranes 
Induced by a Proton Gradient. J. Drug Deliv. 2011, (2011). 
220. Lichtenberg, D. & Barenholz, Y. Liposomes: preparation, characterization, and 
preservation. Methods Biochem. Anal. 33, 337–462 (1988). 
221. Pons, M., Merc, F. & Estelrich, J. Liposomes obtained by the ethanol injection method. Int. 
J. Pharm. 95, 51–56 (1993). 
222. Batzri, S. & Korn, E. Single bilayer liposomes prepared without sonication. Biochim. 
Biophys. Acta 298, 1015–1019 (1973). 
223. Maitani, Y., Igarashi, S., Sato, M. & Hattori, Y. Cationic liposome (DC-Chol/DOPE=1:2) 
and a modified ethanol injection method to prepare liposomes, increased gene expression. 
Int. J. Pharm. 342, 33–39 (2007). 
224. Yang, S., Chen, J., Zhao, D., Han, D. & Chen, X. Comparative study on preparative methods 
of DC-Chol/DOPE liposomes and formulation optimization by determining encapsulation 
efficiency. Int. J. Pharm. 434, 155–160 (2012). 
225. Lasic, D. D. The mechanism of vesicle formation. Biochem. J. 256, 1–11 (1988). 
226. Lasic, D. D. Liposomes in Gene Delivery. (CRC Press, 1997). 
227. Ko, Y. T. & Bickel, U. Liposome-encapsulated polyethylenimine/oligonucleotide 
polyplexes prepared by reverse-phase evaporation technique. AAPS PharmSciTech 13, 373–
378 (2012). 
228. Tong, Q., Li, H., Li, W. & Chen, H. In Vitro and In Vivo Anti-Tumor Effects of 
Gemcitabine Loaded with a New Drug Delivery System. J. Nanosci. Nanotechnol. 11, 
3651–3658 (2011). 
229. Crosasso, P. et al. Antitumoral activity of liposomes and immunoliposomes containing 5-
fluorouridine prodrugs. J. Pharm. Sci. 86, 832–839 (1997). 
 117 
 
230. Whittenton, J. et al. Evaluation of asymmetric liposomal nanoparticles for encapsulation of 
polynucleotides. Langmuir 24, 8533–8540 (2008). 
231. Mokhtarieh, A. A., Cheong, S., Kim, S., Chung, B. H. & Lee, M. K. Asymmetric liposome 
particles with highly efficient encapsulation of siRNA and without nonspecific cell 
penetration suitable for target-specific delivery. Biochim. Biophys. Acta 1818, 1633–1641 
(2012). 
232. Belur, L., McIvor, R. & Wilber, A. Liver-directed gene therapy using the sleeping beauty 
transposon system. Methods Mol. Biol. 434, 267–276 (2008). 
233. Fu, D., Calvo, J. a & Samson, L. D. Balancing repair and tolerance of DNA damage caused 
by alkylating agents. Nat. Rev. Cancer 12, 104–20 (2012). 
234. Osborne, M. R., Wilman, D. E. V & Lawleyt, P. D. Alkylation of DNA by the nitrogen 
mustard Bis (2-chloroethyl)methylamine. Chem. Res. Toxicol. 8, 316–320 (1995). 
235. Vijayanathan, V., Lyall, J., Thomas, T., Shirahata, A. & Thomas, T. J. Ionic, structural, and 
temperature effects on DNA nanoparticles formed by natural and synthetic polyamines. 
Biomacromolecules 6, 1097–103 (2005). 
236. Lobo, B. a et al. Differential scanning calorimetric studies of the thermal stability of plasmid 
DNA complexed with cationic lipids and polymers. J. Pharm. Sci. 91, 454–66 (2002). 
237. Chen, P. S., Toribara, T. Y. & Warner, H. Microdetermination of Phosphorus. Anal. Chem. 
28, 1756–1758 (1956). 
238. Szoka, F. & Papahadjopoulos, D. Procedure for Preparation of Liposomes with Large 
Internal Aqueous Space and High Capture by Reverse-Phase Evaporation. Proc. Natl. Acad. 
Sci. U. S. A. 75, 4194–4198 (1978). 
239. Cortesi, R. et al. Preparation of liposomes by reverse -phase evaporation using alternative 
organic solvents. J. Microencapsul. 16, 251–256 (1999). 
240. Ramana, L. N., Sethuraman, S., Ranga, U. & Krishnan, U. M. Development of a liposomal 
nanodelivery system for nevirapine. J. Biomed. Sci. 17, 57 (2010). 
241. Unezaki, S., Maruyama, K. & Hosoda, J. Direct measurement of the extravasation of 
polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence 
microscopy. Int. J. Pharm. 144, 11–17 (1996). 
242. Semple, S. C. et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles 
using ionizable aminolipids : formation of novel small multilamellar vesicle structures. 
Biochim. Biophys. Acta 1510, 152–166 (2001). 
243. Xu, Y., Hui, S. W., Frederik, P. & Szoka, F. C. Physicochemical characterization and 
purification of cationic lipoplexes. Biophys. J. 77, 341–353 (1999). 
244. Sternberg, B., Sorgi, F. & Huang, L. New structures in complex formation between DNA 
and cationic liposomes visualized by freeze—fracture electron microscopy. FEBS Lett. 356, 
361–366 (1994). 
245. Templeton, N. S. Nonviral delivery for genomic therapy of cancer. World J. Surg. 33, 685–
697 (2009). 
246. Agbavwe, C. & Somoza, M. M. Sequence-dependent fluorescence of cyanine dyes on 
microarrays. PLoS One 6, (2011). 
247. Lupyan, D., Mezei, M., Logothetis, D. E. & Osman, R. A molecular dynamics investigation 
of lipid bilayer perturbation by PIP2. Biophys. J. 98, 240–247 (2010). 
248. Bhise, N. S., Shmueli, R. B., Gonzalez, J. & Green, J. J. A novel assay for quantifying the 
number of plasmids encapsulated by polymer nanoparticles. Small 8, 367–373 (2011). 
249. Clamme, J., Azoulay, J. & Mely, Y. Monitoring of the formation and dissociation of 
polyethylenimine/DNA complexes by two photon fluorescence correlation spectroscopy. 
Biophys. J. 84, 1960–1968 (2003). 
250. Lerman, L. S., Wilkerson, L. S., Venable, J. J. H. & Robinson, B. H. DNA packing in single 
crystals inferred from freeze-fracture-etch replicas. J. Mol. Biol. 108, 271–293 (1976). 
251. Hou, S. et al. Formation and structure of PEI/DNA complexes: quantitative analysis. Soft 
 118 
 
Matter 7, 6967–6972 (2011). 
252. Benita, S., Poly, P. a, Puisieux, F. & Delattre, J. Radiopaque liposomes: effect of 
formulation conditions on encapsulation efficiency. J. Pharm. Sci. 73, 1751–1755 (1984). 
253. Kanasty, R., Dorkin, J. R., Vegas, A. & Anderson, D. Delivery Materials for siRNA 
Therapeutics. Nat. Mater. 12, 967–977 (2013). 
254. Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking Down Barriers: Advances in 
siRNA Delivery. Nat. Rev. Drug Discov. 8, 129–138 (2009). 
255. Seyhan, A. A. RNAi: A Potential New Class of Therapeutic for Human Genetic Disease. 
Hum. Genet. 130, 583–605 (2011). 
256. Haasnoot, J. & Berkhout, B. RNAi and Cellular miRNAs in Infections by Mammalian 
Viruses. Antivir. RNAi Concepts, Methods, Appl. Methods Mol. Biol. 721, 355–371 (2011). 
257. Devi, G. R. siRNA-Based Approaches in Cancer Therapy. Cancer Gene Ther. 13, 819–829 
(2006). 
258. Yim, E.-K. & Park, J.-S. The Role of HPV E6 and E7 Oncoproteins in HPV-Associated 
Cervical Carcinogenesis. Cancer Res. Treat. 37, 319–324 (2005). 
259. Jung, H. S. et al. The synergistic therapeutic effect of cisplatin with Human papillomavirus 
E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo. Int. J. Cancer 
130, 1925–1936 (2012). 
260. Salazar-León, J. et al. Silencing of HPV16 E6 and E7 Oncogenic Activities by Small 
Interference RNA Induces Autophagy and Apoptosis in Human Cervical Cancer Cells. J. 
Nucleic Acids Investig. 2, 59–69 (2011). 
261. Butz, K. et al. siRNA Targeting of the Viral E6 Oncogene Efficiently Kills Human 
Papillomavirus-Positive Cancer Cells. Oncogene 22, 5938–5945 (2003). 
262. Zhou, J. et al. Transcriptional Gene Silencing of HPV16 E6/E7 Induces Growth Inhibition 
via Apoptosis in vitro and in vivo. Gynecol. Oncol. 124, 296–302 (2012). 
263. Jiang, M. & Milner, J. Selective Silencing of Viral Gene Expression in HPV-Positive 
Human Cervical Carcinoma Cells Treated with siRNA, a Primer of RNA Interference. 
Oncogene 21, 6041–6048 (2002). 
264. Chang, J. T.-C. et al. Highly Potent and Specific siRNAs Against E6 or E7 Genes of 
HPV16- or HPV18-Infected Cervical Cancers. Cancer Gene Ther. 17, 827–836 (2010). 
265. Lin, Q., Chen, J., Zhang, Z. & Zheng, G. Lipid-Based Nanoparticles in the Systemic 
Delivery of iRNA. Nanomedicine 9, 105–120 (2014). 
266. Hughes, D. E., Rebello, G. & Al-Nafussi, A. Integrin Expression in Squamous Neoplasia of 
the Cervix. J. Pathol. 173, 97–104 (1994). 
267. Rabinovitz, I., Nagle, R. B. & Cress, A. E. Integrin α6 Expression in Human Prostate 
Carcinoma Cells is Associated with a Migratory and Invasive Phenotype in vitro and in 
vivo. Clin. Exp. Metastasis 13, 481–491 (1995). 
268. Friedrichs, K. et al. High Expression Level of α6 Integrin in Human Breast Carcinoma Is 
Correlated with Reduced Survival. Cancer Res. 55, 901–906 (1995). 
269. Hozumi, K. et al. Cell Adhesive Peptide Screening of the Mouse Laminin α1 Chain G 
Domain. Arch. Biochem. Biophys. 503, 213–222 (2010). 
270. Boussif, O. et al. A Versatile Vector for Gene and Oligonucleotide Transfer into Cells in 
Culture and in vivo: Polyethylenimine. Proc. Natl. Acad. Sci. 92, 7297–7301 (1995). 
271. Liang, W. & Lam, J. K. W. Endosomal Escape Pathways for Non-Viral Nucleic Acid 
Delivery Systems. Mol. Regul. Endocytosis 429–456 (2012). doi:10.5772/46006 
272. Levine, R. M., Pearce, T. R., Adil, M. M., Kokkoli, E. & Pierce, T. R. Preparation and 
Characterization of Liposome-Encapsulated Plasmid DNA for Gene Delivery. Langmuir 
(2013). 
273. Adil, M. M., Levine, R. M. & Kokkoli, E. Increasing Cancer-Specific Gene Expression by 
Targeting Overexpressed α5β1 Integrin and Upregulated Transcriptional Activity of NF-
κB. Mol. Pharm. 11, 849–858 (2014). 
 119 
 
274. Adil, M. M., Erdman, Z. S. & Kokkoli, E. Transfection Mechanisms of Polyplexes, 
Lipoplexes, and Stealth Liposomes in α5β1 Integrin Bearing DLD-1 Colorectal Cancer 
Cells. Langmuir 30, 3802–3810 (2014). 
275. Ma, P. L., Lavertu, M., Winnik, F. M. & Buschmann, M. D. New Insights into Chitosan-
DNA Interactions using Isothermal Titration Microcalorimetry. Biomacromolecules 10, 
1490–1499 (2009). 
276. Utsuno, K. & Uludaǧ, H. Thermodynamics of Polyethylenimine-DNA Binding and DNA 
Condensation. Biophys. J. 99, 201–207 (2010). 
277. Ferreira, E. & Cronjé, M. J. Selection of Suitable Reference Genes for Quantitative Real-
Time PCR in Apoptosis-Induced MCF-7 Breast Cancer Cells. Mol. Biotechnol. 50, 121–
128 (2012). 
278. Wang, X., Ramström, O. & Yan, M. Quantitative Analysis of Multivalent Ligand 
Presentation on Gold Glyconanoparticles and the Impact on Lectin Binding. Anal. Chem. 
82, 9082–9089 (2010). 
279. Hong, S. et al. The Binding Avidity of a Nanoparticle-Based Multivalent Targeted Drug 
Delivery Platform. Chem. Biol. 14, 107–115 (2007). 
280. Margadant, C., Monsuur, H. N., Norman, J. C. & Sonnenberg, A. Mechanisms of Integrin 
Activation and Trafficking. Curr. Opin. Cell Biol. 23, 607–614 (2011). 
281. Choosakoonkriang, S., Lobo, B. A., Koe, G. S., Koe, J. G. & Middaugh, C. R. Biophysical 
Characterization of PEI/DNA Complexes. J. Pharm. Sci. 92, 1710–1722 (2003). 
282. Ikonen, M., Murtomäki, L. & Kontturi, K. Controlled Complexation of Plasmid DNA with 
Cationic Polymers: Effect of Surfactant on the Complexation and Stability of the 
Complexes. Colloids Surfaces B Biointerfaces 66, 77–83 (2008). 
283. Ketola, T.-M. et al. Independent versus Cooperative Binding in Polyethylenimine-DNA. J. 
Phys. Chem. B (2013). 
284. Breunig, M. et al. Mechanistic Investigation of Poly(ethylene imine)-Based siRNA 
Delivery: Disulfide Bonds Boost Intracellular Release of the Cargo. J. Control. Release 130, 
57–63 (2008). 
285. Mao, S. et al. Influence of Polyethylene Glycol Chain Length on the Physicochemical and 
Biological Properties of Poly(ethylene imine)-graft-Poly(ethylene glycol) Block 
Copolymer/siRNA Polyplexes. Bioconjug. Chem. 17, 1209–1218 (2006). 
286. Zheng, M. et al. Targeting the Blind Spot of Polycationic Nanocarrier-Based siRNA 
Delivery. ACS Nano 6, (2012). 
287. Ziebarth, J. D. & Wang, Y. Understanding the protonation behavior of linear 
polyethylenimine in solutions through Monte Carlo simulations. Biomacromolecules 11, 1–
29 (2011). 
288. Wu, S. Y. & McMillan, N. A. J. Lipidic Systems for in vivo siRNA Delivery. AAPS J. 11, 
639–652 (2009). 
289. Guo, Y. et al. How is mRNA expression predictive for protein expression? A correlation 
study on human circulating monocytes. Acta Biochim. Biophys. 40, 426–36 (2008). 
290. Chen, G. et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol. 
Cell. Proteomics 1, 304–13 (2002). 
291. Qi, Z. et al. Effect of simultaneous silencing of HPV-18 E6 and E7 on inducing apoptosis 
in HeLa cells. Biochem. Cell Biol. 88, 697–704 (2010). 
292. Burnett, J. C., Rossi, J. J. & Tiemann, K. Current Progress of siRNA/shRNA Therapeutics 
in Clinical Trials. Biotechnol. J. 6, 1130–1146 (2011). 
293. Xu, C. & Wang, J. Delivery Systems for siRNA Drug Development in Cancer Therapy. 
Asian J. Pharm. Sci. 10, 1–12 (2014). 
294. Li, S.-D., Chen, Y.-C., Hackett, M. J. & Huang, L. Tumor-Targeted Delivery of siRNA by 
Self-Assembled Nanoparticles. Mol. Ther. 16, 163–169 (2008). 
295. Hatakeyama, H. et al. Systemic Delivery of siRNA to Tumors using a Lipid Nanoparticle 
 120 
 
Containing a Tumor-Specific Cleavable PEG-Lipid. Biomaterials 32, 4306–4316 (2011). 
296. Whitehead, K. a et al. Degradable lipid nanoparticles with predictable in vivo siRNA 
delivery activity. Nat. Commun. 5, 4277 (2014). 
297. Judge, A. D. et al. Confirming the RNAi-Mediated Mechanism of Action of siRNA-Based 
Cancer Therapeutics in Mice. J. Clin. Invest. 119, 661–673 (2009). 
298. Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A. & Davis, M. E. Impact of Tumor-
Specific Targeting on the Biodistribution and Efficacy of siRNA Nanoparticles Measured 
by Multimodality in vivo Imaging. Proc. Natl. Acad. Sci. 104, 15549–15554 (2007). 
299. Adil, M. M., Levine, R. M. & Kokkoli, E. Increasing Cancer-Specific Gene Expression by 
Targeting Overexpressed α5β1 Integrin and Upregulated Transcriptional Activity of NF-
κB. Mol. Pharm. 11, 849–858 (2014). 
300. Merkel, O. M. et al. Nonviral siRNA Delivery to the Lung: Investigation of PEG-PEI 
Polyplexes and Their in vivo Performance. Mol. Pharm. 6, 1246–1260 (2009). 
301. Van Rompaey, E., Engelborghs, Y., Sanders, N., De Smedt, S. C. & Demeester, J. 
Interactions Between Oligonucleotides and Cationic Polymers Investigated by Fluorescence 
Correlation Spectroscopy. Pharm. Res. 18, 928–936 (2001). 
302. Sunshine, J. C., Peng, D. Y. & Green, J. J. Uptake and Transfection with Polymeric 
Nanoparticles are Dependent on Polymer End-Group Structure, but Largely Independent of 
Nanoparticle Physical and Chemical Properties. Mol. Pharm. 9, 3375–3383 (2012). 
303. Ghosh, P. S., Kim, C.-K., Han, G., Forbes, N. S. & Rotello, V. M. Efficient Gene Delivery 
Vectors by Tuning the Surface Charge Density of Amino Acid-Functionalized Gold 
Nanoparticles. ACS Nano 2, 2213–2218 (2008). 
304. Tseng, W.-C., Fang, T.-Y., Su, L.-Y. & Tang, C.-H. Dependence of Transgene Expression 
and the Relative Buffering Capacity of Dextran-Grafted Polyethylenimine. Mol. Pharm. 2, 
224–232 (2005). 
305. Sioud, M. Induction of Inflammatory Cytokines and Interferon Responses by Double-
Stranded and Single-Stranded siRNAs is Sequence-Dependent and Requires Endosomal 
Localization. J. Mol. Biol. 348, 1079–1090 (2005). 
306. Li, S. D. & Huang, L. Surface-Modified LPD Nanoparticles for Tumor Targeting. Ann. N. 
Y. Acad. Sci. 1082, 1–8 (2006). 
307. Yang, X. H. et al. CD151 Restricts the a6 Integrin Diffusion Mode. J. Cell Sci. 125, 1478–
1487 (2011). 
308. Caswell, P. T. & Norman, J. C. Integrin Trafficking and the Control of Cell Migration. 
Traffic 7, 14–21 (2006). 
309. Sterk, L. M. T. et al. The Tetraspan Molecule CD151, a Novel Constituent of 
Hemidesmosomes, Associates with the Integrin alpha6beta4 and May Regulate the Spatial 
Organization of Hemidesmosomes Lotus. J. Cell Biol. 149, 969–982 (2000). 
310. Liu, L. et al. Tetraspanin CD151 Promotes Cell Migration by Regulating Integrin 
Trafficking. J. Biol. Chem. 282, 31631–31642 (2007). 
311. Dy, G. K. & Adjei, A. A. Understanding, Recognizing, and Managing Toxicities of 
Targeted Anticancer Therapies. CA. Cancer J. Clin. 63, 249–279 (2013). 
312. Saul, J. M., Annapragada, A. V & Bellamkonda, R. V. A Dual-Ligand Approach for 
Enhancing Targeting Selectivity of Therapeutic Nanocarriers. J. Control. Release 114, 277–
287 (2006). 
313. Barnett, B. G., Tillman, B. W., Curiel, D. T. & Douglas, J. T. Dual Targeting of Adenoviral 
Vectors at the Levels of Transduction and Transcription Enhances the Specificity of Gene 
Expression in Cancer Cells. Mol. Ther. 6, 377–385 (2002). 
314. Barker, S. D. et al. Combined Transcriptional and Transductional Targeting Improves the 
Specificity and Efficacy of Adenoviral Gene Delivery to Ovarian Carcinoma. Gene Ther. 
10, 1198–1204 (2003). 
315. Banerjee, D. & Sengupta, S. Nanoparticles in cancer chemotherapy. Prog. Mol. Biol. Transl. 
 121 
 
Sci. 104, 489–507 (2011). 
316. Gerber, D. E. Targeted therapies: A new generation of cancer treatments. Am. Fam. 
Physician 77, 311–319 (2008). 
317. Davis, M. E., Chen, Z. G. & Shin, D. M. Nanoparticle therapeutics: an emerging treatment 
modality for cancer. Nat. Rev. Drug Discov. 7, 771–782 (2008). 
318. Sanna, V., Pala, N. & Sechi, M. Targeted therapy using nanotechnology: Focus on cancer. 
Int. J. Nanomedicine 9, 467–483 (2014). 
319. Izar, B., Rotow, J., Gainor, J., Clark, J. & Chabner, B. Pharmacokinetics, clinical 
indications, and resistance mechanisms in molecular targeted therapies in cancer. 
Pharmacol. Rev. 65, 1351–1395 (2013). 
320. Prabhu, R. H., Patravale, V. B., & Joshi, M. D. Polymeric nanoparticles for targeted 
treatment in oncology : current insights. Int. J. Nanomedicine 10, 1001–1018 (2015). 
321. Hughes, S. E. Differential expression of the fibroblast growth factor receptor (FGFR) 
multigene family in normal human adult tissues. J. Histochem. Cytochem. 45, 1005–19 
(1997). 
322. Koretz, K., Schlag, P. & Möller, P. Expression of epidermal growth factor receptor in 
normal colorectal mucosa, adenoma, and carcinoma. Virchows Arch. A. Pathol. Anat. 
Histopathol. 416, 343–9 (1990). 
323. Parsons-Wingerter, P. et al. Uniform overexpression and rapid accessibility of alpha5beta1 
integrin on blood vessels in tumors. Am. J. Pathol. 167, 193–211 (2005). 
324. Raschi, E. & De Ponti, F. Cardiovascular toxicity of anticancer-targeted therapy: emerging 
issues in the era of cardio-oncology. Intern. Emerg. Med. 7, 113–31 (2012). 
325. Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in cancer 
chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor 
agent smancs. Cancer Res. 46, 6387–92 (1986). 
326. Lasic, D. D. & Needham, D. The ‘Stealth’ Liposome: A Prototypical Biomaterial. Chem. 
Rev. 95, 2601–2628 (1995). 
327. Yuan, F. et al. Mirovascular Permeability and Interstitial Penetration of Sterically Stabilized 
(Stealth) Liposomes in a Human Tumor Xenograft. Cancer Res. 54, 3352–3356 (1994). 
328. Mukhopadhyay, R., Theriault, R. L. & Price, J. E. Increased levels of alpha6 integrins are 
associated with the metastatic phenotype of human breast cancer cells. Clin. Exp. Metastasis 
17, 325–32 (1999). 
329. Berry, M. G., Gui, G. P. H., Wells, C. a & Carpenter, R. Integrin expression and survival in 
human breast cancer. Eur. J. Surg. Oncol. 30, 484–9 (2004). 
330. Jia, Y. et al. Integrin fibronectin receptors in matrix metalloproteinase-1-dependent invasion 
by breast cancer and mammary epithelial cells. Cancer Res. 64, 8674–81 (2004). 
331. Chao, C. et al. A Function for the Integrin a6b4 in the Invasive Properties of Colorectal 
Carcinoma Cells. Cancer Res. 56, 4811–4819 (1996). 
332. Ellis, L. M. A targeted approach for antiangiogenic therapy of metastatic human colon 
cancer. Am. Surg. 69, 3–10 (2003). 
333. Gong, J. et al. Role of a5b1 integrin in determining malignant properties of colon carcinoma 
cells. Cell Growth Differ. 8, 83–90 (1997). 
334. Dedhar, S., Saulnier, R., Nagle, R. & Overall, C. M. Specific alterations in the expression 
of alpha 3 beta 1 and alpha 6 beta 4 integrins in highly invasive and metastatic variants of 
human prostate carcinoma cells selected by in vitro invasion through reconstituted basement 
membrane. Clin. Exp. Metastasis 11, 391–400 (1993). 
335. Rokhlin, O. W. & Cohen, M. B. Expression of cellular adhesion molecules on human 
prostate tumor cell lines. Prostate 26, 205–12 (1995). 
336. Livant, D. L. et al. Anti-invasive, antitumorigenic, and antimetastatic activities of the 
PHSCN sequence in prostate carcinoma. Cancer Res. 60, 309–320 (2000). 
337. Chen, J., De, S., Brainard, J. & Byzova, T. V. Metastatic properties of prostate cancer cells 
 122 
 
are controlled by VEGF. Cell Commun. Adhes. 11, 1–11 
338. Cruz-Monserrate, Z. & O’Connor, K. Integrin α6β4 promotes migration, invasion through 
Tiam1 upregulation, and subsequent Rac activation. Neoplasia 10, 408–417 (2008). 
339. Mercurio,  a M. & Rabinovitz, I. Towards a mechanistic understanding of tumor invasion--
lessons from the alpha6beta 4 integrin. Semin. Cancer Biol. 11, 129–41 (2001). 
340. Uhlén, M. et al. Tissue-based map of the human proteome. Science 347, 1260419–1260419 
(2015). 
341. Mercurio, A. M. et al. The metastatic odyssey: the integrin connection. Surg. Oncol. Clin. 
N. Am. 10, 313–28, viii–ix (2001). 
342. Laginha, K., Mumbengegwi, D. & Allen, T. Liposomes targeted via two different 
antibodies: assay, B-cell binding and cytotoxicity. Biochim. Biophys. Acta 1711, 25–32 
(2005). 
343. Omolola Eniola,  a & Hammer, D. a. In vitro characterization of leukocyte mimetic for 
targeting therapeutics to the endothelium using two receptors. Biomaterials 26, 7136–44 
(2005). 
344. Kakimoto, S., Moriyama, T., Tanabe, T., Shinkai, S. & Nagasaki, T. Dual-ligand effect of 
transferrin and transforming growth factor alpha on polyethyleneimine-mediated gene 
delivery. J. Control. Release 120, 242–9 (2007). 
345. Singh, S. R. et al. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles 
enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther. 16, 645–
659 (2009). 
346. Kluza, E. et al. Synergistic targeting of alphavbeta3 integrin and galectin-1 with 
heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of 
angiogenesis. Nano Lett. 10, 52–8 (2010). 
347. Kluza, E. et al. Dual-targeting of α(v)β(3) and galectin-1 improves the specificity of 
paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J. Control. Release 158, 
207–214 (2011). 
348. Gunawan, R. & Auguste, D. Immunoliposomes that target endothelium in vitro are 
dependent on lipid raft formation. Mol. Pharm. 7, 1569–1575 (2010). 
349. Gunawan, R. & Auguste, D. The role of antibody synergy and membrane fluidity in the 
vascular targeting of immunoliposomes. Biomaterials 31, 900–907 (2010). 
350. Gunawan, R. C., Almeda, D. & Auguste, D. T. Complementary targeting of liposomes to 
IL-1α and TNF-α activated endothelial cells via the transient expression of VCAM1 and E-
selectin. Biomaterials 32, 9848–53 (2011). 
351. Xu, L. et al. Heterobivalent ligands target cell-surface receptor combinations in vivo. Proc. 
Natl. Acad. Sci. U. S. A. 109, 21295–300 (2012). 
352. Rangger, C. et al. Tumor targeting and imaging with dual-peptide conjugated 
multifunctional liposomal nanoparticles. Int. J. Nanomedicine 8, 4659–71 (2013). 
353. Gao, H. et al. RGD and Interleukin-13 Peptide Functionalized Nanoparticles for Enhanced 
Glioblastoma Cells and Neovasculature Dual Targeting Delivery and Elevated Tumor 
Penetration. Mol. Pharm. 11, 1042–1052 (2014). 
354. Dixit, S. et al. Dual receptor-targeted theranostic nanoparticles for localized delivery and 
activation of PDT drug in glioblastomas. Mol. Pharm. 12, 3250–3260 (2015). 
355. Lauffenburger, D. A. & Linderman, J. Receptors : Models for Binding, Trafficking, and 
Signaling. (Oxford University Press, USA, 1993). 
356. Ghaghada, K. B., Saul, J., Natarajan, J. V, Bellamkonda, R. V & Annapragada, A. V. Folate 
targeting of drug carriers: a mathematical model. J. Control. Release 104, 113–28 (2005). 
357. Handl, H. L. et al. Hitting multiple targets with multimeric ligands. Expert Opin. Ther. 
Targets 8, 565–86 (2004). 
358. Tassa, C. et al. Binding affinity and kinetic analysis of targeted small molecule-modified 
nanoparticles. Bioconjug. Chem. 21, 14–9 (2010). 
 123 
 
359. Müller, K. M., Arndt, K. M. & Plückthun, A. Model and simulation of multivalent binding 
to fixed ligands. Anal. Biochem. 261, 149–58 (1998). 
360. Haun, J. B. & Hammer, D. A. Quantifying nanoparticle adhesion mediated by specific 
molecular interactions. Langmuir 24, 8821–8832 (2008). 
361. English, T. J. & Hammer, D. A. Brownian adhesive dynamics (BRAD) for simulating the 
receptor-mediated binding of viruses. Biophys. J. 86, 3359–3372 (2004). 
362. Caplan, M. R. & Rosca, E. V. Targeting drugs to combinations of receptors: a modeling 
analysis of potential specificity. Ann. Biomed. Eng. 33, 1113–24 (2005). 
363. Nermut, M., Green, N. & Eason, P. Electron microscopy and structural model of human 
fibronectin receptor. EMBO J. 7, 4093–4099 (1988). 
364. Xiong, J.-P., Stehle, T., Goodman, S. L. & Arnaout, M. A. New insights into the structural 
basis of integrin activation. Blood 102, 1155–9 (2003). 
365. Hulme, E. C. & Trevethick, M. a. Ligand binding assays at equilibrium: validation and 
interpretation. Br. J. Pharmacol. 161, 1219–37 (2010). 
366. Fiske, C. & Subbarow, Y. The colorimetric determination of phosphorus. J. Biol. Chem. 66, 
375–400 (1925). 
367. Johnson, I. & Spence, M. T. Z. Molecular Probes Handbook. (2010). 
368. Li, N., Hill, K. S. & Elferink, L. A. Analysis of receptor tyrosine kinase internalization using 
flow cytometry. Methods Mol. Biol. (2008). doi:10.1016/j.bbi.2008.05.010 
369. Weert, A. W. M. Van, Geuze, H. J., Groothuis, B. & Stoorvogel, W. Primaquine interferes 
with membrane recycling from endosomes to the plasma membrane through a direct 
interaction with endosomes which does not involve neutralisation of endosomal pH nor 
osmotic swelling of endosomes. 399, 394–399 (2000). 
370. Silverstein, S. C., Steinman, R. M. & Cohn, Z. A. Endocytosis. Annu. Rev. Biochem. 46, 
669–722 (1977). 
371. Weddell, J. C. & Imoukhuede, P. I. Quantitative characterization of cellular membrane-
receptor heterogeneity through statistical and computational modeling. PLoS One 9, (2014). 
372. Kimmig, R., Pfeiffer, D., Landsmann, H. & Hepp, H. Quantitative determination of the 
epidermal growth factor receptor in cervical cancer and normal cervical epithelium by 2-
color flow cytometry: Evidence for down-regulation in cervical cancer. Int. J. Cancer 74, 
365–373 (1997). 
373. Shankaran, H., Zhang, Y., Tan, Y. & Resat, H. Model-Based Analysis of HER Activation 
in Cells Co-Expressing EGFR, HER2 and HER3. PLoS Comput. Biol. 9, (2013). 
374. Hackel, B. J., Neil, J. R., White, F. M. & Wittrup, K. D. Epidermal growth factor receptor 
downregulation by small heterodimeric binding proteins. Protein Eng. Des. Sel. 25, 47–57 
(2012). 
375. Pangburn, T. O., Bates, F. S. & Kokkoli, E. Polymersomes functionalized via ‘“ click ”’ 
chemistry with the fibronectin mimetic peptides PR _ b and GRGDSP for targeted delivery 
to cells with different levels of α5β1 expression. Soft Matter 8, 4449–4461 (2012). 
376. Schaffner, F., Ray, A. M. & Dontenwill, M. Integrin a5b1, the fibronectin receptor, as a 
pertinent therapeutic target in solid tumors. Cancers (Basel). 5, 27–47 (2013). 
377. Skubitz, A. P. N., Bast, R. C., Wayner, E. A., Letourneau, P. C. & Wilke, M. S. Expression 
of a64 integrins in serous ovarian carcinoma correlates with expression of the basement 
membrane protein laminin. Am. J. Pathol. 148, 1445–1461 (1996). 
378. Figini, M. et al. Reversion of transformed phenotype in ovarian cancer cells by intracellular 
expression of anti folate receptor antibodies. Gene Ther. 10, 1018–1025 (2003). 
379. Folgiero, V. et al. Induction of ErbB-3 expression by alpha6beta4 integrin contributes to 
tamoxifen resistance in ERbeta1-negative breast carcinomas. PLoS One 3, e1592 (2008). 
380. Chavez, K., Garimella, S. & Lipkowitz, S. Triple negative breast cancer cell lines: one tool 
in the search for better treatment of triple negative breast cancer. Breast Dis. 32, 35–48 
(2010). 
 124 
 
381. Mardilovich, A. & Kokkoli, E. Patterned biomimetic membranes: effect of concentration 
and pH. Langmuir 21, 7468–75 (2005). 
382. Cluzel, C. et al. The mechanisms and dynamics of αvβ3 integrin clustering in living cells. 
J. Cell Biol. 171, 383–392 (2005). 
383. Roca-Cusachs, P., Gauthier, N. C., Del Rio, A. & Sheetz, M. P. Clustering of 
alpha(5)beta(1) integrins determines adhesion strength whereas alpha(v)beta(3) and talin 
enable mechanotransduction. Proc. Natl. Acad. Sci. 106, 16245–16250 (2009). 
384. Van Kooyk, Y. & Figdor, C. G. Avidity regulation of integrins: The driving force in 
leukocyte adhesion. Curr. Opin. Cell Biol. 12, 542–547 (2000). 
385. Erdmann, T. & Schwarz, U. S. Impact of receptor-ligand distance on adhesion cluster 
stability. Eur. Phys. J. E 22, 123–137 (2007). 
386. Jamali, Y., Jamali, T. & Mofrad, M. R. K. An agent based model of integrin clustering: 
Exploring the role of ligand clustering, integrin homo-oligomerization, integrin-ligand 
affinity, membrane crowdedness and ligand mobility. J. Comput. Phys. 244, 264–278 
(2013). 
387. Lortat-Jacob, H., Chouin, E., Cusack, S. & van Raaij, M. J. Kinetic analysis of adenovirus 
fiber binding to its receptor reveals an avidity mechanism for trimeric receptor-ligand 
interactions. J. Biol. Chem. 276, 9009–15 (2001). 
388. Onodera, Y., Nam, J. M. & Sabe, H. Intracellular trafficking of integrins in cancer cells. 
Pharmacol. Ther. 140, 1–9 (2013). 
389. Wiseman, P. W. et al. Spatial mapping of integrin interactions and dynamics during cell 
migration by image correlation microscopy. J. Cell Sci. 117, 5521–5534 (2004). 
390. Gaborski, T. R., Clark, A., Waugh, R. E. & McGrath, J. L. Membrane mobility of beta2 
integrins and rolling associated adhesion molecules in resting neutrophils. Biophys. J. 95, 
4934–4947 (2008). 
391. Yokoyama, Y. & Ramakrishnan, S. Binding of endostatin to human ovarian cancer cells 
inhibits cell attachment. Int. J. Cancer 121, 2402–9 (2007). 
392. Godbey, W. T., Wu, K. K., Hirasaki, G. J. & Mikos, A. G. Improved packing of 
poly(ethylenimine)/DNA complexes increases transfection efficiency. Gene Ther. 6, 1380–
1388 (1999). 
393. Jeong, J. H., Song, S. H., Lim, D. W., Lee, H. & Park, T. G. DNA transfection using linear 
poly(ethylenimine) prepared by controlled acid hydrolysis of poly(2-ethyl-2-oxazoline). J. 
Control. Release 73, 391–9 (2001). 
 125 
 
Appendix A: Binding Equations and Matlab Code Used to Create the Heteromultivalent Model 
𝐿 + 𝑅 −
𝑘𝑓
𝑘𝑟
− 𝐶 
𝑅 = 𝑅0 − 𝐶 
𝑑𝐿
𝑑𝑡
= 𝑘𝑟𝐶 − 𝑘𝑓𝐿𝑅 
L – unbound nanoparticle 
q – valency of ligand A 
r – valency of ligand B 
Ra – unbound Receptor A 
Rb – unbound Receptor B 
Ra0 – Initial Receptor A 
Rb0 – Initial Receptor B 
Cna – complex between ligand A and receptor A of valency n 
Cmb – complex between ligand B and receptor B of valency m 
kfa – forward reaction rate for binding of unbound nanoparticle to a cell via ligand A-receptor A interactions 
kfb – forward reaction rate for binding of unbound nanoparticle to a cell via ligand B-receptor B interactions 
kxa – forward reaction rate for binding of ligand A from an already bound nanoparticle 
kxb – forward reaction rate for binding of ligand B from an already bound nanoparticle 
kra – rate of dissociation of ligand A 
krb – rate of dissociation of ligand B 
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q=8, r=0 
𝑅𝑎 = 𝑅𝑎0 − (𝐶1𝑎) − 2(𝐶2𝑎) − 3(𝐶3𝑎) − 4(𝐶4𝑎) − 5(𝐶5𝑎) − 6(𝐶6𝑎) − 7(𝐶7𝑎) − 8(𝐶8𝑎) 
𝑑𝐿
𝑑𝑡
= 𝑘𝑟𝑎𝐶1𝑎𝑚 − 8𝑘𝑓𝑎𝐿𝑅𝑎𝑚 + 𝑘𝑟𝑎𝐶1𝑎𝑛 − 8𝑘𝑓𝑎𝐿𝑅𝑎𝑛 + 𝑘𝑟𝑎𝐶1𝑎𝑝 − 8𝑘𝑓𝑎𝐿 
𝑑𝐶1𝑎
𝑑𝑡
= 2𝑘−𝑥𝑎𝐶2𝑎 + 𝑞𝑘𝑓𝑎𝐿𝑅𝑎 − 𝐶1𝑎[(𝑞 − 1)𝑘𝑥𝑎𝑅𝑎 + 𝑘𝑟𝑎] 
𝑑𝐶2𝑎
𝑑𝑡
= 3𝑘−𝑥𝑎𝐶3𝑎 + (𝑞 − 1)𝑘𝑥𝑎𝐶1𝑎𝑅𝑎 − 𝐶2𝑎[(𝑞 − 2)𝑘𝑥𝑎𝑅𝑎 + 2𝑘−𝑥𝑎] 
𝑑𝐶3𝑎
𝑑𝑡
= 4𝑘−𝑥𝑎𝐶4𝑎 + (𝑞 − 2)𝑘𝑥𝑎𝐶2𝑎𝑅𝑎 − 𝐶3𝑎[(𝑞 − 3)𝑘𝑥𝑎𝑅𝑎 + 3𝑘−𝑥𝑎] 
𝑑𝐶4𝑎
𝑑𝑡
= 5𝑘−𝑥𝑎𝐶5𝑎 + (𝑞 − 3)𝑘𝑥𝑎𝐶3𝑎𝑅𝑎 − 𝐶4𝑎[(𝑞 − 4)𝑘𝑥𝑎𝑅𝑎 + 4𝑘−𝑥𝑎] 
𝑑𝐶5𝑎
𝑑𝑡
= 6𝑘−𝑥𝑎𝐶6𝑎 + (𝑞 − 4)𝑘𝑥𝑎𝐶4𝑎𝑅𝑎 − 𝐶5𝑎[(𝑞 − 5)𝑘𝑥𝑎𝑅𝑎 + 5𝑘−𝑥𝑎] 
𝑑𝐶6𝑎
𝑑𝑡
= 7𝑘−𝑥𝑎𝐶7𝑎 + (𝑞 − 5)𝑘𝑥𝑎𝐶5𝑎𝑅𝑎 − 𝐶6𝑎[(𝑞 − 6)𝑘𝑥𝑎𝑅𝑎 + 6𝑘−𝑥𝑎] 
𝑑𝐶7𝑎
𝑑𝑡
= 8𝑘−𝑥𝑎𝐶8𝑎 + (𝑞 − 6)𝑘𝑥𝑎𝐶6𝑎𝑅𝑎 − 𝐶7𝑎[(𝑞 − 7)𝑘𝑥𝑎𝑅𝑎 + 7𝑘−𝑥𝑎] 
𝑑𝐶8𝑎
𝑑𝑡
= (𝑞 − 7)𝑘𝑥𝑎𝐶7𝑎𝑅𝑎 − 𝐶8𝑎[8𝑘−𝑥𝑎] 
 
q=6, r=2 
𝑅𝑎 = 𝑅𝑎0 − (𝐶1𝑎 + 𝐶1𝑎1𝑏 + 𝐶1𝑎2𝑏) − 2(𝐶2𝑎 + 𝐶2𝑎1𝑏 + 𝐶2𝑎2𝑏) − 3(𝐶3𝑎 + 𝐶3𝑎1𝑏 + 𝐶3𝑎2𝑏) − 4(𝐶4𝑎 + 𝐶4𝑎1𝑏 + 𝐶4𝑎2𝑏) + 5(𝐶5𝑎 + 𝐶5𝑎1𝑏 + 𝐶5𝑎2𝑏) + 6(𝐶6𝑎
+ 𝐶6𝑎1𝑏 + 𝐶6𝑎2𝑏) 
𝑅𝑏 = 𝑅𝑏0 − (𝐶1𝑏 + 𝐶1𝑎1𝑏 + 𝐶2𝑎1𝑏 + 𝐶3𝑎1𝑏+𝐶4𝑎1𝑏 + 𝐶5𝑎1𝑏+𝐶6𝑎1𝑏) − 2(𝐶2𝑏 + 𝐶1𝑎2𝑏 + 𝐶2𝑎2𝑏 + 𝐶3𝑎2𝑏 + 𝐶4𝑎2𝑏 + 𝐶5𝑎2𝑏 + 𝐶6𝑎2𝑏) 
𝑑𝐿
𝑑𝑡
= 𝑘𝑟𝑎𝐶1𝑎𝑚 + 𝑘𝑟𝑏𝐶1𝑏𝑚 − 𝐿(𝑞𝑘𝑓𝑎𝑅𝑎𝑚 + 𝑟𝑘𝑓𝑏𝑅𝑏𝑚) + 𝑘𝑟𝑎𝐶1𝑎𝑛 + 𝑘𝑟𝑏𝐶1𝑏𝑛 − 𝐿(𝑞𝑘𝑓𝑎𝑅𝑎𝑛 + 𝑟𝑘𝑓𝑏𝑅𝑏𝑛) + 𝑘𝑟𝑎𝐶1𝑎𝑝 + 𝑘𝑟𝑏𝐶1𝑏𝑝 − 𝐿(𝑞𝑘𝑓𝑎𝑅𝑎𝑝 + 𝑟𝑘𝑓𝑏𝑅𝑏𝑝) 
 127 
 
𝑑𝐶1𝑎
𝑑𝑡
= 2𝑘−𝑥𝑎𝐶2𝑎 + 𝑘−𝑥𝑏𝐶1𝑎1𝑏 + 𝑞𝑘𝑓𝑎𝐿𝑅𝑎 − 𝐶1𝑎((𝑞 − 1)𝑘𝑥𝑎𝑅𝑎 + 𝑟𝑘𝑥𝑏𝑅𝑏 + 𝑘𝑟𝑎) 
𝑑𝐶2𝑎
𝑑𝑡
= 3𝑘−𝑥𝑎𝐶3𝑎 + 𝑘−𝑥𝑏𝐶2𝑎1𝑏 + (𝑞 − 1)𝑘𝑥𝑎𝐶1𝑎𝑅𝑎 − 𝐶2𝑎((𝑞 − 2)𝑘𝑥𝑎𝑅𝑎 + 𝑟𝑘𝑥𝑏𝑅𝑏 + 2𝑘−𝑥𝑎) 
𝑑𝐶3𝑎
𝑑𝑡
= 4𝑘−𝑥𝑎𝐶4𝑎 + 𝑘−𝑥𝑏𝐶3𝑎1𝑏 + (𝑞 − 2)𝑘𝑥𝑎𝐶2𝑎𝑅𝑎 − 𝐶3𝑎((𝑞 − 3)𝑘𝑥𝑎𝑅𝑎 + 𝑟𝑘𝑥𝑏𝑅𝑏 + 3𝑘−𝑥𝑎) 
𝑑𝐶4𝑎
𝑑𝑡
= 5𝑘−𝑥𝑎𝐶5𝑎 + 𝑘−𝑥𝑏𝐶4𝑎1𝑏 + (𝑞 − 3)𝑘𝑥𝑎𝐶3𝑎𝑅𝑎 − 𝐶4𝑎((𝑞 − 4)𝑘𝑥𝑎𝑅𝑎 + 𝑟𝑘𝑥𝑏𝑅𝑏 + 4𝑘−𝑥𝑎) 
𝑑𝐶5𝑎
𝑑𝑡
= 6𝑘−𝑥𝑎𝐶6𝑎 + 𝑘−𝑥𝑏𝐶5𝑎1𝑏 + (𝑞 − 4)𝑘𝑥𝑎𝐶4𝑎𝑅𝑎 − 𝐶5𝑎((𝑞 − 5)𝑘𝑥𝑎𝑅𝑎 + 𝑟𝑘𝑥𝑏𝑅𝑏 + 5𝑘−𝑥𝑎) 
𝑑𝐶6𝑎
𝑑𝑡
= 𝑘−𝑥𝑏𝐶6𝑎1𝑏 + (𝑞 − 5)𝑘𝑥𝑎𝐶5𝑎𝑅𝑎 − 𝐶6𝑎(𝑟𝑘𝑥𝑏𝑅𝑏 + 6𝑘−𝑥𝑎) 
𝑑𝐶1𝑏
𝑑𝑡
= 𝑘−𝑥𝑎𝐶1𝑎1𝑏 + 2𝑘−𝑥𝑏𝐶2𝑏 + 𝑟𝑘𝑓𝑏𝐿𝑅𝑏 − 𝐶1𝑏(𝑞𝑘𝑥𝑎𝑅𝑎 + (𝑟 − 1)𝑘𝑥𝑏𝑅𝑏 + 𝑘𝑟𝑏) 
𝑑𝐶1𝑎1𝑏
𝑑𝑡
= 2𝑘−𝑥𝑎𝐶2𝑎1𝑏 + 2𝑘−𝑥𝑏𝐶1𝑎2𝑏 + 𝑞𝑘𝑥𝑎𝐶1𝑏𝑅𝑎 + 𝑟𝑘𝑥𝑏𝐶1𝑎𝑅𝑏 − 𝐶1𝑎1𝑏((𝑞 − 1)𝑘𝑥𝑎𝑅𝑎 + (𝑟 − 1)𝑘𝑥𝑏𝑅𝑏 + 𝑘−𝑥𝑎 + 𝑘−𝑥𝑏) 
𝑑𝐶2𝑎1𝑏
𝑑𝑡
= 3𝑘−𝑥𝑎𝐶3𝑎1𝑏 + 2𝑘−𝑥𝑏𝐶2𝑎2𝑏 + (𝑞−1)𝑘𝑥𝑎𝐶1𝑎1𝑏𝑅𝑎 + 𝑟𝑘𝑥𝑏𝐶2𝑎𝑅𝑏 − 𝐶2𝑎1𝑏((𝑞 − 2)𝑘𝑥𝑎𝑅𝑎 + (𝑟 − 1)𝑘𝑥𝑏𝑅𝑏 + 2𝑘−𝑥𝑎 + 𝑘−𝑥𝑏) 
𝑑𝐶3𝑎1𝑏
𝑑𝑡
= 4𝑘−𝑥𝑎𝐶4𝑎1𝑏 + 2𝑘−𝑥𝑏𝐶3𝑎2𝑏 + (𝑞−2)𝑘𝑥𝑎𝐶2𝑎1𝑏𝑅𝑎 + 𝑟𝑘𝑥𝑏𝐶3𝑎𝑅𝑏 − 𝐶3𝑎1𝑏((𝑞 − 3)𝑘𝑥𝑎𝑅𝑎 + (𝑟 − 1)𝑘𝑥𝑏𝑅𝑏 + 3𝑘−𝑥𝑎 + 𝑘−𝑥𝑏) 
𝑑𝐶4𝑎1𝑏
𝑑𝑡
= 5𝑘−𝑥𝑎𝐶5𝑎1𝑏 + 2𝑘−𝑥𝑏𝐶4𝑎2𝑏 + (𝑞−3)𝑘𝑥𝑎𝐶3𝑎1𝑏𝑅𝑎 + 𝑟𝑘𝑥𝑏𝐶4𝑎𝑅𝑏 − 𝐶4𝑎1𝑏((𝑞 − 4)𝑘𝑥𝑎𝑅𝑎 + (𝑟 − 1)𝑘𝑥𝑏𝑅𝑏 + 4𝑘−𝑥𝑎 + 𝑘−𝑥𝑏) 
𝑑𝐶5𝑎1𝑏
𝑑𝑡
= 6𝑘−𝑥𝑎𝐶6𝑎1𝑏 + 2𝑘−𝑥𝑏𝐶5𝑎2𝑏 + (𝑞−4)𝑘𝑥𝑎𝐶4𝑎1𝑏𝑅𝑎 + 𝑟𝑘𝑥𝑏𝐶5𝑎𝑅𝑏 − 𝐶5𝑎1𝑏((𝑞 − 5)𝑘𝑥𝑎𝑅𝑎 + (𝑟 − 1)𝑘𝑥𝑏𝑅𝑏 + 5𝑘−𝑥𝑎 + 𝑘−𝑥𝑏) 
𝑑𝐶6𝑎1𝑏
𝑑𝑡
= 2𝑘−𝑥𝑏𝐶6𝑎2𝑏 + (𝑞−5)𝑘𝑥𝑎𝐶5𝑎1𝑏𝑅𝑎 + 𝑟𝑘𝑥𝑏𝐶6𝑎𝑅𝑏 − 𝐶6𝑎1𝑏((𝑟 − 1)𝑘𝑥𝑏𝑅𝑏 + 6𝑘−𝑥𝑎 + 𝑘−𝑥𝑏) 
𝑑𝐶2𝑏
𝑑𝑡
= 𝑘−𝑥𝑎𝐶1𝑎2𝑏 + (𝑟 − 1)𝑘𝑥𝑏𝐶1𝑏𝑅𝑏 − 𝐶2𝑏(𝑞𝑘𝑥𝑎𝑅𝑎 + 2𝑘−𝑥𝑏) 
 128 
 
𝑑𝐶1𝑎2𝑏
𝑑𝑡
= 2𝑘−𝑥𝑎𝐶2𝑎2𝑏 + 𝑞𝑘𝑥𝑎𝐶2𝑏𝑅𝑎 + (𝑟 − 1)𝑘𝑥𝑏𝐶1𝑎1𝑏𝑅𝑏 − 𝐶1𝑎2𝑏((𝑞 − 1)𝑘𝑥𝑎𝑅𝑎 + 𝑘−𝑥𝑎 + 2𝑘−𝑥𝑏) 
𝑑𝐶2𝑎2𝑏
𝑑𝑡
= 3𝑘−𝑥𝑎𝐶3𝑎2𝑏 + (𝑞 − 1)𝑘𝑥𝑎𝐶1𝑎2𝑏𝑅𝑎 + (𝑟 − 1)𝑘𝑥𝑏𝐶2𝑎1𝑏𝑅𝑏 − 𝐶2𝑎2𝑏((𝑞 − 2)𝑘𝑥𝑎𝑅𝑎 + 2𝑘−𝑥𝑎 + 2𝑘−𝑥𝑏) 
𝑑𝐶3𝑎2𝑏
𝑑𝑡
= 4𝑘−𝑥𝑎𝐶4𝑎2𝑏 + (𝑞 − 2)𝑘𝑥𝑎𝐶2𝑎2𝑏𝑅𝑎 + (𝑟 − 1)𝑘𝑥𝑏𝐶3𝑎1𝑏𝑅𝑏 − 𝐶3𝑎2𝑏((𝑞 − 3)𝑘𝑥𝑎𝑅𝑎 + 3𝑘−𝑥𝑎 + 2𝑘−𝑥𝑏) 
𝑑𝐶4𝑎2𝑏
𝑑𝑡
= 5𝑘−𝑥𝑎𝐶5𝑎2𝑏 + (𝑞 − 3)𝑘𝑥𝑎𝐶3𝑎2𝑏𝑅𝑎 + (𝑟 − 1)𝑘𝑥𝑏𝐶4𝑎1𝑏𝑅𝑏 − 𝐶4𝑎2𝑏((𝑞 − 4)𝑘𝑥𝑎𝑅𝑎 + 4𝑘−𝑥𝑎 + 2𝑘−𝑥𝑏) 
𝑑𝐶5𝑎2𝑏
𝑑𝑡
= 6𝑘−𝑥𝑎𝐶6𝑎2𝑏 + (𝑞 − 4)𝑘𝑥𝑎𝐶4𝑎2𝑏𝑅𝑎 + (𝑟 − 1)𝑘𝑥𝑏𝐶5𝑎1𝑏𝑅𝑏 − 𝐶5𝑎2𝑏((𝑞 − 5)𝑘𝑥𝑎𝑅𝑎 + 5𝑘−𝑥𝑎 + 2𝑘−𝑥𝑏) 
𝑑𝐶6𝑎2𝑏
𝑑𝑡
= (𝑞 − 5)𝑘𝑥𝑎𝐶5𝑎2𝑏𝑅𝑎 + (𝑟 − 1)𝑘𝑥𝑏𝐶6𝑎1𝑏𝑅𝑏 − 𝐶6𝑎2𝑏(6𝑘−𝑥𝑎 + 2𝑘−𝑥𝑏) 
 
q=4, r=4; 
𝑅𝑎 = 𝑅𝑎0 − (𝐶1𝑎 + 𝐶1𝑎1𝑏 + 𝐶1𝑎2𝑏 + 𝐶1𝑎3𝑏 + 𝐶1𝑎4𝑏) − 2(𝐶2𝑎 + 𝐶2𝑎1𝑏 + 𝐶2𝑎2𝑏 + 𝐶2𝑎3𝑏 + 𝐶2𝑎4𝑏) − 3(𝐶3𝑎 + 𝐶3𝑎1𝑏 + 𝐶3𝑎2𝑏 + 𝐶3𝑎3𝑏 + 𝐶3𝑎4𝑏) − 4(𝐶4𝑎 + 𝐶4𝑎1𝑏
+ 𝐶4𝑎2𝑏 + 𝐶4𝑎3𝑏 + 𝐶4𝑎4𝑏) 
𝑅𝑏 = 𝑅𝑏0 − (𝐶1𝑏 + 𝐶1𝑎1𝑏 + 𝐶2𝑎1𝑏 + 𝐶3𝑎1𝑏+𝐶4𝑎1𝑏) − 2(𝐶2𝑏 + 𝐶1𝑎2𝑏 + 𝐶2𝑎2𝑏 + 𝐶3𝑎2𝑏 + 𝐶4𝑎2𝑏) − 3(𝐶3𝑏 + 𝐶1𝑎3𝑏 + 21𝑎3𝑏 + 𝐶3𝑎3𝑏 + 𝐶4𝑎3𝑏) − 4(𝐶4𝑏 + 𝐶1𝑎4𝑏
+ 𝐶2𝑎4𝑏 + 𝐶3𝑎4𝑏 + 𝐶4𝑎4𝑏) 
𝑑𝐿
𝑑𝑡
= (𝑘𝑟𝑎𝐶1𝑎𝑚 + 𝑘𝑟𝑏𝐶1𝑏𝑚) − 𝐿(𝑞𝑘𝑓𝑎𝑅𝑎𝑚 + 𝑟𝑘𝑓𝑏𝑅𝑏𝑚) + (𝑘𝑟𝑎𝐶1𝑎𝑛 + 𝑘𝑟𝑏𝐶1𝑏𝑛) − 𝐿(𝑞𝑘𝑓𝑎𝑅𝑎𝑛 + 𝑟𝑘𝑓𝑏𝑅𝑏𝑛) + (𝑘𝑟𝑎𝐶1𝑎𝑝 + 𝑘𝑟𝑏𝐶1𝑏𝑝) − 𝐿(𝑞𝑘𝑓𝑎𝑅𝑎𝑝 + 𝑟𝑘𝑓𝑏𝑅𝑏𝑝) 
𝑑𝐶1𝑎
𝑑𝑡
= 2𝑘−𝑥𝑎𝐶2𝑎 + 𝑘−𝑥𝑏𝐶1𝑎1𝑏 + 𝑞𝑘𝑓𝑎𝐿𝑅𝑎 − 𝐶1𝑎((𝑞 − 1)𝑘𝑥𝑎𝑅𝑎 + 𝑟𝑘𝑥𝑏𝑅𝑏 + 𝑘𝑟𝑎) 
𝑑𝐶2𝑎
𝑑𝑡
= 3𝑘−𝑥𝑎𝐶3𝑎 + 𝑘−𝑥𝑏𝐶2𝑎1𝑏 + (𝑞 − 1)𝑘𝑥𝑎𝐶1𝑎𝑅𝑎 − 𝐶2𝑎((𝑞 − 2)𝑘𝑥𝑎𝑅𝑎 + 𝑟𝑘𝑥𝑏𝑅𝑏 + 2𝑘−𝑥𝑎) 
𝑑𝐶3𝑎
𝑑𝑡
= 4𝑘−𝑥𝑎𝐶4𝑎 + 𝑘−𝑥𝑏𝐶3𝑎1𝑏 + (𝑞 − 2)𝑘𝑥𝑎𝐶2𝑎𝑅𝑎 − 𝐶3𝑎((𝑞 − 3)𝑘𝑥𝑎𝑅𝑎 + 𝑟𝑘𝑥𝑏𝑅𝑏 + 3𝑘−𝑥𝑎) 
𝑑𝐶4𝑎
𝑑𝑡
= 𝑘−𝑥𝑏𝐶4𝑎1𝑏 + (𝑞 − 3)𝑘𝑥𝑎𝐶3𝑎𝑅𝑎 − 𝐶4𝑎(𝑟𝑘𝑥𝑏𝑅𝑏 + 4𝑘−𝑥𝑎) 
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𝑑𝐶1𝑏
𝑑𝑡
= 𝑘−𝑥𝑎𝐶1𝑎1𝑏 + 2𝑘−𝑥𝑏𝐶2𝑏 + 𝑟𝑘𝑓𝑏𝐿𝑅𝑏 − 𝐶1𝑏(𝑞𝑘𝑥𝑎𝑅𝑎 + (𝑟 − 1)𝑘𝑥𝑏𝑅𝑏 + 𝑘𝑟𝑏) 
𝑑𝐶1𝑎1𝑏
𝑑𝑡
= 2𝑘−𝑥𝑎𝐶2𝑎1𝑏 + 2𝑘−𝑥𝑏𝐶1𝑎2𝑏 + 𝑞𝑘𝑥𝑎𝐶1𝑏𝑅𝑎 + 𝑟𝑘𝑥𝑏𝐶1𝑎𝑅𝑏 − 𝐶1𝑎1𝑏((𝑞−1)𝑘𝑥𝑎𝑅𝑎 + (𝑟 − 1)𝑘𝑥𝑏𝑅𝑏 + 𝑘−𝑥𝑎 + 𝑘−𝑥𝑏) 
𝑑𝐶2𝑎1𝑏
𝑑𝑡
= 3𝑘−𝑥𝑎𝐶3𝑎1𝑏 + 2𝑘−𝑥𝑏𝐶2𝑎2𝑏 + (𝑞−1)𝑘𝑥𝑎𝐶1𝑎1𝑏𝑅𝑎 + 𝑟𝑘𝑥𝑏𝐶2𝑎𝑅𝑏 − 𝐶2𝑎1𝑏((𝑞−2)𝑘𝑥𝑎𝑅𝑎 + (𝑟 − 1)𝑘𝑥𝑏𝑅𝑏 + 2𝑘−𝑥𝑎 + 𝑘−𝑥𝑏) 
𝑑𝐶3𝑎1𝑏
𝑑𝑡
= 4𝑘−𝑥𝑎𝐶4𝑎1𝑏 + 2𝑘−𝑥𝑏𝐶3𝑎2𝑏 + (𝑞−2)𝑘𝑥𝑎𝐶2𝑎1𝑏𝑅𝑎 + 𝑟𝑘𝑥𝑏𝐶3𝑎𝑅𝑏 − 𝐶3𝑎1𝑏((𝑞−3)𝑘𝑥𝑎𝑅𝑎 + (𝑟 − 1)𝑘𝑥𝑏𝑅𝑏 + 3𝑘−𝑥𝑎 + 𝑘−𝑥𝑏) 
𝑑𝐶4𝑎1𝑏
𝑑𝑡
= 2𝑘−𝑥𝑏𝐶4𝑎2𝑏 + (𝑞−3)𝑘𝑥𝑎𝐶3𝑎1𝑏𝑅𝑎 + 𝑟𝑘𝑥𝑏𝐶4𝑎𝑅𝑏 − 𝐶4𝑎1𝑏((𝑟 − 1)𝑘𝑥𝑏𝑅𝑏 + 4𝑘−𝑥𝑎 + 𝑘−𝑥𝑏) 
𝑑𝐶2𝑏
𝑑𝑡
= 𝑘−𝑥𝑎𝐶1𝑎2𝑏 + 3𝑘−𝑥𝑏𝐶3𝑏 + (𝑟 − 1)𝑘𝑥𝑏𝐶1𝑏𝑅𝑏 − 𝐶2𝑏(𝑞𝑘𝑥𝑎𝑅𝑎 + (𝑟 − 2)𝑘𝑥𝑏𝑅𝑏 + 2𝑘−𝑥𝑏) 
𝑑𝐶1𝑎2𝑏
𝑑𝑡
= 2𝑘−𝑥𝑎𝐶2𝑎2𝑏 + 3𝑘−𝑥𝑏𝐶1𝑎3𝑏 + 𝑞𝑘𝑥𝑎𝐶2𝑏𝑅𝑎 + (𝑟 − 1)𝑘𝑥𝑏𝐶1𝑎1𝑏𝑅𝑏 − 𝐶1𝑎2𝑏((𝑞−1)𝑘𝑥𝑎𝑅𝑎 + (𝑟 − 2)𝑘𝑥𝑏𝑅𝑏 + 𝑘−𝑥𝑎 + 2𝑘−𝑥𝑏) 
𝑑𝐶2𝑎2𝑏
𝑑𝑡
= 3𝑘−𝑥𝑎𝐶3𝑎2𝑏 + 3𝑘−𝑥𝑏𝐶2𝑎3𝑏 + (𝑞 − 1)𝑘𝑥𝑎𝐶1𝑎2𝑏𝑅𝑎 + (𝑟 − 1)𝑘𝑥𝑏𝐶2𝑎1𝑏𝑅𝑏 − 𝐶2𝑎2𝑏((𝑞−2)𝑘𝑥𝑎𝑅𝑎 + (𝑟 − 2)𝑘𝑥𝑏𝑅𝑏 + 2𝑘−𝑥𝑎 + 2𝑘−𝑥𝑏) 
𝑑𝐶3𝑎2𝑏
𝑑𝑡
= 4𝑘−𝑥𝑎𝐶4𝑎2𝑏 + 3𝑘−𝑥𝑏𝐶3𝑎3𝑏 + (𝑞 − 2)𝑘𝑥𝑎𝐶2𝑎2𝑏𝑅𝑎 + (𝑟 − 1)𝑘𝑥𝑏𝐶3𝑎1𝑏𝑅𝑏 − 𝐶3𝑎2𝑏((𝑞−3)𝑘𝑥𝑎𝑅𝑎 + (𝑟 − 2)𝑘𝑥𝑏𝑅𝑏 + 3𝑘−𝑥𝑎 + 2𝑘−𝑥𝑏) 
𝑑𝐶4𝑎2𝑏
𝑑𝑡
= 3𝑘−𝑥𝑏𝐶4𝑎3𝑏 + (𝑞 − 3)𝑘𝑥𝑎𝐶3𝑎2𝑏𝑅𝑎 + (𝑟 − 1)𝑘𝑥𝑏𝐶4𝑎1𝑏𝑅𝑏 − 𝐶4𝑎2𝑏((𝑟 − 2)𝑘𝑥𝑏𝑅𝑏 + 4𝑘−𝑥𝑎 + 2𝑘−𝑥𝑏) 
𝑑𝐶3𝑏
𝑑𝑡
= 𝑘−𝑥𝑎𝐶1𝑎3𝑏 + 4𝑘−𝑥𝑏𝐶4𝑏 + (𝑟 − 2)𝑘𝑥𝑏𝐶2𝑏𝑅𝑏 − 𝐶3𝑏(𝑞𝑘𝑥𝑎𝑅𝑎 + (𝑟 − 3)𝑘𝑥𝑏𝑅𝑏 + 3𝑘−𝑥𝑏) 
𝑑𝐶1𝑎3𝑏
𝑑𝑡
= 2𝑘−𝑥𝑎𝐶2𝑎3𝑏 + 4𝑘−𝑥𝑏𝐶1𝑎4𝑏 + 𝑞𝑘𝑥𝑎𝐶3𝑏𝑅𝑎 + (𝑟 − 2)𝑘𝑥𝑏𝐶1𝑎2𝑏𝑅𝑏 − 𝐶1𝑎3𝑏((𝑞−1)𝑘𝑥𝑎𝑅𝑎 + (𝑟 − 3)𝑘𝑥𝑏𝑅𝑏 + 𝑘−𝑥𝑎 + 3𝑘−𝑥𝑏) 
𝑑𝐶2𝑎3𝑏
𝑑𝑡
= 3𝑘−𝑥𝑎𝐶3𝑎3𝑏 + 4𝑘−𝑥𝑏𝐶2𝑎4𝑏 + (𝑞 − 1)𝑘𝑥𝑎𝐶1𝑎3𝑏𝑅𝑎 + (𝑟 − 2)𝑘𝑥𝑏𝐶2𝑎2𝑏𝑅𝑏 − 𝐶2𝑎3𝑏((𝑞−2)𝑘𝑥𝑎𝑅𝑎 + (𝑟 − 3)𝑘𝑥𝑏𝑅𝑏 + 2𝑘−𝑥𝑎 + 3𝑘−𝑥𝑏) 
𝑑𝐶3𝑎3𝑏
𝑑𝑡
= 4𝑘−𝑥𝑎𝐶4𝑎3𝑏 + 4𝑘−𝑥𝑏𝐶3𝑎4𝑏 + (𝑞 − 2)𝑘𝑥𝑎𝐶2𝑎3𝑏𝑅𝑎 + (𝑟 − 2)𝑘𝑥𝑏𝐶3𝑎2𝑏𝑅𝑏 − 𝐶3𝑎3𝑏((𝑞−3)𝑘𝑥𝑎𝑅𝑎 + (𝑟 − 3)𝑘𝑥𝑏𝑅𝑏 + 3𝑘−𝑥𝑎 + 3𝑘−𝑥𝑏) 
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𝑑𝐶4𝑎3𝑏
𝑑𝑡
= 4𝑘−𝑥𝑎𝐶4𝑎4𝑏 + (𝑞 − 3)𝑘𝑥𝑎𝐶3𝑎3𝑏𝑅𝑎 + (𝑟 − 2)𝑘𝑥𝑏𝐶4𝑎2𝑏𝑅𝑏 − 𝐶4𝑎3𝑏((𝑟 − 3)𝑘𝑥𝑏𝑅𝑏 + 4𝑘−𝑥𝑎 + 3𝑘−𝑥𝑏) 
𝑑𝐶4𝑏
𝑑𝑡
= 𝑘−𝑥𝑎𝐶1𝑎4𝑏 + (𝑟 − 3)𝑘𝑥𝑏𝐶3𝑏𝑅𝑏 − 𝐶4𝑏(𝑞𝑘𝑥𝑎𝑅𝑎 + 4𝑘−𝑥𝑏) 
𝑑𝐶1𝑎4𝑏
𝑑𝑡
= 2𝑘−𝑥𝑎𝐶2𝑎4𝑏 + 𝑞𝑘𝑥𝑎𝐶4𝑏𝑅𝑎 + (𝑟 − 3)𝑘𝑥𝑏𝐶1𝑎3𝑏𝑅𝑏 − 𝐶1𝑎4𝑏((𝑞−1)𝑘𝑥𝑎𝑅𝑎 + 𝑘−𝑥𝑎 + 4𝑘−𝑥𝑏) 
𝑑𝐶2𝑎4𝑏
𝑑𝑡
= 3𝑘−𝑥𝑎𝐶3𝑎4𝑏 + (𝑞 − 1)𝑘𝑥𝑎𝐶1𝑎4𝑏𝑅𝑎 + (𝑟 − 3)𝑘𝑥𝑏𝐶2𝑎3𝑏𝑅𝑏 − 𝐶2𝑎4𝑏((𝑞−2)𝑘𝑥𝑎𝑅𝑎 + 2𝑘−𝑥𝑎 + 4𝑘−𝑥𝑏) 
𝑑𝐶3𝑎4𝑏
𝑑𝑡
= 4𝑘−𝑥𝑎𝐶4𝑎4𝑏 + (𝑞 − 2)𝑘𝑥𝑎𝐶2𝑎4𝑏𝑅𝑎 + (𝑟 − 3)𝑘𝑥𝑏𝐶3𝑎3𝑏𝑅𝑏 − 𝐶3𝑎4𝑏((𝑞−3)𝑘𝑥𝑎𝑅𝑎 + 3𝑘−𝑥𝑎 + 4𝑘−𝑥𝑏) 
𝑑𝐶4𝑎4𝑏
𝑑𝑡
= (𝑞 − 3)𝑘𝑥𝑎𝐶3𝑎4𝑏𝑅𝑎 + (𝑟 − 3)𝑘𝑥𝑏𝐶4𝑎3𝑏𝑅𝑏 − 𝐶4𝑎4𝑏(4𝑘−𝑥𝑎 + 4𝑘−𝑥𝑏) 
Parrallel equations were written and used for q and r combinations of 0,1; 0,2; 0;3, 0;4, 0;5, 0;6, 0,7; 0,8; 1,0; 1,1; 1,2; 2,3; 1,4; 1,5; 1,6; 1,7; 2,0; 
2,1; 2,2; 2,3; 2,4; 2,5; 2,6; 3,0; 3,1; 3,2; 3,3; 3,4; 3,5; 4,0; 4,1; 4,2; 4,3; 4,4; 5,0; 5,1; 5,2; 5,3; 6,0; 6,1; 6,2; 7,0; 7,1; 8,0. 
 
 
 
 
 
 
 
 
 
 
 
 
 131 
 
Matlab code for heteromultivalent kinetic model used in Chapter 4 
%% dual targeting. graph Mtotal, Ntotal, Ptotal. Calculate Specificity 
  
clear  
clc 
format shortg 
c=clock 
tic 
  
p.N = 6.022e23;          %avagadro's number 
p.V = 4e-9;              %Vol (L/cell) - 200 uL/50,000 cells 
kfa = 3e2;               %on rate ligand-receptor pair a [1/(M*s)] 
kda = 3.3e-6;            %dissociation rate [M] 
kfb = kfa;               %on rate ligand-receptor pair a [1/(M*s)] 
kdb = 3.3e-6;            %dissociation rate [M] 
hwell = 6.22;            %height of media in the well (mm) 
hbind = 2e-6;            %binding height (mm) 
h = hwell/hbind;         %ratio of binding volume 
  
p.kfa = kfa/(p.N*p.V);   %on rate ligand-receptor pair a [cell/(#*s)] 
p.kra  = kda*kfa;        %off rate ligand-receptor pair a [1/s] 
p.kxa = p.kfa*h;         %affinity on rate ligand-receptor pair a [cell/(#*s)] 
p.k_xa = p.kra;          %affinity off rate ligand-receptor pair a [1/s] 
p.kfb  = kfb/(p.N*p.V);  %on rate ligand-receptor pair a [cell/(#*s)] 
p.krb = kdb*kfb;         %off rate ligand-receptor pair b [1/s] 
p.kxb  = p.kfb*h;        %5e-6;%affinity on rate ligand-receptor pair b [cell/(#*s)] 
p.k_xb = p.krb;          %affinity off rate ligand-receptor pair b [1/s] 
  
p.tf=240000*3600;%diffEQ time (s) 
p.Lg= 2.5e-14; 
  
Mtotal = [NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, NaN, 
NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, 
NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, 
NaN, NaN, NaN, NaN, NaN, NaN]; 
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Ntotal = [NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, NaN, 
NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, 
NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, 
NaN, NaN, NaN, NaN, NaN, NaN]; 
Ptotal = [NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, NaN, 
NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, 
NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN, NaN;NaN, NaN, NaN, 
NaN, NaN, NaN, NaN, NaN, NaN]; 
  
q=0; 
r=0; 
p.Ram0 = 200000; 
p.Rbm0 = p.Ram0; 
p.Ran0 = p.Ram0; 
p.Rbn0 = p.Rbm0/8; 
p.Rap0 = p.Ram0/8; 
p.Rbp0 = p.Rbm0; 
for countq=0:1:8 
    for countr=0:1:8-countq 
    q=countq; 
    r=countr; 
%% initial conditions for bound complexes (all=0) 
p.C1am = 0;%all units #/cell 
p.C2am = 0; 
p.C3am = 0; 
p.C4am = 0; 
p.C5am = 0; 
p.C6am = 0; 
p.C7am = 0; 
p.C8am = 0; 
p.C1bm = 0; 
p.C1a1bm = 0; 
p.C2a1bm = 0; 
p.C3a1bm = 0; 
p.C4a1bm = 0; 
p.C5a1bm = 0; 
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p.C6a1bm = 0; 
p.C7a1bm = 0; 
p.C2bm = 0; 
p.C1a2bm = 0; 
p.C2a2bm = 0; 
p.C3a2bm = 0; 
p.C4a2bm = 0; 
p.C5a2bm = 0; 
p.C6a2bm = 0; 
p.C3bm = 0; 
p.C1a3bm = 0; 
p.C2a3bm = 0; 
p.C3a3bm = 0; 
p.C4a3bm = 0; 
p.C5a3bm = 0; 
p.C4bm = 0; 
p.C1a4bm = 0; 
p.C2a4bm = 0; 
p.C3a4bm = 0; 
p.C4a4bm = 0; 
  
p.C1an = 0; 
p.C2an = 0; 
p.C3an = 0; 
p.C4an = 0; 
p.C5an = 0; 
p.C6an = 0; 
p.C7an = 0; 
p.C8an = 0; 
p.C1bn = 0; 
p.C1a1bn = 0; 
p.C2a1bn = 0; 
p.C3a1bn = 0; 
p.C4a1bn = 0; 
p.C5a1bn = 0; 
p.C6a1bn = 0; 
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p.C7a1bn = 0; 
p.C2bn = 0; 
p.C1a2bn = 0; 
p.C2a2bn = 0; 
p.C3a2bn = 0; 
p.C4a2bn = 0; 
p.C5a2bn = 0; 
p.C6a2bn = 0; 
p.C3bn = 0; 
p.C1a3bn = 0; 
p.C2a3bn = 0; 
p.C3a3bn = 0; 
p.C4a3bn = 0; 
p.C5a3bn = 0; 
p.C4bn = 0; 
p.C1a4bn = 0; 
p.C2a4bn = 0; 
p.C3a4bn = 0; 
p.C4a4bn = 0; 
  
p.C1ap = 0; 
p.C2ap = 0; 
p.C3ap = 0; 
p.C4ap = 0; 
p.C5ap = 0; 
p.C6ap = 0; 
p.C7ap = 0; 
p.C8ap = 0; 
p.C1bp = 0; 
p.C1a1bp = 0; 
p.C2a1bp = 0; 
p.C3a1bp = 0; 
p.C4a1bp = 0; 
p.C5a1bp = 0; 
p.C6a1bp = 0; 
p.C7a1bp = 0; 
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p.C2bp = 0; 
p.C1a2bp = 0; 
p.C2a2bp = 0; 
p.C3a2bp = 0; 
p.C4a2bp = 0; 
p.C5a2bp = 0; 
p.C6a2bp = 0; 
p.C3bp = 0; 
p.C1a3bp = 0; 
p.C2a3bp = 0; 
p.C3a3bp = 0; 
p.C4a3bp = 0; 
p.C5a3bp = 0; 
p.C4bp = 0; 
p.C1a4bp = 0; 
p.C2a4bp = 0; 
p.C3a4bp = 0; 
p.C4a4bp = 0; 
%% ODE and total complexes summation 
modelname=sprintf('%s%d%s%d', 'modelq', q,'r',r); 
modelname2=str2func(modelname); 
totalname=sprintf('%s%d%s%d', 'totalq', q,'r',r); 
totalname2=str2func(totalname); 
%setting initial conditions 
y0=[p.Lg p.C1am p.C2am p.C3am p.C4am p.C5am p.C6am p.C7am p.C8am p.C1bm p.C1a1bm p.C2a1bm p.C3a1bm p.C4a1bm p.C5a1bm 
p.C6a1bm p.C2bm p.C1a2bm p.C2a2bm p.C3a2bm p.C4a2bm p.C5a2bm p.C6a2bm p.C3bm p.C1a3bm p.C2a3bm p.C3a3bm p.C4a3bm p.C4bm 
p.C1a4bm p.C2a4bm p.C3a4bm p.C4a4bm p.C1an p.C2an p.C3an p.C4an p.C5an p.C6an p.C7an p.C8an p.C1bn p.C1a1bn p.C2a1bn p.C3a1bn 
p.C4a1bn p.C5a1bn p.C6a1bn p.C2bn p.C1a2bn p.C2a2bn p.C3a2bn p.C4a2bn p.C5a2bn p.C6a2bn p.C3bn p.C1a3bn p.C2a3bn p.C3a3bn 
p.C4a3bn p.C4bn p.C1a4bn p.C2a4bn p.C3a4bn p.C4a4bn p.C1ap p.C2ap p.C3ap p.C4ap p.C5ap p.C6ap p.C7ap p.C8ap p.C1bp p.C1a1bp 
p.C2a1bp p.C3a1bp p.C4a1bp p.C5a1bp p.C6a1bp p.C2bp p.C1a2bp p.C2a2bp p.C3a2bp p.C4a2bp p.C5a2bp p.C6a2bp p.C3bp p.C1a3bp 
p.C2a3bp p.C3a3bp p.C4a3bp p.C4bp p.C1a4bp p.C2a4bp p.C3a4bp p.C4a4bp]; 
%passing constants, initial conditions to ODE solver and diffEQs 
 options = odeset('AbsTol', 1e-7, 'RelTol', 1e-5); 
     [t,y] = ode15s(modelname2, [0 p.tf], y0, options, p);  
     [M,N,P,Mu,Nu,Pu] = totalname2(y); 
     [u,~]=size(y); 
 136 
 
     Mtotal(countq+1,countr+1)=Mu; 
     Ntotal(countq+1,countr+1)=Nu; 
     Ptotal(countq+1,countr+1)=Pu;     
     Q(countq+1)=q; 
     R(countr+1)=r; 
    end 
toc 
end 
  
     SpecN=Mtotal./Ntotal; 
     SpecP=Mtotal./Ptotal; 
     Spec = min(SpecN, SpecP); 
%      [maxSpecN,ind] = max(SpecN(:)); 
% [h,k] = ind2sub(size(SpecN),ind); 
% maxQN = Q(h) 
% maxRN = R(k) 
% [maxSpecP,ind] = max(SpecP(:)); 
% [H,K] = ind2sub(size(SpecP),ind); 
% maxQP = Q(H) 
% maxRP = R(K) 
%      [maxSpecN,ind] = max(Spec(:)); 
% [h,k] = ind2sub(size(SpecN),ind); 
% maxQ = Q(h) 
% maxR = R(k) 
% %verify that equilibrium has been reached 
% figure(1)  
% plot(t,y) 
%plot Binding vs. Receptor Density and Q 
figure('units','inches','position',[0 0 6 6],'Color',[1,1,1]); 
subplot(2,2,1) 
pcolor(Q,R,Mtotal) 
%colorbar 
xlabel('Ligand B (Valency)') 
ylabel('Ligand A (Valency)') 
axis([0 8 0 8]) 
%title('++/++ Cell Line') 
 137 
 
caxis([0 55]) 
colormap parula 
set(gca,'FontSize',10) 
set(findall(gcf,'type','text'),'FontSize',10,'FontName','Arial') 
  
subplot(2,2,2) 
pcolor(Q,R,Ntotal) 
xlabel('Ligand B (Valency)') 
ylabel('Ligand A (Valency)') 
axis([0 8 0 8]) 
%colorbar 
%title('++/+ Cell Line') 
caxis([0 55]) 
colormap parula 
set(gca,'FontSize',10) 
set(findall(gcf,'type','text'),'FontSize',10,'FontName','Arial') 
  
subplot(2,2,3) 
pcolor(Q,R,Ptotal) 
axis([0 8 0 8]) 
%colorbar 
xlabel('Ligand B (Valency)') 
ylabel('Ligand A (Valency)') 
%title('+/++ Cell Line') 
caxis([0 55]) 
colormap parula 
set(gca,'FontSize',10) 
set(findall(gcf,'type','text'),'FontSize',10,'FontName','Arial') 
  
subplot(2,2,4) 
pcolor(Q,R,Spec) 
axis([0 8 0 8]) 
%colorbar 
xlabel('Ligand B (Valency)') 
ylabel('Ligand A (Valency)') 
%title('Specificity') 
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caxis([0 55]) 
colormap parula 
set(gca,'FontSize',10) 
set(findall(gcf,'type','text'),'FontSize',10,'FontName','Arial') 
  
toc 
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Appendix B: Heteromultivalent Kinetic Model Sensitivity Analysis 
 
Figure B1. Theoretical Binding of Heteromultivalent Nanoparticles to 3 Representative Cell Types 
The heteromultivalent kinetic binding model was used to calculate nanoparticles bound to cells with high 
dual expression of receptors (RA=200,000, RB=200,000) (A), higher expression of receptor A (RA=200,000, 
RB=25,000) (B) of higher expression of receptor B (RA=25,000, RB=200,000) (C). Valency of ligand A and 
B were varied 0-4 and binding to each cell was measured, as well as specificity (D) of (A) compared to (B) 
and (C). L = 2.5*10-14 nanoparticles, Kda= 3.3*10-6 M, Kdb=0.367*10-6 M , kfa=kfb=300 M-1s-1, 
kra=krb=Kda*kfa, k-xa= k-xb =kra, kxa= kxb =9.3*108 M-1s-1.  
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Figure B2. Maximum specificity and dual valency that achieves maximum specificity were calculated with 
varying Kd. All other variables are the same as in Figure B1. 
 
 
Figure B3. Maximum specificity and dual valency that achieves maximum specificity were calculated at 
various receptor expression levels. All other variables are the same as in Figure B1. 
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